<SEC-DOCUMENT>0001104659-16-160414.txt : 20161202
<SEC-HEADER>0001104659-16-160414.hdr.sgml : 20161202
<ACCEPTANCE-DATETIME>20161202160206
ACCESSION NUMBER:		0001104659-16-160414
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		12
FILED AS OF DATE:		20161202
DATE AS OF CHANGE:		20161202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-214882
		FILM NUMBER:		162031173

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>a16-22161_1s3.htm
<DESCRIPTION>S-3
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As filed with the Securities and Exchange Commission on December&nbsp;2, 2016</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Registration Statement No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:3.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:16.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:16.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:16.0pt;font-weight:bold;">FORM&nbsp;S-3</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:4.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:16.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(Exact name of Registrant as Specified in Its Charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">13-3191702</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(State   of Incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(I.R.S.   Employer Identification Number)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Perryville III Building, 53 Frontage Road, Suite&nbsp;220</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Hampton, New Jersey 08827</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(908) 200-7500</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(Address, including zip code and telephone number, including area code, of Registrant&#146;s principal executive offices)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Avery W. Catlin</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Chief Financial Officer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Perryville III Building, 53 Frontage Road, Suite&nbsp;220</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Hampton, New Jersey 08827</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(908) 200-7500</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(Name, address, including zip code and telephone number, including area code, of agent for service)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Copies to:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Anthony O. Pergola,&nbsp;Esq.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Lowenstein Sandler LLP</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">1251 Avenue of the Americas</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">New York, New York 10020</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(212) 262-6700</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Approximate Date of Commencement of Proposed Sale to the Public: From time to time after this Registration Statement becomes effective, as determined by the Registrant.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">If the only securities being registered on this Form&nbsp;are being offered pursuant to dividend or interest reinvestment plans, please check the following box. </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">If any of the securities being registered on this Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. </font><font size="1" face="Wingdings" style="font-size:8.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">If this Form&nbsp;is used to register additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same offering. </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">If this Form&nbsp;is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same offering. </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">If this Form&nbsp;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&nbsp;462(e)&nbsp;under the Securities Act, check the following box. </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">If this Form&nbsp;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&nbsp;413(b)&nbsp;under the Securities Act, check the following box. </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Indicate by check mark whether each registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.66%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Large   accelerated filer </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>    </td>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.08%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Accelerated   filer </font><font size="1" face="Wingdings" style="font-size:8.0pt;">x</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Non-accelerated filer </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>    </td>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.58%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Smaller   reporting company </font><font size="1" face="Wingdings" style="font-size:8.0pt;">o</font></p>    </td>   </tr>
<tr>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.66%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.08%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(Do not check if a smaller reporting </font></p>    </td>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.58%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.66%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.08%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">company)</font></p>    </td>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.58%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CALCULATION OF REGISTRATION FEE</font></b></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="47%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:47.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:3.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="21%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:3.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="21%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:3.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="47%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">Title&nbsp;of&nbsp;Each&nbsp;Class&nbsp;of<br>   Securities&nbsp;to&nbsp;be&nbsp;Registered</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="21%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">Proposed&nbsp;Maximum<br>   Aggregate&nbsp;Offering<br>   Price(1)(2)(3)</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="21%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:6.0pt;font-weight:bold;">Amount&nbsp;of<br>   Registration&nbsp;Fee(2)</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Common Stock, par value $0.001 per share</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Preferred Stock</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Warrants</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Depositary Shares</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Units(4)</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.14%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="47%" valign="top" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:47.16%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total:</font></b></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">$</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:19.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">250,000,000</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.58%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">$</font></p>    </td>
<td width="19%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:19.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">28,975</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="black" style="background:white;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:3.52%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(5)</font></p>    </td>   </tr>
<tr height="0">
<td width="334" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="11" style="border:none;"></td>
<td width="138" style="border:none;"></td>
<td width="25" style="border:none;"></td>
<td width="11" style="border:none;"></td>
<td width="138" style="border:none;"></td>
<td width="25" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(1)</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">The amount to be registered and the proposed   maximum aggregate offering price per security are not specified as to each   class of securities to be registered pursuant to General Instruction II.D. of   Form&nbsp;S-3 under the Securities Act of 1933, as amended (the &#147;Securities   Act&#148;). The securities covered by this registration statement may be sold or   otherwise distributed separately or together with any other securities covered   by this registration statement.</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(2)</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">The registrant is hereby registering an   indeterminate amount of each identified class of securities up to a proposed   maximum aggregate offering price of $250,000,000, which may be offered from   time to time in unspecified amounts at unspecified prices. The registrant has   estimated the proposed maximum aggregate offering price solely for the   purpose of calculating the registration fee pursuant to   Rule&nbsp;457(o)&nbsp;under the Securities Act. Securities registered hereunder   may be sold separately, together or as units with other securities registered   hereunder. The securities registered hereunder include securities that may be   purchased by underwriters to cover over-allotments, if any.</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(3)</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Pursuant to Rule&nbsp;416 under the Securities   Act, this registration statement also covers any additional securities that   may be offered or issued in connection with any stock split, stock dividend   or similar transaction. Includes consideration to be received by the   registrant, if applicable, for registered securities that are issuable upon   exercise, conversion or exchange of other registered securities.</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(4)</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Consisting of some or all of the securities listed   above, in any combination, including common stock, preferred stock, warrants   and depositary shares.</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">(5)</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:8.0pt;">Pursuant to Rule&nbsp;415(a)(6)&nbsp;under the   Securities Act, the securities registered pursuant to the registration   statement include $48,805,097.42 of unsold securities previously registered   on the registrant&#146;s prospectus supplement dated May 19, 2016 to the   registrant&#146;s registration statement on Form&nbsp;S-3ASR filed on   December&nbsp;3, 2013 which became effective upon filing with the Securities   and Exchange Commission (File No.&nbsp;333-192640) (the &#147;Prior Registration   Statement&#148;). The Prior Registration Statement registered securities for a   proposed maximum aggregate offering price of $60,000,000, of which   $48,805,097.42 remain unsold. In connection with the filing of the Prior   Registration Statement, the registrant paid a registration fee of $5,657 in   respect of such unsold securities. In accordance with Question 212.24 of the   Securities and Exchange Commission, Division of Corporation Finance&#146;s   Compliance and Disclosure Interpretations regarding Securities Act Rules, the   registrant is not required to pay any additional fee with respect to the   $48,805,097.42 of unsold securities being included in this registration in   reliance on Rule&nbsp;415(a)(6), because such unsold securities (and   associated fees) are being moved from the Prior Registration Statement to   this registration statement. Accordingly, the registrant paid only the   registration fee of $23,318 attributable to the $201,194,902.58 of new   securities registered on this registration statement. Pursuant to   Rule&nbsp;415(a)(6)&nbsp;of the Securities Act, the $5,657 registration fee   previously paid by the registrant relating to the unsold securities included   on this registration statement will continue to be applied to such unsold   securities.</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="95%" valign="top" style="padding:0in 0in 0in 0in;width:95.68%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:4.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:5.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:5.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109559\16-22161-1\task8192442\22161-1-ba.htm',USER='109559',CD='Dec  2 16:37 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXPLANANTORY NOTE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This registration statement contains two prospectuses:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a base prospectus that covers the offering, issuance and sale by the registrant of its common stock, preferred stock, warrants, depositary shares and/or units up to a maximum aggregate offering price of $250,000,000; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>an at the market offering prospectus covering the offering, issuance and sale by the registrant of shares of the registrant&#146;s common stock up to a maximum aggregate offering price of $48,805,097 from time to time through Cantor Fitzgerald&nbsp;&amp; Co. acting as agent pursuant to the terms of a sales agreement between the registrant and Cantor Fitzgerald&nbsp;&amp; Co.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The at the market offering prospectus, or ATM prospectus, immediately follows the base prospectus.&#160; The common stock that may be offered, issued and sold under the ATM prospectus is included in the $250,000,000 of securities that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the sales agreement with Cantor Fitzgerald &amp; Co., any portion of the $48,805,097 included in the at the market offering prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $250,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108698\16-22161-1\task8192443\22161-1-bc.htm',USER='108698',CD='Dec  2 16:35 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">Subject to Completion, dated December&nbsp;2, 2016</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img border="0" width="137" height="43" src="g221611bei001.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$250,000,000</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common Stock<br> Preferred Stock<br> Warrants<br> Depositary Shares<br> Units</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc. may offer, issue and sell from time to time, together or separately, in one or more offerings, any combination of:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our common stock,</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our preferred stock, which we may issue in one or more series,</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>warrants,</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>depositary shares, and</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>units,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">up to a maximum aggregate offering price of $250,000,000.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus provides a general description of the securities we may offer.&#160; Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus (which includes an at-the-market offering prospectus). The prospectus supplement may also add, update or change information contained in this prospectus.&#160; You should read this prospectus and the accompanying prospectus supplement, as well as the documents incorporated or deemed incorporated by reference in this prospectus, carefully before you make your investment decision. Our common stock is traded on the NASDAQ Global Market under the symbol &#147;CLDX.&#148; On November 30, 2016, the last reported sale price of our common stock on the NASDAQ Global Market was $3.81 per share. You are urged to obtain current market quotations of the common stock. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus may not be used to sell securities unless accompanied by a prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may offer to sell these securities on a continuous or delayed basis, through agents, dealers or underwriters, or directly to purchasers. The prospectus supplement for each offering of securities will describe in detail the plan of distribution for that offering. If our agents or any dealers or underwriters are involved in the sale of the securities, the applicable prospectus supplement will set forth the names of the agents, dealers or underwriters and any applicable commissions or discounts. Our net proceeds from the sale of securities will also be set forth in the applicable prospectus supplement. For general information about the distribution of securities offered, please see &#147;Plan of Distribution&#148; in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Investing in our securities involves risks. Before making an investment decisions, you should carefully review the information contained in this prospectus under the heading &#147;Risk Factors&#148; beginning on page&nbsp;3 of this prospectus.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\105201\16-22161-1\task8190749\22161-1-be.htm',USER='105201',CD='Dec  1 15:25 2016' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION OR REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\105201\16-22161-1\task8190749\22161-1-be.htm',USER='105201',CD='Dec  1 15:25 2016' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="TableOfContents"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ABOUTTHISPROSPECTUS_093140" title="Click to goto ">ABOUT THIS PROSPECTUS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PROSPECTUSSUMMARY_093143">PROSPECTUS   SUMMARY</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#SPECIALNOTEREGARDINGFORWARDLOOKI_093150" title="Click to goto ">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RISKFACTORS_093152" title="Click to goto ">RISK FACTORS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RATIOSOFCOMBINEDFIXEDCHARGESANDP_093155" title="Click to goto ">RATIOS OF COMBINED FIXED CHARGES AND PREFERRED STOCK   DIVIDENDS TO EARNINGS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#USEOFPROCEEDS_093159" title="Click to goto ">USE OF PROCEEDS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DESCRIPTIONSOFSECURITIESWEMAYOFF_093205" title="Click to goto ">DESCRIPTIONS OF SECURITIES WE MAY&nbsp;OFFER</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DESCRIPTIONOFCOMMONSTOCK_093207" title="Click to goto ">DESCRIPTION OF COMMON STOCK</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DESCRIPTIONOFPREFERREDSTOCK_093213" title="Click to goto ">DESCRIPTION OF PREFERRED STOCK</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DESCRIPTIONOFWARRANTS_093438" title="Click to goto ">DESCRIPTION OF WARRANTS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DESCRIPTIONOFDEPOSITARYSHARES_094803" title="Click to goto ">DESCRIPTION OF DEPOSITARY SHARES</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DESCRIPTIONOFUNITS_094804" title="Click to goto ">DESCRIPTION OF UNITS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PLANOFDISTRIBUTION_094807" title="Click to goto ">PLAN OF DISTRIBUTION</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#LEGALMATTERS_094811" title="Click to goto ">LEGAL MATTERS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EXPERTS_094813" title="Click to goto ">EXPERTS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#WHEREYOUCANFINDMOREINFORMATION_094814" title="Click to goto ">WHERE YOU CAN FIND MORE INFORMATION</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#INCORPORATIONOFCERTAINDOCUMENTSB_094816" title="Click to goto ">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105924\16-22161-1\task8184571\22161-1-bg.htm',USER='105924',CD='Nov 24 19:10 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></b><a name="ABOUTTHISPROSPECTUS_093140"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus. You should read the registration statement and the accompanying exhibits for further information.&#160; The registration statement, including the exhibits and the documents incorporated or deemed incorporated herein by reference, can be read and are available to the public over the Internet at the SEC&#146;s website at <i>http://www.sec.gov</i> as described under the heading &#147;Where You Can Find More Information.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus provides you with a general description of the securities we may offer. Each time we sell securities pursuant to this prospectus, we will provide a prospectus supplement (which term includes, as applicable, the at-the-market offering prospectus filed with the registration statement of which this prospectus forms a part) containing specific information about the terms of a particular offering by us. That prospectus supplement may include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may add, update or change information in this prospectus. If the information in the prospectus is inconsistent with a prospectus supplement, you should rely on the information in that prospectus supplement. You should read both this prospectus and, if applicable, any prospectus supplement. See &#147;Where You Can Find More Information&#148; for more information.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any prospectus supplement. This prospectus and any prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus or any prospectus supplement is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any prospectus supplement is delivered or securities are sold on a later date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Unless this prospectus indicates otherwise or the context otherwise requires, the terms &#147;we,&#148; &#147;our,&#148; &#147;us,&#148; &#147;Celldex&#148; or the &#147;Company&#148; as used in this prospectus refer to Celldex Therapeutics,&nbsp;Inc. and its subsidiaries, except that such terms refer to only Celldex Therapeutics,&nbsp;Inc. and not its subsidiaries in the sections entitled &#147;Description of Common Stock,&#148; &#147;Description of Preferred Stock,&#148; &#147;Description of Warrants,&#148; &#147;Description of Depositary Shares,&#148; and &#147;Description of Units.&#148;</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS SUMMARY</font></b><a name="PROSPECTUSSUMMARY_093143"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are </font>a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Our drug candidates are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are using these technologies to develop targeted immunotherapeutics comprised of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our latest stage drug candidate, glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase&nbsp;2b study for the treatment of triple negative breast cancer and a Phase&nbsp;2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient&#146;s immune response against their cancer. We established proof of concept in a Phase&nbsp;1 study with varlilumab, which has allowed several combination studies to begin in</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="PB_1_092418_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bi.htm',USER='109512',CD='Dec  1 11:53 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">various indications. We also have a number of earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells, or APCs, for cancer indications, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, and CDX-014, an antibody drug conjugate targeting TIM-1. Our drug candidates address market opportunities for which we believe current therapies are inadequate or non-existent.&#160; As discussed below, we recently acquired Kolltan Pharmaceuticals,&nbsp;Inc. thereby expanding our pipeline of drug candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are building a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Our program assets provide us with the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Developments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On November&nbsp;29, 2016, we consummated the transactions contemplated by that certain Agreement and Plan of Merger dated as of November&nbsp;1, 2016 by and among Celldex, Kolltan Pharmaceuticals,&nbsp;Inc., a Delaware corporation, Connemara Merger Sub 1 Inc. a Delaware corporation and a wholly-owned subsidiary of Celldex&#160; and Connemara Merger Sub 2 LLC., a Delaware limited liability company and a wholly-owned subsidiary of Celldex. Upon consummation of the transactions, Kolltan became a wholly-owned subsidiary of Celldex.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prior to the merger, Kolltan was a privately-held clinical-stage company focused on the discovery and development of novel, antibody-based drug candidates targeting reception tyrosine kinases, or RTKs. Kolltan&#146;s programs include: (i)&nbsp;KTN0158, a humanized monoclonal antibody that is a potent inhibitor of KIT activation and receptor dimerization in tumor cells and mast cells, which is currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors (GIST); (ii)&nbsp;KTN3379, a human monoclonal antibody designed to block the activity of ErbB3 (HER3), which recently completed a Phase 1b study with combination cohorts where meaningful responses and stable disease were observed in cetuximab (Erbitux</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>) refractory patients in head and neck squamous cell carcinoma and in BRAF-mutant non-small cell lung cancer (NSCLC); and (iii)&nbsp;a multi-faceted TAM program, a broad antibody discovery effort underway to generate antibodies that modulate the TAM family of RTKs, comprised of Tyro3, AXL and MerTK, which are expressed on tumor-infiltrating macrophages, dendritic cells and some tumors. Research supports TAMs having broad application and potential across immuno-oncology and inflammatory diseases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the Merger Agreement, upon consummation of the transactions contemplated by the Merger Agreement, Kolltan&#146;s investors received, in exchange for their share and debt interests in Kolltan, an aggregate of 18,257,996 shares of Celldex&#146;s common stock with a calculated value of $62.5 million, based on the average closing price of Celldex&#146;s stock for the five trading day period ending on October&nbsp;28, 2016, the third calendar day prior to the date of the Merger Agreement, as adjusted downward pursuant to the terms of the Merger Agreement. The Merger Agreement provides that the number of shares that can be issued at the closing can be increased or decreased by no more than 5% in either direction based on the comparable average closing prices over the five trading days prior to the closing date.&#160; Therefore, because the average closing price of Celldex&#146;s stock over the five trading days prior to the closing date was higher than the comparable average closing prices over the five trading days prior to the date of the Merger Agreement, there was a full 5% downward adjustment in the number of shares issued at closing.&#160; In addition, following closing, certain officers of Kolltan will receive an aggregate of 437,901 shares of Celldex&#146;s common stock in lieu of cash severance obligations owed to them by Kolltan.&#160; In addition, in the event that certain specified preclinical and clinical development milestones related to Kolltan&#146;s development programs and/or Celldex&#146;s development programs and certain commercial milestones related to Kolltan&#146;s product candidates are achieved, Celldex will be required to pay Kolltan&#146;s stockholders milestone payments of up to $172.5 million, which milestone payments may be made, at Celldex&#146;s sole election, in cash, in shares of Celldex&#146;s common stock or a combination of both, subject to NASDAQ listing requirements and provisions of the Merger Agreement.&#160; The number of shares of Celldex common stock issued in connection with a milestone payment, if any, will be determined based on the average closing price per share of Celldex common stock for the five trading day period ending three calendar days prior to the achievement of such milestone. Pursuant to applicable NASDAQ listing rules, we are required to obtain stockholder approval of such issuances of our common stock to the extent that such issuances exceed 19.9% of our common stock outstanding prior to the merger.&#160; If we do not obtain stockholder approval of such common stock issuances, we may elect to pay the milestone consideration in cash to maintain compliance with applicable NASDAQ listing standards.&#160; We may still decide to pay cash even if we obtain stockholder approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corporate Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a Delaware corporation organized in 1983.&#160; Our principal executive offices are located at Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, New Jersey 08827 and our telephone number is (908) 200-7500.&#160; Our corporate website is www.celldex.com.&#160; The information on our website is not incorporated by reference into this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_092430_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bi.htm',USER='109512',CD='Dec  1 11:53 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></b><a name="SPECIALNOTEREGARDINGFORWARDLOOKI_093150"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as &#147;anticipate,&#148; &#147;estimate,&#148; &#147;plans,&#148; &#147;projects,&#148; &#147;continuing,&#148; &#147;ongoing,&#148; &#147;expects,&#148; &#147;management believes,&#148; &#147;we believe,&#148; &#147;we intend&#148; and similar words or phrases. Accordingly, these statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forward-looking statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management&#146;s expectations and assumptions at the time the statements are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the forward-looking statements for many reasons including the factors described in the section entitled &#147;Risk Factors&#148; in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made.&#160; We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in this prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RISK FACTORS</font></b><a name="RISKFACTORS_093152"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks and other information we include or incorporate by reference in this prospectus and any prospectus supplement. In particular, you should consider the risk factors under the heading &#147;Risk Factors&#148; included in our most recent Annual Report on Form&nbsp;10-K, or 10-K/A, as applicable, as may be revised or supplemented by our subsequent Quarterly Reports on Form&nbsp;10-Q or Current Reports on Form&nbsp;8-K, each of which are on file with the SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect our business operations. Additional risk factors may be included in a prospectus supplement relating to a particular offering of securities.&nbsp;Our business, financial condition or results of operations could be materially adversely affected by any of these risks.&nbsp;The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment.&nbsp;This prospectus is qualified in its entirety by these risk factors.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RATIOS OF COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS</font></b><a name="RATIOSOFCOMBINEDFIXEDCHARGESANDP_093155"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth our consolidated ratios of earnings to combined fixed charges and preferred stock dividends for the years ended December&nbsp;31, 2015, 2014, 2013, 2012 and 2011.&#160; We do not have any outstanding shares of preferred stock and therefore have not paid any preferred stock dividends.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_092458_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bi.htm',USER='109512',CD='Dec  1 11:53 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Ratios of Combined Fixed Charges and Preferred Stock Dividends to Earnings</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.82%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine months<br>   ended<br>   September<br>   30, 2016</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="69%" colspan="9" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:69.3%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Year&nbsp;ended&nbsp;December&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.82%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2016</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.34%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.82%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.52%;">
<p align="right" style="margin:0in 0in .0001pt 10.1pt;text-align:right;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp; Due to our losses from continuing operations for the nine months ended September 30, 2016 and for the years ended December&nbsp;31, 2015, 2014, 2013, 2012 and 2011 earnings were insufficient to cover fixed charges by $98.1 million, $129.5 million, $122.4 million, $81.4 million, $58.1 million, and $43.3 million, respectively.&nbsp; For this reason, no ratios are provided.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">USE OF PROCEEDS</font></b><a name="USEOFPROCEEDS_093159"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise provided in the applicable prospectus supplement to this prospectus used to offer specific securities, we expect to use the net proceeds from any offering of securities by us for general corporate purposes, which may include acquisitions, capital expenditures, investments, and the repayment, redemption or refinancing of all or a portion of any indebtedness or other securities outstanding at a particular time, to fund our operations until we receive FDA approval of our products and are able to commercialize our products and to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities in anticipation of FDA approval of our products.&#160; Pending the application of the net proceeds, we expect to invest the net proceeds in short-term, interest-bearing instruments with a maturity of three months or less at the date of purchase and consist primarily of investments in money market mutual funds with commercial banks and financial institutions or other investment-grade securities.&#160; Such investments may include depositing such net proceeds into, and maintaining cash balances with, financial institutions in excess of insured limits.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTIONS OF SECURITIES WE MAY&nbsp;OFFER</font></b><a name="DESCRIPTIONSOFSECURITIESWEMAYOFF_093205"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus contains summary descriptions of the common stock, preferred stock, warrants, depositary shares and units that we may offer and sell from time to time. The preferred stock may also be exchangeable for and/or convertible into shares of common stock or another series of preferred stock. When one or more of these securities are offered in the future, a prospectus supplement will explain the particular terms of the securities and the extent to which these general provisions may apply. These summary descriptions and any summary descriptions in the applicable prospectus supplement do not purport to be complete descriptions of the terms and conditions of each security and are qualified in their entirety by reference to our third restated certificate of incorporation, as amended, our by-laws and by applicable Delaware law and any other documents referenced in such summary descriptions and from which such summary descriptions are derived. If any particular terms of a security described in the applicable prospectus supplement differ from any of the terms described herein, then the terms described herein will be deemed superseded by the terms set forth in that prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may issue securities in book-entry form through one or more depositaries, such as The Depository Trust Company, Euroclear or Clearstream, named in the applicable prospectus supplement. Each sale of a security in book-entry form will settle in immediately available funds through the applicable depositary, unless otherwise stated. We will issue the securities only in registered form, without coupons, although we may issue the securities in bearer form if so specified in the applicable prospectus supplement. If any securities are to be listed or quoted on a securities exchange or quotation system, the applicable prospectus supplement will say so.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF COMMON STOCK</font></b><a name="DESCRIPTIONOFCOMMONSTOCK_093207"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of November 30, 2016 we are authorized to issue up to 297,000,000 shares of common stock, $.001 par value per share. As of November 30, 2016, approximately 119,507,692 shares of common stock were outstanding.&#160; All outstanding shares of our common stock are fully paid and non-assessable. Our common stock is listed on the NASDAQ Global Market under the symbol &#147;CLDX&#148;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_092822_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bi.htm',USER='109512',CD='Dec  1 11:53 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Dividends</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors may, out of funds legally available, at any regular or special meeting, declare dividends to the holders of shares of our common stock as and when they deem expedient, subject to the rights of holders of the preferred stock, if any.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Voting</font></i></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each share of common stock entitles the holders to one vote per share on all matters requiring a vote of the stockholders, including the election of directors. No holders of shares of common stock shall have the right to vote such shares cumulatively in any election for the board of directors.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Rights Upon Liquidation</font></i></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders of our common stock will be entitled to share equally in our assets available for distribution after payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in full.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Miscellaneous</font></i></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No holders of shares of our common stock shall have any preemptive rights to subscribe for, purchase or receive any shares of any class, whether now or hereafter authorized, or any options or warrants to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be issued, sold or offered for sale by Celldex.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Anti-Takeover Provisions</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain provisions in our third restated certificate of incorporation, as amended, and applicable Delaware corporate, as well as our shareholder rights agreement, may have the effect of discouraging a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders receiving a substantial premium over the current market price of our shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of our corporation. These provisions may also tend to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to elect even a single director.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Computershare Trust Company, N.A. is presently the transfer agent and registrar for our common stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF PREFERRED STOCK</font></b><a name="DESCRIPTIONOFPREFERREDSTOCK_093213"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At November 30, 2016, the Company had authorized preferred stock comprised of 3,000,000 shares of Class&nbsp;C Preferred Stock of which 350,000 shares has been designated as Class&nbsp;C-1 Junior Participating Cumulative Preferred Stock, the terms of which are to be determined by our Board of Directors. As of November 30, 2016, there was no preferred stock outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Class&nbsp;C Preferred Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This section describes the general terms and provisions of our Class&nbsp;C Preferred Stock. The applicable prospectus supplement will describe the specific terms of the shares of preferred stock offered through that prospectus supplement, as well as any general terms described in this section that will not apply to those shares of preferred stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our board of directors has been authorized to provide for the issuance of the 2,650,000 unissued and undesignated shares of our Class&nbsp;C Preferred Stock&nbsp;In general, our third restated certificate of incorporation, as amended, authorizes our board of directors to issue new shares of our common stock or preferred stock without further stockholder action, provided that there are sufficient authorized shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="PB_5_092833_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bi.htm',USER='109512',CD='Dec  1 11:53 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to each series of our Class&nbsp;C Preferred Stock, our board of directors has the authority to fix the following terms:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the designation of the series;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the number of shares within the series;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether dividends are cumulative and, if cumulative, the dates from which dividends are cumulative;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the rate of any dividends, any conditions upon which dividends are payable, and the dates of payment of dividends;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under &#147;Description of Depositary Shares&#148;;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the shares are redeemable, the redemption price and the terms of redemption;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the amount payable to you for each share you own if we dissolve or liquidate;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the shares are convertible or exchangeable, the price or rate of conversion or exchange, and the applicable terms and conditions;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any restrictions on issuance of shares in the same series or any other series;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>voting rights applicable to the series of preferred stock; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any other rights, priorities, preferences, restrictions or limitations of such series.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The rights with respect to any shares of our Class&nbsp;C Preferred Stock will be subordinate to the rights of our general creditors. Shares of our Class&nbsp;C Preferred Stock that we issue in accordance with their terms will be fully paid and nonassessable, and will not be entitled to preemptive rights unless specified in the applicable prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to issue preferred stock, or rights to purchase such shares, could discourage an unsolicited acquisition proposal. For example, we could impede a business combination by issuing a series of preferred stock containing class voting rights that would enable the holders of such preferred stock to block a business combination transaction. Alternatively, we could facilitate a business combination transaction by issuing a series of preferred stock having sufficient voting rights to provide a required percentage vote of the stockholders. Additionally, under certain circumstances, our issuance of preferred stock could adversely affect the voting power of the holders of our common stock. Although our board of directors is required to make any determination to issue any preferred stock based on its judgment as to the best interests of our stockholders, our board of directors could act in a manner that would discourage an acquisition attempt or other transaction that some, or a majority, of our stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over prevailing market prices of such stock. Our board of directors does not at present intend to seek stockholder approval prior to any issuance of currently authorized stock, unless otherwise required by law or applicable stock exchange requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Terms of the Preferred Stock That We May&nbsp;Offer and Sell to You</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We summarize below some of the provisions that will apply to the preferred stock that we may offer to you unless the applicable prospectus supplement provides otherwise. This summary may not contain all information that is important to you. You should read the prospectus supplement, which will contain additional information and which may update or change some of the information below. Prior to the issuance of a new series of preferred stock, we will further amend our third restated certificate of incorporation, as amended, designating the stock of that series and the terms of that series. We will file a copy of the certificate of designation that contains the terms of each new series</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="PB_6_092922_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bi.htm',USER='109512',CD='Dec  1 11:53 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of preferred stock with the SEC each time we issue a new series of preferred stock. Each certificate of designation will establish the number of shares included in a designated series and fix the designation, powers, privileges, preferences and rights of the shares of each series as well as any applicable qualifications, limitations or restrictions. You should refer to the applicable certificate of designation as well as our third restated certificate of incorporation, as amended, before deciding to buy shares of our preferred stock as described in the applicable prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our board of directors has the authority, without further action by the stockholders, to issue preferred stock in one or more series and to fix the number of shares, dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any other rights, preferences, privileges and restrictions applicable to each such series of preferred stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of any preferred stock could adversely affect the rights of the holders of common stock and, therefore, reduce the value of the common stock. The ability of our board of directors to issue preferred stock could discourage, delay or prevent a takeover or other corporate action.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The terms of any particular series of preferred stock will be described in the prospectus supplement relating to that particular series of preferred stock, including, where applicable:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the designation, stated value and liquidation preference of such preferred stock;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the number of shares within the series;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the offering price;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and whether such dividends shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under &#147;Description of Depositary Shares&#148;);</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any redemption or sinking fund provisions;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the amount that shares of such series shall be entitled to receive in the event of our liquidation, dissolution or winding-up;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the terms and conditions, if any, on which shares of such series shall be convertible or exchangeable for shares of our stock of any other class or classes, or other series of the same class;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the voting rights, if any, of shares of such series; the status as to reissuance or sale of shares of such series redeemed, purchased or otherwise reacquired, or surrendered to us on conversion or exchange;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the conditions and restrictions, if any, on the payment of dividends or on the making of other distributions on, or the purchase, redemption or other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior to the shares of such series as to dividends or upon liquidation;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the conditions and restrictions, if any, on the creation of indebtedness by us or by any subsidiary, or on the issuance of any additional stock ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any additional dividend, liquidation, redemption, sinking or retirement fund and other rights, preferences, privileges, limitations and restrictions of such preferred stock.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="PB_7_093428_2553"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The description of the terms of a particular series of preferred stock in the applicable prospectus supplement will not be complete. You should refer to the applicable amendment to our third restated certificate of incorporation, as amended, for complete information regarding a series of preferred stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The preferred stock will, when issued against payment of the consideration payable therefor, be fully paid and nonassessable. Unless otherwise specified in the applicable prospectus supplement, each series of preferred stock will, upon issuance, rank senior to the common stock and on a parity in all respects with each other outstanding series of preferred stock. The rights of the holders of our preferred stock will be subordinate to that of our general creditors.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF WARRANTS</font></b><a name="DESCRIPTIONOFWARRANTS_093438"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We summarize below some of the provisions that will apply to the warrants unless the applicable prospectus supplement provides otherwise. This summary may not contain all information that is important to you. The complete terms of the warrants will be contained in the applicable warrant certificate and warrant agreement. These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the warrant certificate and the warrant agreement. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may issue, together with other securities or separately, warrants to purchase common stock, preferred stock or other securities. We may issue the warrants under warrant agreements to be entered into between us and a bank or trust company, as warrant agent, all as set forth in the applicable prospectus supplement. The warrant agent would act solely as our agent in connection with the warrants of the series being offered and would not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The applicable prospectus supplement will describe the following terms, where applicable, of warrants in respect of which this prospectus is being delivered:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the title of the warrants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the designation, amount and terms of the securities for which the warrants are exercisable and the procedures and conditions relating to the exercise of such warrants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of warrants issued with each such security;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the price or prices at which the warrants will be issued;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the aggregate number of warrants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the price or prices at which the securities purchasable upon exercise of the warrants may be purchased;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will be separately transferable;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if applicable, a discussion of the material U.S. federal income tax considerations applicable to the warrants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="PB_8_093520_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the date on which the right to exercise the warrants shall commence and the date on which the right shall expire;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if applicable, the maximum or minimum number of warrants which may be exercised at any time;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the identity of the warrant agent;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any mandatory or optional redemption provision;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the warrants are to be issued in registered or bearer form;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the warrants are extendible and the period or periods of such extendibility;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>information with respect to book-entry procedures, if any; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any other terms of the warrants.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding-up or to exercise voting rights, if any.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exercise of Warrants</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each warrant will entitle the holder thereof to purchase such number of shares of common stock or preferred stock or other securities at the exercise price as will in each case be set forth in, or be determinable as set forth in, the applicable prospectus supplement. Warrants may be exercised at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be exercised as set forth in the applicable prospectus supplement relating to the warrants offered thereby. Upon receipt of payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants represented by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Enforceability of Rights of Holders of Warrants</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, that holder&#146;s warrant(s).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Modification of the Warrant Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The warrant agreement will permit us and the warrant agent, without the consent of the warrant holders, to supplement or amend the agreement in the following circumstances:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to cure any ambiguity;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="PB_9_093530_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to correct or supplement any provision which may be defective or inconsistent with any other provisions; or</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to add new provisions regarding matters or questions that we and the warrant agent may deem necessary or desirable and which do not adversely affect the interests of the warrant holders.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF DEPOSITARY SHARES</font></b><a name="DESCRIPTIONOFDEPOSITARYSHARES_094803"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We summarize below some of the provisions that will apply to depositary shares unless the applicable prospectus supplement provides otherwise. This summary may not contain all information that is important to you. The complete terms of the depositary shares will be contained in the depositary agreement and depositary receipt applicable to any depositary shares. These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the depositary agreement and the depositary receipt. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may, at our option, elect to offer fractional or multiple shares of common stock or preferred stock, rather than single shares of common stock or preferred stock (to be set forth in the prospectus supplement relating to such depositary shares). In the event we elect to do so, depositary receipts evidencing depositary shares will be issued to the public.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The shares of common stock or any class or series of preferred stock represented by depositary shares will be deposited under a deposit agreement among us, a depositary selected by us, and the holders of the depositary receipts. The depositary will be a bank or trust company having its principal office in the United States and having a combined capital and surplus of at least $50,000,000. Subject to the terms of the deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of common stock or preferred stock represented by such depositary share, to all the rights and preferences of the shares of common stock or preferred stock represented by the depositary share, including dividend, voting, redemption and liquidation rights.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the fractional shares of common stock or the related class or series of preferred shares in accordance with the terms of the offering described in the related prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF UNITS</font></b><a name="DESCRIPTIONOFUNITS_094804"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the terms of the unit agreement governing the units;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>United States federal income tax considerations relevant to the units; and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="PB_10_093542_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>whether the units will be issued in fully registered global form.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their entirety by reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. The forms of the unit agreements and other documents relating to a particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to you.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></b><a name="PLANOFDISTRIBUTION_094807"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants and subscriptions. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>at a fixed price or prices, which may be changed;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>at market prices prevailing at the time of sale;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>at prices related to such prevailing market prices;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>at varying prices determined at the time of sale; or</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>at negotiated prices.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A prospectus supplement or supplements will describe the terms of the offering of the securities, including:</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the name or names of the underwriters, dealers or agents participating in the offering, if any;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the purchase price of the securities sold by us to any underwriter or dealer and the net proceeds we expect to receive from the offering;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any over-allotment options under which underwriters may purchase additional securities from us;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any agency fees or underwriting discounts or commissions and other items constituting agents&#146; or underwriters&#146; compensation;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any public offering price;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any discounts or concessions allowed or reallowed or paid to dealers; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any securities exchange or market on which the securities may be listed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="PB_11_093610_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or commissions or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may sell securities directly or through agents we designate from time to time.&#160; We will name any agent involved in the offering and sale of securities and we will describe any commissions and other compensation we will pay the agent in the prospectus supplement.&#160; Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities.&#160; Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents or underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is currently no market for any of the offered securities, other than our common stock which is listed on the NASDAQ Global Market. We have no current plans for listing of the preferred stock, warrants or subscription rights on any securities exchange or quotation system; any such listing with respect to any particular preferred stock, warrants or subscription rights will be described in the applicable prospectus supplement or other offering materials, as the case may be.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act.&#160; Overallotment involves sales in excess of the offering size, which create a short position.&#160; Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.&#160; Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions.&#160; Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions.&#160; Those activities may cause the price of the securities to be higher than it would otherwise be.&#160; If commenced, the underwriters may discontinue any of the activities at any time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any agents and underwriters who are qualified market makers on the NASDAQ Global Market may engage in passive market making transactions in the securities on the NASDAQ Global Market in accordance with Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities.&#160; Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers.&#160; In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LEGAL MATTERS</font></b><a name="LEGALMATTERS_094811"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us by Lowenstein Sandler LLP, New York, New York. If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus are passed upon by counsel for the </font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="PB_12_093916_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXPERTS</font></b><a name="EXPERTS_094813"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form&nbsp;10-K/A for the year ended December&nbsp;31, 2015 have been so incorporated in reliance on the report&nbsp;of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></b><a name="WHEREYOUCANFINDMOREINFORMATION_094814"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act of which this prospectus forms a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of certain agreements or documents that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is qualified in all respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at <i>http://www.sec.gov</i>. The SEC&#146;s website contains reports, proxy statements and other information regarding issuers, such as Celldex Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room, located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room.&nbsp;We make available free of charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, Proxy Statements on Schedule 14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. Our website address is <i>http://www.celldextherapeutics.com</i>. Please note that our website address is provided as an inactive textual reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font></b><a name="INCORPORATIONOFCERTAINDOCUMENTSB_094816"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information we have filed with the SEC, which means that we can disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by reference into this prospectus the information contained in the documents listed below, which is considered to be a part of this prospectus:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Our Annual Report on Form&nbsp;10-K/A for the fiscal year ended December&nbsp;31, 2015, filed with the SEC on February&nbsp;25, 2016;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2016, June&nbsp;30, 2016 and September&nbsp;30, 2016, filed on May&nbsp;5, 2016, August&nbsp;8, 2016 and November&nbsp;7, 2016, respectively;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Our Current Reports on Form&nbsp;8-K filed with the SEC on February&nbsp;23, 2016, March&nbsp;7, 2016, May&nbsp;19, 2016, June&nbsp;9, 2016, August&nbsp;11, 2016, November&nbsp;1, 2016 and November&nbsp;29, 2016 (in each case, not including any information furnished under Items 2.02 or 7.01 of Form&nbsp;8-K, including the related exhibits, which information is not incorporated by reference herein);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="PB_13_093934_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;21, 2016 (other than the portions thereof which are furnished and not filed); and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The description of our common stock contained in our Registration Statement on Form&nbsp;8-A, filed on November&nbsp;8, 2004, as amended by Form&nbsp;8-A/A filed on October&nbsp;22, 2007 and March&nbsp;7, 2008.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act (a)&nbsp;after the initial filing date of the registration statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold. The most recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this prospectus, commencing on the date on which the document is filed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item 2.02 or 7.01 of Form&nbsp;8-K.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by reference other than exhibits to those documents.&#160; Requests should be addressed to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Perryville III Building, 53 Frontage Road, Suite&nbsp;220,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hampton, New Jersey 08827</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(908) 200-7500</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="PB_14_094006_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bk.htm',USER='109512',CD='Dec  1 12:02 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">SUBJECT TO COMPLETION, DATED DECEMBER 2, 2016</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS</font></b><a name="PROSPECTUS_121014"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img border="0" width="137" height="43" src="g221611bmi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:14.0pt;font-weight:bold;">Up to&nbsp;$48,805,097</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:14.0pt;font-weight:bold;">Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have entered into a Controlled Equity Offering</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font>&nbsp;Sales Agreement, or sales agreement, with Cantor&nbsp;Fitzgerald&nbsp;&amp; Co., or Cantor Fitzgerald, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $60 million from time to time through Cantor&nbsp;Fitzgerald acting as sales agent. As of December 2, 2016, we had issued and sold shares of our common stock having an aggregate offering price of $11,194,903 pursuant to our prior registration statement on Form S-3 (File No. 333-192640).&#160; Accordingly, we may issue and sell additional shares of our common stock having an aggregate offering price of up to $48,805,097 pursuant to this prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our common stock is traded on the NASDAQ Global Market, or NASDAQ, under the symbol &#147;CLDX&#148;. On November 30, 2016, the last reported sales price of our common stock on NASDAQ was $3.81 per share.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an &#147;at the market offering&#148; as defined in Rule&nbsp;415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Cantor Fitzgerald is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cantor&nbsp;Fitzgerald and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cantor Fitzgerald will be entitled to compensation at a fixed commission rate equal to 3.0% of the gross sales price per share sold. In connection with the sale of our common stock on our behalf, Cantor&nbsp;Fitzgerald will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Investing in our common stock involves risks. Before buying any shares, you should read the discussion of material risks of investing in our common stock in &#147;<u>Risk Factors</u>&#148; beginning on page&nbsp;ATM-5 of this prospectus supplement, and in the risks discussed in the documents incorporated by reference in this prospectus supplement and accompanying prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement and accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img border="0" width="219" height="77" src="g221611bmi002.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;, 2016.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109512\16-22161-1\task8190449\22161-1-bm.htm',USER='109512',CD='Dec  1 12:32 2016' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PROSPECTUS_121014" title="Click to goto "><b>Prospectus</b></a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ABOUTTHISPROSPECTUSSUPPLEMENT_124607" title="Click to goto ">ABOUT THIS PROSPECTUS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-1</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PROSPECTUSSUPPLEMENTSUMMARY_073003" title="Click to goto ">PROSPECTUS SUMMARY</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-2</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RISKFACTORS_124946" title="Click to goto ">RISK FACTORS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-5</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#SPECIALNOTEREGARDINGFORWARDLOOKI_124951" title="Click to goto ">SPECIAL NOTE REGARDING FORWARD-LOOKING   STATEMENTS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-7</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#USEOFPROCEEDS_124956" title="Click to goto ">USE OF PROCEEDS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-9</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#MARKETPRICEFOROURCOMMONSTOCK_125338" title="Click to goto ">MARKET PRICE FOR OUR COMMON STOCK</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-10</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DILUTION_125339" title="Click to goto ">DILUTION</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-11</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PLANOFDISTRIBUTION_125343" title="Click to goto ">PLAN OF DISTRIBUTION</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-12</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#LEGALMATTERS_125345" title="Click to goto ">LEGAL MATTERS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-13</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#EXPERTS_125346" title="Click to goto ">EXPERTS</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-13</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#WHEREYOUCANFINDMOREINFORMATION_125348" title="Click to goto ">WHERE YOU CAN FIND MORE INFORMATION</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-13</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#INCORPORATIONOFDOCUMENTSBYREFERE_125349" title="Click to goto ">INCORPORATION OF DOCUMENTS BY REFERENCE</a></font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-13</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107899\16-22161-1\task8184706\22161-1-bo.htm',USER='107899',CD='Nov 25 01:10 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></b><a name="ABOUTTHISPROSPECTUSSUPPLEMENT_124607"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><a name="PB_1_221239_6193"></a><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. Under the shelf registration process, we may offer and sell shares of our common stock having an aggregate offering price of up to $48,805,097 from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of offering. This prospectus is deemed a prospectus supplement to the base prospectus contained in the registration statement of which this prospectus forms a part.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus. You should read the registration statement and the accompanying exhibits for further information.&nbsp; The registration statement, including the exhibits and the documents incorporated or deemed incorporated herein by reference, can be read and are available to the public over the Internet at the SEC&#146;s website at&nbsp;<i>http://www.sec.gov</i>&nbsp;as described under the heading &#147;Where You Can Find More Information.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus describes the specific terms of the common stock we are offering and also adds to, and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference into this prospectus - the statement in the document having the later date modifies or supersedes the earlier statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should rely only on the information contained in, or incorporated by reference into this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Cantor Fitzgerald&nbsp;&amp; Co., or Cantor, has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Cantor is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for the person to make an offer or solicitation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Unless this prospectus indicates otherwise or the context otherwise requires, the terms &#147;we,&#148; &#147;our,&#148; &#147;us,&#148; &#147;Celldex&#148; or the &#147;Company&#148; as used in this prospectus refer to Celldex Therapeutics,&nbsp;Inc. and its subsidiaries</font>.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>1<a name="PB_1_104525_7533"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-1',FILE='C:\jms\105201\16-22161-1\task8190749\22161-1-bq.htm',USER='105201',CD='Dec  1 15:28 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS SUMMARY</font></b><a name="PROSPECTUSSUPPLEMENTSUMMARY_073003"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus.&#160; Because this is only a summary, however, it does not contain all of the information that may be important to you.&#160; You should carefully read this prospectus, including the documents incorporated by reference, which are described under &#147;Incorporation of Documents by Reference&#148; and &#147;Where You Can Find More Information&#148; in this prospectus.&#160; You should also carefully consider the matters discussed in the section titled &#147;Risk Factors&#148; in this prospectus and in other periodic reports incorporated by reference herein.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Our Company</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><a name="PB_2_221339_7056"></a><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are </font>a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Our drug candidates are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are using these technologies to develop targeted immunotherapeutics comprised of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our latest stage drug candidate, glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase&nbsp;2b study for the treatment of triple negative breast cancer and a Phase&nbsp;2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient&#146;s immune response against their cancer. We established proof of concept in a Phase&nbsp;1 study with varlilumab, which has allowed several combination studies to begin in various indications. We also have a number of earlier stage drug candidates in clinical development, including CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells, or APCs, for cancer indications, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, and CDX-014, an antibody drug conjugate targeting TIM-1. Our drug candidates address market opportunities for which we believe current therapies are inadequate or non-existent.&#160; As discussed below, we recently acquired Kolltan Pharmaceuticals,&nbsp;Inc. thereby expanding our pipeline of drug candidates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are building a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Our program assets provide us with the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Developments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">On November&nbsp;29, 2016, we consummated the transactions contemplated by that certain Agreement and Plan of Merger dated as of November&nbsp;1, 2016 by and among Celldex, Kolltan Pharmaceuticals,&nbsp;Inc., a Delaware corporation, Connemara Merger Sub 1 Inc. a Delaware corporation and a wholly-owned subsidiary of Celldex &#160;and Connemara Merger Sub 2 LLC., a Delaware limited liability company and a wholly-owned subsidiary of Celldex.</font>  </font>Upon consummation of the transactions, Kolltan became a wholly-owned subsidiary of Celldex.&#160; </p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prior to the merger, Kolltan was a privately-held clinical-stage company focused on the discovery and development of novel, antibody-based drug candidates targeting reception tyrosine kinases, or RTKs. Kolltan&#146;s programs include: (i)&nbsp;KTN0158, a humanized monoclonal antibody that is a potent inhibitor of KIT activation and receptor dimerization in tumor cells and mast cells, which is currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors (GIST); (ii)&nbsp;KTN3379, a human monoclonal antibody designed to block the activity of ErbB3 (HER3), which recently completed a Phase 1b study with combination cohorts where meaningful responses and stable disease were observed in cetuximab (Erbitux</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>) refractory patients in head and neck squamous cell carcinoma and in BRAF-mutant non-small cell lung cancer (NSCLC); and (iii)&nbsp;a multi-faceted TAM program, a broad antibody discovery effort underway to generate antibodies that modulate the TAM family of RTKs, comprised of Tyro3, AXL and MerTK, which are expressed on tumor-infiltrating macrophages, dendritic cells and some tumors. Research supports TAMs having broad application and potential across immuno-oncology and inflammatory diseases.</p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>2<a name="PB_2_105302_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-2',FILE='C:\jms\105201\16-22161-1\task8190749\22161-1-bq.htm',USER='105201',CD='Dec  1 15:28 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the Merger Agreement, upon consummation of the transactions contemplated by the Merger Agreement, Kolltan&#146;s investors received, in exchange for their share and debt interests in Kolltan, an aggregate of 18,257,996 shares of Celldex&#146;s common stock with a calculated value of $62.5 million, based on the average closing price of Celldex&#146;s stock for the five trading day period ending on October 28, 2016, the third calendar day prior to the date of the Merger Agreement, as adjusted downward pursuant to the terms of the Merger Agreement. The Merger Agreement provides that the number of shares that can be issued at the closing can be increased or decreased by no more than 5% in either direction based on the comparable average closing prices over the five trading days prior to the closing date.&#160; Therefore, because the average closing price of Celldex&#146;s stock over the five trading days prior to the closing date was higher than the comparable average closing prices over the five trading days prior to the date of the Merger Agreement, there was a full 5% downward adjustment in the number of shares issued at closing.&#160; In addition, following closing, certain officers of Kolltan will receive an aggregate of 437,901 shares of Celldex&#146;s common stock in lieu of cash severance obligations owed to them by Kolltan.&#160; In addition, in the event that certain specified preclinical and clinical development milestones related to Kolltan&#146;s development programs and/or Celldex&#146;s development programs and certain commercial milestones related to Kolltan&#146;s product candidates are achieved, Celldex will be required to pay Kolltan&#146;s stockholders milestone payments of up to $172.5 million, which milestone payments may be made, at Celldex&#146;s sole election, in cash, in shares of Celldex&#146;s common stock or a combination of both, subject to NASDAQ listing requirements and provisions of the Merger Agreement.&#160; The number of shares of Celldex common stock issued in connection with a milestone payment, if any, will be determined based on the average closing price per share of Celldex common stock for the five trading day period ending three calendar days prior to the achievement of such milestone. Pursuant to applicable NASDAQ listing rules, we are required to obtain stockholder approval of such issuances of our common stock to the extent that such issuances exceed 19.9% of our common stock outstanding prior to the merger.&#160; If we do not obtain stockholder approval of such common stock issuances, we may elect to pay the milestone consideration in cash to maintain compliance with applicable NASDAQ listing standards.&#160; We may still decide to pay cash even if we obtain stockholder approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corporate Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a Delaware corporation organized in 1983.&#160; Our principal executive offices are located at Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, New Jersey 08827 and our telephone number is (908) 200-7500.&#160; Our corporate website is www.celldex.com.&#160; The information on our website is not incorporated by reference into this prospectus.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>3<a name="PB_3_105334_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-3',FILE='C:\jms\105201\16-22161-1\task8190749\22161-1-bq.htm',USER='105201',CD='Dec  1 15:28 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Offering</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common stock offered by us</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares of our common stock having an aggregate   offering price of up to $48,805,097.</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common   stock to be outstanding after this offering </font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Up to 114,058,558 shares, assuming sales at a price   of $3.81 per share, which was the closing price of our common stock on The   NASDAQ Global Market, or NASDAQ, on November 30, 2016. The actual number of   shares issued will vary depending on the sales price under this offering. </font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Manner of offering </font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;At the market offering&#148; that may be made from time   to time through our sales agent, Cantor Fitzgerald&nbsp;&amp; Co. See &#147;Plan   of Distribution&#148; beginning on page&nbsp;ATM-15 of this prospectus. </font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of Proceeds </font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently intend to use the net proceeds from   this offering for working capital and other general corporate purposes.&nbsp; See &#147;Use of Proceeds&#148; on page&nbsp;S-12 of this   prospectus. </font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risk Factors </font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investing in our common stock involves a high degree   of risk. See &#147;Risk Factors&#148; beginning on page&nbsp;ATM-8 of this prospectus   and under similar headings in the other documents that are filed after the   date hereof and incorporated by reference in this prospectus for a discussion   of factors to consider before deciding to purchase shares of our common   stock. </font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NASDAQ Global Market symbol </font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="60%" valign="top" style="padding:0in 0in 0in 0in;width:60.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;CLDX&#148; </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The total number of shares of common stock to be outstanding immediately after this offering is based on 101,248,821&nbsp;shares of common stock issued and outstanding as of September 30, 2016, which does not include the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.5pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>10,150,598 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $11.26 per share as of September 30, 2016;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>3,641,582 shares available for future issuance under our equity compensation plans as of September 30, 2016, and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>18,695,897 shares issued in connection with closing of the Kolltan acquisition on November 29, 2016.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise stated, all information in this prospectus:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.5pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>assumes no exercise of outstanding options to purchase common stock and no issuance of shares available for future issuance under our equity compensation plans; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.5pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>reflects all currency in U.S. dollars.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>4<a name="PB_4_110217_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-4',FILE='C:\jms\105201\16-22161-1\task8190749\22161-1-bq.htm',USER='105201',CD='Dec  1 15:28 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RISK FACTORS</font></b><a name="RISKFACTORS_124946"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">An investment in our securities involves a high degree of risk.&#160; You should carefully consider the risks described under &#147;Risk Factors&#148; in this prospectus and our Annual Report on Form&nbsp;10-K/A for the year ended December&nbsp;31, 2015, respectively, as updated by any other document that we subsequently file with the Securities and Exchange Commission and that is incorporated by reference into this prospectus, as well as the risks described below and all of the other information contained in this prospectus, and incorporated by reference into this prospectus, including our financial statements and related notes, before investing in our securities.&#160; These risks and uncertainties are not the only ones facing us and there may be additional matters that we are unaware of or that we currently consider immaterial.&#160; All of these could adversely affect our business, business prospects, cash flow, results of operations and financial condition.&#160; In such case, the trading price of our common stock could decline, and you could lose all or part of your investment in our common stock.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to this Offering</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we have not designated the amount of net proceeds received by us from this offering to be used for any particular purpose, our management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering.&#160; Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">You may experience immediate and substantial dilution in the book value per share of the common stock you purchase.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because the price per share of our common stock being offered may be higher than the book value per share of our common stock, you may suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering.&#160; See the section entitled &#147;Dilution&#148; below for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.&#160; In addition, we have a significant number of options and restricted stock outstanding.&#160; If the holders of these securities exercise them or become vested in them, as applicable, you may incur further dilution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">You may experience future dilution as a result of future equity offerings or if we issue shares to former Kolltan stockholders upon achievement of certain specified milestones.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </font>In addition, pursuant to the terms of the merger agreement between Kolltan and us, in the event that certain specified preclinical and clinical development milestones related to Kolltan&#146;s development programs and/or Celldex&#146;s development programs and certain commercial milestones related to Kolltan&#146;s product candidates are achieved, we will be required to pay Kolltan&#146;s former stockholders milestone payments of up to $172.5 million, which milestone payments may be made, at our sole election, in cash, in shares of our common stock or a combination of both, subject to NASDAQ listing requirements and provisions of the Merger Agreement.&#160; As a result, we may issue additional shares of our common stock having a value of up to $172.5 million if the specified preclinical and clinical development milestones for the Celldex programs and the Kolltan programs and the commercial milestones for the Kolltan programs are achieved, which would result in further dilution to our stockholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Sales of a substantial number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We have agreed, without the prior written consent of Cantor Fitzgerald&nbsp;&amp; Co. and subject to certain exceptions set forth in the sales agreement, not to sell or otherwise dispose of any common stock or securities convertible into or exchangeable for shares of common stock, warrants or any rights to purchase or acquire common stock during the period beginning on the fifth trading day immediately prior to the delivery of any placement notice delivered by us to Cantor Fitzgerald&nbsp;&amp; Co. and ending on the fifth trading day immediately following the final settlement date with respect to the shares sold pursuant to such notice. We have further agreed, subject to certain exceptions set forth in the sales agreement, not to sell or otherwise dispose of any common stock or securities convertible into or exchangeable for shares of common stock, warrants or any rights to purchase or acquire common stock in any other &#147;at-the-market&#148; or continuous equity transaction prior to the termination of the sales agreement with Cantor Fitzgerald&nbsp;&amp; Co. Therefore, it is possible that we could issue and sell additional shares of our common stock in the public markets. We cannot predict the effect that future sales of our common stock would have on the market price of our common stock</font>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Our share price has been and could remain volatile.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The market price of our common stock has historically experienced and may continue to experience significant volatility. From January&nbsp;2014 through November 30, 2016, the market price of our common stock has fluctuated from a high of $33.33 per share in the first quarter of 2014, to a low of $2.85 per share in the fourth quarter of 2016. Our progress in developing and commercializing our</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>5<a name="PB_5_112635_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-5',FILE='C:\JMS\109512\16-22161-1\task8190639\22161-1-bs.htm',USER='109512',CD='Dec  1 13:59 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock, especially if those sales are made during a short period of time, those sales could adversely affect the market price of our common stock and could impair our ability to raise capital. In addition, in recent years, the stock market has experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in substantial costs and diversion of management&#146;s attention and resources and could harm our stock price, business, prospects, results of operations and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never declared or paid cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>6<a name="PB_6_112635_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-6',FILE='C:\JMS\109512\16-22161-1\task8190639\22161-1-bs.htm',USER='109512',CD='Dec  1 13:59 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></b><a name="SPECIALNOTEREGARDINGFORWARDLOOKI_124951"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus and the documents incorporated by reference herein contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&#160; Forward-looking statements represent our management&#146;s judgment regarding future events.&#160; In many cases, you can identify forward- looking statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;intend,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other words of similar import, although some forward-looking statements are expressed differently.&#160; All statements other than statements of historical fact included in this prospectus and the documents incorporated by reference herein regarding our financial position, business strategy and plans or objectives for future operations are forward-looking statements.&#160; Without limiting the broader description of forward-looking statements above, we specifically note that statements regarding potential drug candidates, their potential therapeutic effect, the possibility of obtaining regulatory approval, our expected timing for completing clinical trials and clinical trial milestones for our drug candidates, our ability or the ability of our collaborators to manufacture and sell any products, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate or to discover new drugs in the future are all forward-looking in nature.&#160; We cannot guarantee the accuracy of forward-looking statements, and you should be aware that results and events could differ materially and adversely from those described in the forward-looking statements due to a number of factors, including:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to successfully complete research and further development, including animal, preclinical and clinical studies, and, if we obtain regulatory approval, commercialization of glembatumumab vedotin and other drug candidates and the growth of the markets for those drug candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to raise sufficient capital to fund our clinical studies and to meet our long-term liquidity needs, on terms acceptable to us, or at all. If we are unable to raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or part of our business;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to negotiate strategic partnerships, where appropriate, for our programs, which may include, glembatumumab vedotin and varlilumab;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font>&#160;&#160;&#160;&#160;&#160; our ability to successfully integrate our and Kolltan&#146;s businesses and to operate the combined business efficiently;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font>&#160;&#160;&#160;&#160;&#160; our ability to realize the anticipated benefits from the acquisition of Kolltan;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to manage multiple clinical trials for a variety of drug candidates at different stages of development;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the cost, timing, scope and results of ongoing safety and efficacy trials of glembatumumab vedotin, and other preclinical and clinical testing;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the cost, timing, and uncertainty of obtaining regulatory approvals for our drug candidates;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the availability, cost, delivery and quality of clinical management services provided by our clinical research organization partners;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, suppliers and partners, who may be the sole source of supply;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to develop technological capabilities, including identification of novel and clinically important targets, exploiting our existing technology platforms to develop new product candidates and expand our focus to broader markets for our existing targeted immunotherapeutics;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to adapt our proprietary antibody-targeted technology, or APC Targeting Technology&#153;, to develop new, safe and effective therapeutics for oncology and infectious disease indications; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" face="Symbol" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>our ability to protect our intellectual property rights, including the ability to successfully defend patent oppositions filed against a European patent related to technology we use in varlilumab, and our ability to avoid intellectual property litigation, which can be costly and divert management time and attention.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>7<a name="PB_7_112635_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-7',FILE='C:\JMS\109512\16-22161-1\task8190639\22161-1-bs.htm',USER='109512',CD='Dec  1 13:59 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should also consider carefully the statements set forth in the section entitled &#147;Risk Factors&#148; in this prospectus and in our Annual Report on Form&nbsp;10-K/A for the year ended December&nbsp;31, 2015, respectively, as updated by any other document that we subsequently filed with the Securities and Exchange Commission and that is incorporated by reference into this prospectus, which address various factors that could cause results or events to differ from those described in the forward-looking statements.&#160; All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements.&#160; We have no plans to update these forward-looking statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>8<a name="PB_8_192115_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-8',FILE='C:\JMS\109512\16-22161-1\task8190639\22161-1-bs.htm',USER='109512',CD='Dec  1 13:59 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">USE OF PROCEEDS</font></b><a name="USEOFPROCEEDS_124956"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Cantor Fitzgerald as a source of financing.&#160; We currently expect to use the net proceeds from this offering for working capital and other general corporate purposes.&#160; Until we use the net proceeds of this offering, we intend to invest the funds in short-term, investment grade, interest-bearing securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The amount and timing of actual expenditures for the purposes set forth above may vary based on several factors, and our management will retain broad discretion as to the ultimate allocation of the proceeds.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>9<a name="PB_9_112635_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-9',FILE='C:\JMS\109512\16-22161-1\task8190639\22161-1-bs.htm',USER='109512',CD='Dec  1 13:59 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">MARKET PRICE FOR OUR COMMON STOCK</font></b><a name="MARKETPRICEFOROURCOMMONSTOCK_125338"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our common stock currently trades on NASDAQ under the symbol &#147;CLDX&#148;. The following table sets forth for the periods indicated the high and low sale prices per share for our common stock, as reported by NASDAQ.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="70%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fiscal&nbsp;Period</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">High</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Low</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Year Ending   December&nbsp;31, 2016</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">First Quarter</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.61</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.96</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Quarter </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.13</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.40</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Quarter</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.83</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.23</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth Quarter   (through November 30, 2016)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.02</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.85</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Year   Ended December&nbsp;31, 2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">First Quarter</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.82</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.81</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Quarter</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30.28</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.62</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Quarter</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28.08</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.11</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth Quarter</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.62</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.15</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Year   Ended December&nbsp;31, 2014</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">First Quarter</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33.33</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.58</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Quarter</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.52</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.76</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Quarter</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.30</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.93</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth Quarter</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.70</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.11</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On November 30, 2016 the closing price of our common stock, as reported by NASDAQ, was $3.81 per share. We have not paid any dividends on our common stock since our inception and do not intend to pay any dividends in the foreseeable future.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>10<a name="PB_10_114946_4587"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-10',FILE='C:\JMS\108698\16-22161-1\task8192443\22161-1-bu.htm',USER='108698',CD='Dec  2 16:36 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DILUTION</font></b><a name="DILUTION_125339"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the price per share you pay in this offering and our pro forma net tangible book value per share after this offering.&#160; We calculate net tangible book value per share by dividing our net tangible book value, which is tangible assets less total liabilities, by the number of outstanding shares of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our net tangible book value as of September 30, 2016 was approximately $188.1 million, or $1.86 per share.&#160; Net tangible book value per share after this offering gives effect to the sale of $48.8 million of common stock in this offering at an assumed offering price of $3.81 per share, which was the closing price of our common stock as reported on NASDAQ on November 30, 2016, after deducting offering commissions and estimated expenses payable by us. Our net tangible book value as of September 30, 2016, after giving effect to this offering as described above, would have been approximately $235.4 million, or $2.06 per share of common stock.&#160; This represents an immediate increase in pro forma net tangible book value of $0.20 per share to existing stockholders and an immediate dilution of $1.75 per share to new investors purchasing our common stock in this offering.&#160; The following table illustrates the per share dilution:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.02%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assumed offering   price per share</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:6.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.81</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.02%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net tangible   book value per share as of September 30, 2016</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.86</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.02%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Increase in net   tangible book value per share attributable to new investors</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.20</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" style="padding:0in 0in 0in 0in;width:78.02%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pro forma net   tangible book value per share as of September 30, 2016, after giving effect   to this offering</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:8.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.06</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="78%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:78.02%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dilution per share   to new investors in this offering</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="6%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:6.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.75</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The above table is based on 101,248,821 shares of our common stock issued and outstanding as of September 30, 2016, which does not include the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>10,150,598 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $11.26 per share as of September 30, 2016;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.5pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>3,641,582 shares available for future issuance under our equity compensation plans as of September 30, 2016; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>18,695,897 shares issued in connection with the closing of the Kolltan acquisition on November 29, 2016.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>11<a name="PB_11_114956_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-11',FILE='C:\JMS\108698\16-22161-1\task8192443\22161-1-bu.htm',USER='108698',CD='Dec  2 16:36 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></b><a name="PLANOFDISTRIBUTION_125343"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have entered into a Controlled Equity Offering</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font>&#160;sales agreement with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor, pursuant to which we may offer and sell up to $60 million of shares of our common stock, $0.001 par value per share, from time to time through Cantor acting as agent. This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement has been filed as an exhibit to a Current Report on Form 8-K under the Exchange Act and is incorporated by reference into the registration statement of which this prospectus is a part. See &#147;Where You Can Find More Information&#148; below. As of December 2, 2016, we had issued and sold shares of our common stock having an aggregate offering price of $11,194,903 pursuant to our prior registration statement on Form S-3ASR (File No. 333-192640).&#160; Accordingly, we may issue and sell additional shares of our common stock having an aggregate offering price of up to $48,805,097 pursuant to this prospectus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon delivery of a placement notice and subject to the terms and conditions of the sales agreement, Cantor may sell our common stock by any method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule&nbsp;415(a)(4) promulgated under the Securities Act. We or Cantor may suspend or terminate the offering of our common stock upon notice and subject to other conditions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will pay Cantor in cash, upon each sale of our common stock pursuant to the sales agreement, a commission in an amount equal to 3.0% of the aggregate gross proceeds from each sale of our common stock. Because there is no minimum offering amount required as a condition to this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have agreed to reimburse a portion of Cantor&#146;s expenses, including legal fees, in connection with this offering up to a maximum of $50,000. We estimate that the total expenses for the offering, excluding compensation and expense reimbursement payable to Cantor under the terms of the sales agreement, will be approximately $110,000.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Settlement for sales of common stock will occur on the third business day following the date on which any sales are made, or on some other date that is agreed upon by us and Cantor in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Cantor may agree upon.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cantor will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal laws, rules&nbsp;and regulations and the rules&nbsp;of NASDAQ. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor against certain civil liabilities, including liabilities under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The offering of our common stock pursuant to the sales agreement will terminate as permitted therein. We or Cantor may terminate the sales agreement at any time upon ten (10)&nbsp;days&#146; prior notice.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cantor and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus in electronic format may be made available on a website maintained by Cantor and Cantor may distribute this prospectus electronically.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>12<a name="PB_12_115001_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-12',FILE='C:\JMS\108698\16-22161-1\task8192443\22161-1-bu.htm',USER='108698',CD='Dec  2 16:36 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LEGAL MATTERS</font></b><a name="LEGALMATTERS_125345"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lowenstein Sandler&nbsp;LLP, Roseland, New Jersey, will provide us with an opinion as to the validity of the shares of common stock offered by this prospectus.&#160; Cantor is being represented in connection with this offering by Cooley LLP, New York, New York.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXPERTS</font></b><a name="EXPERTS_125346"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form&nbsp;10-K/A for the year ended December&nbsp;31, 2015 have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></b><a name="WHEREYOUCANFINDMOREINFORMATION_125348"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC.&#160; We have also filed a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act with respect to the securities offered by this prospectus.&#160; This prospectus is a part of the registration statement but do not contain all of the information included in the registration statement or the exhibits.&#160; You may read and copy the registration statement and any other document that we file at the SEC&#146;s public reference room at 100&nbsp;F Street, N.E., Room&nbsp;1580, Washington D.C. 20549.&#160; You can call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference room.&#160; You can also find our public filings with the SEC on the Internet at a web site maintained by the SEC located at <i>http://www.sec.gov</i>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCORPORATION OF DOCUMENTS BY REFERENCE</font></b><a name="INCORPORATIONOFDOCUMENTSBYREFERE_125349"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus certain information.&#160; This means that we can disclose important information to you by referring you to those documents that contain the information.&#160; The information we incorporate by reference is considered a part of this prospectus, and later information we file with the SEC will automatically update and supersede this information.&#160; We incorporate by reference the documents listed below and any future filings we make with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act, on or after the date of this prospectus (other than information &#147;furnished&#148; under Items&nbsp;2.02 or 7.01 (or corresponding information furnished under Item&nbsp;9.01 or included as an exhibit)) of any Current Report on Form&nbsp;8-K or otherwise &#147;furnished&#148; to the SEC, unless otherwise stated) until this offering is completed:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font>&#160;&#160;&#160;&#160;&#160; Our Annual Report on Form&nbsp;10-K/A for the fiscal year ended December&nbsp;31, 2015, filed with the SEC on February&nbsp;25, 2016;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font>&#160;&#160;&#160;&#160;&#160; Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2016, June&nbsp;30, 2016 and September&nbsp;30, 2016, filed on May&nbsp;5, 2016, August&nbsp;8, 2016 and November&nbsp;7, 2016, respectively;</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font>&#160;&#160;&#160;&#160;&#160; Our Current Reports on Form&nbsp;8-K filed with the SEC on February&nbsp;23, 2016, March&nbsp;7, 2016, May&nbsp;19, 2016, June&nbsp;9, 2016, August&nbsp;11, 2016, November&nbsp;1, 2016, and November&nbsp;29, 2016 (in each case, not including any information furnished under Items 2.02 or 7.01 of Form&nbsp;8-K, including the related exhibits, which information is not incorporated by reference herein);</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font>&#160;&#160;&#160;&#160;&#160; Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;21, 2016 (other than the portions thereof which are furnished and not filed); and</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font>&#160;&#160;&#160;&#160;&#160; The description of our common stock contained in our Registration Statement on Form&nbsp;8-A, filed on November&nbsp;8, 2004, as amended by Form&nbsp;8-A/A filed on October&nbsp;22, 2007 and March&nbsp;7, 2008.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You may request a copy of these filings, at no cost, by writing to or telephoning us at the following address:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary<br> Celldex Therapeutics,&nbsp;Inc.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Perryville III Building, 53 Frontage Road, Suite&nbsp;220,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hampton, New Jersey 08827 <br> (908) 200-7500</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement.&#160; Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should rely only on information contained in, or incorporated by reference into, this prospectus and the accompanying prospectus.&#160; We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference in this prospectus.&#160; We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-</font>13<a name="PB_13_115010_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM-13',FILE='C:\JMS\108698\16-22161-1\task8192443\22161-1-bu.htm',USER='108698',CD='Dec  2 16:36 2016' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img border="0" width="137" height="43" src="g221611bwi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:14.0pt;font-weight:bold;">Up to $48,805,097</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:14.0pt;font-weight:bold;">Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img border="0" width="219" height="77" src="g221611bwi002.gif"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">, 2016</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109512\16-22161-1\task8190683\22161-1-bw.htm',USER='109512',CD='Dec  1 14:45 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INFORMATION NOT REQUIRED IN THE PROSPECTUS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;14.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Expenses of Issuance and Distribution.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth the estimated costs and expenses payable by the Registrant in connection with the registration of the securities being registered under this Registration Statement. All amounts shown are estimates except the Securities and Exchange Commission registration statement filing fee:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.46%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration Statement filing fee</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28,975</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.46%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Printing fees</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.46%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Legal fees and   expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.46%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounting fees</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.46%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Miscellaneous</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.8%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.46%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.86%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>These fees are calculated on the securities offered and the number of issuances and accordingly cannot be estimated at this time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 51.7pt;text-indent:-51.7pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 15.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnification of Directors and Officers.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex is a Delaware corporation. In accordance with the Delaware General Corporation Law (the &#147;DGCL&#148;), Article&nbsp;Six of the Registrant&#146;s Third Restated Certificate of Incorporation, as amended, provides that no director of the Registrant shall be personally liable to the Registrant or its stockholders for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s duty of loyalty to Celldex or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL, or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The DGCL permits, but does not require, a corporation to indemnify its directors, officers, employees or agents and expressly provides that the indemnification provided for under the DGCL shall not be deemed exclusive of any indemnification right under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The DGCL permits indemnification against expenses and certain other liabilities arising out of legal actions brought or threatened against such persons for their conduct on behalf of the corporation, provided that each such person acted in good faith and in a manner that he or she reasonably believed was in or not opposed to the corporation&#146;s best interests and in the case of a criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The DGCL does not allow indemnification of directors in the case of an action by or in the right of the corporation (including stockholder derivative suits) unless the directors successfully defend the action or indemnification is ordered by the court. The Amended and Restated Bylaws of Celldex (the &#147;Bylaws&#148;) provide for indemnification to the directors, officers, employees and agents of Celldex consistent with that authorized by the DGCL. Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors and officers of Celldex pursuant to the foregoing provision or otherwise, Celldex has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Exchange Act of 1934, as amended, and is therefore, unenforceable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex currently carries a directors&#146; and officers&#146; liability insurance policy which provides for payment of expenses of Celldex&#146;s directors and officers in connection with threatened, pending or completed actions, suits or proceedings against them in their capacities as directors and officers, in accordance with the Bylaws and the DGCL.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>1<a name="PB_1_010146_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-1',FILE='C:\JMS\106747\16-22161-1\task8190694\22161-1-ga.htm',USER='106747',CD='Dec  1 14:44 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 16.&#160; Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="6%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Location</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales Agreement, dated May 19, 2016, between Celldex   Therapeutics,&nbsp;Inc. and Cantor Fitzgerald&nbsp;&amp; Co.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;10.1 of   Celldex&#146;s Current Report on Form&nbsp;8-K, filed May 19, 2016.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;2.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and Plan of Merger, dated as of   November&nbsp;1, 2016, by and among Kolltan Pharmaceuticals,&nbsp;Inc.,   Celldex Therapeutics,&nbsp;Inc., Connemara Merger Sub 1 Inc. and Connemara   Merger Sub 2 LLC.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;2.1   Celldex&#146;s Current Report on Form&nbsp;8-K, filed November&nbsp;1, 2016.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215),   filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215),   filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.2 of   Celldex&#146;s Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215),   filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of Celldex&#146;s   Quarterly Report on Form&nbsp;10-Q, filed May&nbsp;10, 2002</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended and Restated By-Laws of Celldex as of   March&nbsp;14, 2007</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.5 of   Celldex&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;18, 2008</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Designations, Preferences and Rights   of a Series&nbsp;of Preferred Stock of Celldex classifying and designating   the Series&nbsp;C-1 Junior Participating Cumulative Preferred Stock</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Registration Statement on Form&nbsp;8-A filed November&nbsp;8, 2004</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Elimination of Series&nbsp;C-1 Junior   Participating Cumulative Preferred Stock</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.6 of   Celldex&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;16, 2005</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fifth Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.2 of   Celldex&#146;s Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>2<a name="PB_2_010151_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-2',FILE='C:\JMS\106747\16-22161-1\task8190694\22161-1-ga.htm',USER='106747',CD='Dec  1 14:44 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen of Common Stock Certificate</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.11</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Warrant Agreement</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.12</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Warrant Certificate</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included in Exhibit&nbsp;4.14)</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.13</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen of Preferred Stock Certificate</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.14</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Depositary Agreement</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.15</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Depositary Receipt</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included in Exhibit&nbsp;4.17)</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.16</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Unit Agreement</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Opinion of Lowenstein Sandler LLP as to the legality   of the securities being registered</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Computation of Ratio of Combined Fixed Charges and   Preferred Stock Dividends to Earnings</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent of PricewaterhouseCoopers   LLP,&nbsp;Independent Registered Public Accounting Firm</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.2</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent of Lowenstein Sandler LLP</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included in Exhibit&nbsp;5.1</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Powers of Attorney</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included on signature pages&nbsp;to this Registration   Statement</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>3<a name="PB_3_010157_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-3',FILE='C:\JMS\106747\16-22161-1\task8190694\22161-1-ga.htm',USER='106747',CD='Dec  1 14:44 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt 40.5pt;text-indent:-40.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 51.7pt;text-indent:-51.7pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 17.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Undertakings.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The undersigned registrant hereby undertakes:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-22.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;&#160; To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">provided, however</font></i>, Paragraphs (a)(1)(i), (a)(1)(ii)&nbsp;and (a)(1)(iii)&nbsp;of this section do not apply if the registration statement is on Form&nbsp;S-3 or Form&nbsp;F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d)&nbsp;of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;that is part of the registration statement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<i> bona fide</i> offering thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&nbsp;&#160; To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&nbsp;&#160; That, for the purpose of determining liability under the Securities Act to any purchaser, (A)&nbsp;each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and (B)&nbsp;each prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7)&nbsp;as part of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a)&nbsp;of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>4<a name="PB_4_010203_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-4',FILE='C:\JMS\106747\16-22161-1\task8190694\22161-1-ga.htm',USER='106747',CD='Dec  1 14:44 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&nbsp;&#160; That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&nbsp;&#160;&#160; Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&nbsp;&#160; Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&nbsp; The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&nbsp; Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d)&nbsp;of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<i> bona fide</i> offering thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>5<a name="PB_5_010209_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-5',FILE='C:\JMS\106747\16-22161-1\task8190694\22161-1-ga.htm',USER='106747',CD='Dec  1 14:44 2016' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&nbsp;S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hampton, State of New Jersey, on December&nbsp;2, 2016.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX   THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Anthony S. Marucci</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony S. Marucci</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief   Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES AND POWER OF ATTORNEY</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Anthony S. Marucci and Avery W. Catlin, or any one of them, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including pre-effective and post-effective amendments) to this registration statement on Form&nbsp;S-3 and any subsequent registration filed pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Signature</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Title</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Date</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Anthony S. Marucci</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony S. Marucci</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" rowspan="2" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director, Chief Executive Officer and President   (Principal Executive Officer)</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Avery W. Catlin</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery W. Catlin</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" rowspan="3" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice President, Treasurer and Chief Financial   Officer (Principal Financial Officer and Principal Accounting Officer)</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Larry Ellberger</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Larry Ellberger</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Herbert J. Conrad</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Herbert J. Conrad</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ George O. Elston</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">George O. Elston</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Harry H. Penner,&nbsp;Jr.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Harry H. Penner,&nbsp;Jr.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>6<a name="PB_6_010331_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-6',FILE='C:\JMS\109512\16-22161-1\task8190683\22161-1-jc.htm',USER='109512',CD='Dec  1 14:50 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Karen L. Shoos</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Karen L. Shoos</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Richard A. Van Den Broek</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Richard A. Van Den Broek</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>7<a name="PB_7_010331_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-7',FILE='C:\JMS\109512\16-22161-1\task8190683\22161-1-jc.htm',USER='109512',CD='Dec  1 14:50 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="6%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="45%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Location</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales Agreement, dated May&nbsp;19, 2016, between   Celldex Therapeutics,&nbsp;Inc. and Cantor Fitzgerald&nbsp;&amp; Co.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;10.1 of   Celldex&#146;s Current Report on Form&nbsp;8-K, filed May&nbsp;19, 2016.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and Plan of Merger, dated as of   November&nbsp;1, 2016, by and among Kolltan Pharmaceuticals,&nbsp;Inc.,   Celldex Therapeutics,&nbsp;Inc., Connemara Merger Sub 1 Inc. and Connemara   Merger Sub 2 LLC.</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;2.1   Celldex&#146;s Current Report on Form&nbsp;8-K, filed November&nbsp;1, 2016.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of Celldex&#146;s   Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed   July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215),   filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.2 of   Celldex&#146;s Registration Statement on Form&nbsp;S-4 (Reg. No.&nbsp;333-59215),   filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Quarterly Report on Form&nbsp;10-Q, filed May&nbsp;10, 2002</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended and Restated By-Laws of Celldex as of   March&nbsp;14, 2007</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.5 of   Celldex&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;18, 2008</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Designations, Preferences and Rights   of a Series&nbsp;of Preferred Stock of Celldex classifying and designating   the Series&nbsp;C-1 Junior Participating Cumulative Preferred Stock</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Registration Statement on Form&nbsp;8-A filed November&nbsp;8, 2004</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Elimination of Series&nbsp;C-1 Junior   Participating Cumulative Preferred Stock</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.6 of   Celldex&#146;s Annual Report on Form&nbsp;10-K, filed March&nbsp;16, 2005</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.1 of   Celldex&#146;s Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fifth Certificate of Amendment of Third Restated   Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit&nbsp;3.2 of   Celldex&#146;s Current Report on Form&nbsp;8-K filed on March&nbsp;11, 2008</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen of Common Stock Certificate</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>8<a name="PB_8_010331_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-8',FILE='C:\JMS\109512\16-22161-1\task8190683\22161-1-jc.htm',USER='109512',CD='Dec  1 14:50 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.11</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Warrant Agreement</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.12</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Warrant Certificate</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included in Exhibit&nbsp;4.14)</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.13</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen of Preferred Stock Certificate</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.14</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Depositary Agreement</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.15</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Depositary Receipt</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included in Exhibit&nbsp;4.17)</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.16</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of Unit Agreement</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be filed subsequently by an amendment to the   Registration Statement or by a Current Report of the Registrant on a Current   Report on Form&nbsp;8-K and incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Opinion of Lowenstein Sandler LLP as to the legality   of the securities being registered</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Computation of Ratio of Combined Fixed Charges and   Preferred Stock Dividends to Earnings</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent of PricewaterhouseCoopers   LLP,&nbsp;Independent Registered Public Accounting Firm</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.2</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent of Lowenstein Sandler PC</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included in Exhibit&nbsp;5.1</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.1</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Powers of Attorney</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included on signature pages&nbsp;to this   Registration Statement</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-</font>9<a name="PB_9_010331_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-9',FILE='C:\JMS\109512\16-22161-1\task8190683\22161-1-jc.htm',USER='109512',CD='Dec  1 14:50 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>2
<FILENAME>a16-22161_1ex4d10.htm
<DESCRIPTION>EX-4.10
<TEXT>


<html>
<head>



  </head>
<body link="blue" lang="EN-US">
<div>
<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 4.10</font></b></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS#   . COMMON STOCK PAR VALUE $0.001 COMMON STOCK THIS CERTIFICATE IS TRANSFERABLE   IN CANTON, MA, JERSEY CITY, NJ AND COLLEGE STATION, TX Shares * * 000000 * *   * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * *   * * * * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * *   * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * Certificate   Number ZQ00000000 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample   **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David THIS CERTIFIES THAT Sample **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander Alexander David SamMple ***R* Mr.   A.lexaSnderADavidMSampPle ***L* MrE. Alexan&amp;der DavMid SamRple **S** Mr..   AleSxandeAr DaMvid SamPple *L*** MEr. Alex&amp;ander David Sample **** David   Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****   Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample   Sample **** Mr. AlexandeMr DaviRd Sam.ple S**** MAr. AleMxandePr DavLid   SEample *&amp;*** Mr. AMlexanRder DaSvid S.ampSle ***A* Mr.MAlexanPder   DLavidESample **** Mr. Alexander **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David SEE REVERSE FOR CERTAIN DEFINITIONS   David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample   **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample   **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Sample ****   Mr. Sample is the owner of   **000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares***   *000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****   000000**Shar*es****0*000Z00**SEhareRs****00O0000**ShHares**U**0000N00**SDhares*R***000E000**DShares**T**000H000**SOhares*U***000S000**AShareNs****00D0000**Shares****0   00000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00   0000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000   000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0000   00**Shares****0Z0000E0**ShRares***O*000000*H*ShareUs****0N00000D**SharRes****0E0000D0**ShareAs****0N00000D**SharesZ****00E0000R**SharOes****0*000*00**Shares****00000   0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000   **Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000*   *Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**   Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S   FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, $0.001 PAR VALUE   PER SHARE, OF CELLDEX THERAPEUTICS, INC. transferable on the books of the   Corporation by the holder hereof in person or by duly authorized attorney,   upon surrender of this Certificate properly endorsed. This Certificate is not   valid unless countersigned by the Transfer Agent and registered by the   Registrar. WITNESS the facsimile seal of the Corporation and the facsimile   signatures of its duly authorized officers. DATED DD-MMM-YYYY COUNTERSIGNED   AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND   REGISTRAR, President and Chief Executive Officer By Senior Vice President and   Chief Financial Officer AUTHORIZED SIGNATURE CUSIP Holder ID Insurance Value   Number of Shares DTC Certificate Numbers 1234567890/1234567890   1234567890/1234567890 1234567890/1234567890 1234567890/1234567890   1234567890/1234567890 1234567890/1234567890 Total Transaction XXXXXX XX X   XXXXXXXXXX 1,000,000.00 123456 12345678 123456789012345 PO BOX 43004,   Providence, RI 02940-3004 Num/No. Denom. Total 1 2 3 4 5 6 7 1 2 3 4 5 6 1 2   3 4 5 6 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 CUSIP 15117B   10 3 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1046" height="635" src="g221611kg01i001.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108736\16-22161-1\task8192944\22161-1-kg-01.htm',USER='108736',CD='Dec  3 00:35 2016' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">. (Cust)   (Minor) (State) and not as tenants in common (Cust) (Minor) PLEASE INSERT   SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received,   hereby sell, assign and transfer unto (PLEASE PRINT OR TYPEWRITE NAME AND   ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares represented by the   within Certificate, and do hereby irrevocably constitute and appoint Attorney   to transfer the said shares on the books of the within-named Corporation with   full power of substitution in the premises. Dated: 20 Signature: Signature:   Notice: The signature to this assignment must correspond with the name as   written upon the face of the certificate, in every particular, without   alteration or enlargement, or any change whatever. Signature(s) Guaranteed:   Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN   ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan   Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE   GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. The following   abbreviations, when used in the inscription on the face of this certificate,   shall be construed as though they were written out in full according to   applicable laws or regulations: TEN COM - as tenants in commonUNIF GIFT MIN   ACT-. . . . . . . . . .Custodian . . . . . . . . . . . . . . . TEN ENT - as   tenants by the entiretiesunder Uniform Gifts to Minors Act . . . . . . . . .   . . . . JT TEN-as joint tenants with right of survivorshipUNIF TRF MIN ACT .   . . . . . . . . . . . . . .Custodian (until age. . . ). . . . . . . . . . .   under Uniform Transfers to Minors Act. . . . . . . . . . (State) Additional   abbreviations may also be used though not in the above list. </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="1120" src="g221611kg03i001.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108736\16-22161-1\task8192938\22161-1-kg-03.htm',USER='108736',CD='Dec  3 00:31 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>a16-22161_1ex5d1.htm
<DESCRIPTION>EX-5.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;5.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Perryville III Building</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53 Frontage Road, Suite&nbsp;220</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hampton, NJ 08827</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re: Shelf Registration Statement of Celldex Therapeutics,&nbsp;Inc. on Form&nbsp;S-3</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have acted as counsel to Celldex Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;Company&#148;), in connection with its filing of a shelf registration statement on Form&nbsp;S-3 (the &#147;Registration Statement&#148;), including the base prospectus constituting a part thereof (the &#147;Base Prospectus&#148;)&nbsp;and the ATM prospectus constituting a part thereof (the &#147;ATM Prospectus&#148;),&nbsp;to which this opinion is attached, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). We have been requested by the Company to render this opinion in connection with the filing of the Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Base Prospectus provides that it will be supplemented in the future by one or more supplements to the Prospectus (each a &#147;Prospectus Supplement&#148;). The Prospectus, as supplemented by various Prospectus Supplements, will provide for the registration by the Company of up to $250,000,000 aggregate offering price of (i) shares of preferred stock, par value $0.001 per share, in one or more series or classes (the &#147;Preferred Stock&#148;), (ii)&nbsp;shares of common stock, par value $0.001 per share (the &#147;Common Stock&#148;), (iii)&nbsp;warrants to purchase Common Stock or Preferred Stock (the &#147;Warrants&#148;), (iv)&nbsp;depositary shares (evidenced by depositary receipts) representing fractional interests in shares of Common Stock or Preferred Stock (the &#147;Depositary Shares&#148;), or (v)&nbsp;units composed of the foregoing (the &#147;Units&#148;). The Preferred Stock, Common Stock, Warrants, Depositary Shares and the Units are collectively referred to herein as the &#147;Securities.&#148; The Preferred Stock may be exchangeable for and/or convertible into shares of Common Stock or another series of Preferred Stock. The Units may be exchangeable and/or settled into the Securities comprising the Units.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The ATM Prospectus relates to the sale by the Company of shares of common stock having an aggregate offering price of up to $48,805,097 (the &#147;ATM Shares&#148;) under a sales agreement dated as of May&nbsp;19, 2016, (the &#147;Sales Agreement&#148;) between the Company and Cantor Fitzgerald&nbsp;&amp; Co.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In rendering our opinion, we have reviewed the Registration Statement and the exhibits thereto and the Sales Agreement. We have also reviewed such corporate documents and records of the Company, such certificates of public officials and officers of the Company and such other matters as we have deemed necessary or appropriate for purposes of this opinion.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except to the extent we opine as to the binding effect of certain documents as set forth in paragraphs 3, 4 and 5 below, we have assumed that all documents referenced below are the valid and binding obligations of and enforceable against the parties thereto. We have also assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the conformity to authentic original documents of all documents submitted to us as certified, conformed or photostatic copies and the legal capacities of all natural persons.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on the foregoing, and subject to the assumptions, limitations and qualifications set forth herein, we are of the opinion that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&nbsp;When a new class or series of Preferred Stock has been duly established in accordance with the terms of the restated certificate of incorporation of the Company, as amended (&#147;Charter&#148;), the by-laws of the Company (&#147;Bylaws&#148;) and applicable law (in the event that the Preferred Stock is a new class or series of Preferred Stock), and upon adoption by the Board of Directors of the Company of a resolution in form and content as required by applicable law, and (b)&nbsp;assuming that appropriate certificates of amendment to the</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109559\16-22161-1\task8192442\22161-1-ki.htm',USER='109559',CD='Dec  2 16:36 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company&#146;s Charter relating to such class or series of Preferred Stock have been duly approved by the Company&#146;s Board of Directors and been filed with and accepted for record by the State of Delaware, and (c)&nbsp;assuming that the Registration Statement and any required post-effective amendment(s)&nbsp;thereto and any and all Prospectus Supplement(s)&nbsp;required by applicable laws have become effective under the Securities Act, and (d)&nbsp;assuming that upon the issuance of such Preferred Stock, the total number of issued and outstanding shares of the applicable class or series of Preferred Stock will not exceed the total number of shares of Preferred Stock or the number of shares of such class or series of Preferred Stock that the Company is then authorized to issue under its Charter, then upon issuance and delivery of and payment for such shares in the manner contemplated by the Registration Statement, the Prospectus and the related Prospectus Supplement(s)&nbsp;and by such resolution, such shares of such class or series of Preferred Stock (including any Preferred Stock duly issued upon (i)&nbsp;the exchange or conversion of any shares of Preferred Stock that are exchangeable or convertible into another class or series of Preferred Stock, (ii)&nbsp;the exercise of any duly issued Warrants exercisable for Preferred Stock, or (iii)&nbsp;the exchange or settlement of Units that are exchangeable or able to be settled for Preferred Stock), will be validly issued, fully paid and non-assessable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&nbsp;Except for the ATM Shares, upon adoption by the Board of Directors of the Company of a resolution in form and content as required by applicable law authorizing the issuance and sale of Common Stock, and (b)&nbsp;assuming that the Registration Statement and any required post-effective amendment(s)&nbsp;thereto and any and all Prospectus Supplement(s)&nbsp;required by applicable laws have become effective under the Securities Act, and (c)&nbsp;assuming that upon the issuance of such Common Stock, the total number of issued and outstanding shares of Common Stock will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its Charter, then upon issuance and delivery of and payment for such shares in the manner contemplated by the Registration Statement, the Prospectus and the related Prospectus Supplement(s)&nbsp;and by such resolution, such shares of Common Stock being issued by the Company (including any Common Stock duly issued upon (i)&nbsp;the exchange or conversion of any shares of Preferred Stock that are exchangeable or convertible into Common Stock, (ii)&nbsp;the exercise of any duly issued Warrants exercisable for Common Stock, or (iii)&nbsp;the exchange or settlement of Units that are exchangeable or able to be settled for Common Stock), will be validly issued, fully paid and non-assessable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>With respect to the ATM Shares, (a)&nbsp;when the Registration Statement has become effective under the Securities Act, and (b)&nbsp;when the ATM Shares have been issued and sold in accordance with the Sales Agreement, and as described in the Registration Statement and ATM Prospectus, the ATM Shares will be validly issued, fully paid and non-assessable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&nbsp;When a warrant agreement relating to the Warrants has been duly authorized (the &#147;Warrant Agreement&#148;), executed and delivered and the Warrants and the securities of the Company for which the Warrants will be exercisable have been duly authorized by the Company&#146;s Board of Directors, and (b)&nbsp;assuming that the terms of the Warrants and of their issuance and sale have been duly established in conformity with the Company&#146;s Charter and Bylaws and the Warrant Agreement, and (c)&nbsp;assuming that the Registration Statement and any required post-effective amendment thereto and any and all Prospectus Supplement(s)&nbsp;required by applicable laws have all become effective under the Securities Act, and (d)&nbsp;assuming that the terms of the Warrants as executed and delivered are as described in the Registration Statement, the Prospectus and the related Prospectus Supplement(s), and (e)&nbsp;assuming that the Warrants, as executed and delivered, do not violate any law applicable to the Company or result in a default under or breach of any agreement or instrument binding upon the Company, and (f)&nbsp;assuming that the Warrants as executed and delivered comply with all requirements and restrictions, if any, applicable to the Company, whether imposed by any court or governmental or regulatory body having jurisdiction over the Company, and (g)&nbsp;assuming that the Warrants are then issued and sold as contemplated in the Registration Statement, the Prospectus and the Prospectus Supplement(s), then upon issuance of and delivery of and payment for such Warrants in the manner contemplated by the Registration Statement, the Prospectus and the related Prospectus Supplement and the Warrant Agreement and by such resolution, the Warrants (including any Warrants issued upon the exchange or settlement of Units that are exchangeable or able to be settled for Warrants) will constitute valid and binding obligations of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&nbsp;When a depositary agreement relating to the Depositary Shares has been duly authorized (the</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109559\16-22161-1\task8192442\22161-1-ki.htm',USER='109559',CD='Dec  2 16:36 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Depositary Agreement&#148;), executed and delivered and the Depositary Shares have been duly authorized by the Company&#146;s Board of Directors, and (b)&nbsp;assuming that the terms of the Depositary Shares and of their issuance and sale have been duly established in conformity with the Company&#146;s Charter and Bylaws and the Depositary Agreement, and (c)&nbsp;assuming that the Registration Statement and any required post-effective amendment thereto and any and all Prospectus Supplement(s)&nbsp;required by applicable laws have all become effective under the Securities Act, and (d)&nbsp;assuming that the terms of the Depositary Shares as executed and delivered are as described in the Registration Statement, the Prospectus and the related Prospectus Supplement(s), and (e)&nbsp;assuming that the Depositary Shares, as executed and delivered, do not violate any law applicable to the Company or result in a default under or breach of any agreement or instrument binding upon the Company, and (f)&nbsp;assuming that the Depositary Shares as executed and delivered comply with all requirements and restrictions, if any, applicable to the Company, whether imposed by any court or governmental or regulatory body having jurisdiction over the Company, and (g)&nbsp;assuming the depositary receipts evidencing the Depositary Shares have been duly issued against the deposit of the Common Stock or Preferred Stock in accordance with the Depositary Agreement and issued and sold as contemplated in the Registration Statement, the Prospectus and the Prospectus Supplement(s), then upon issuance of and delivery of and payment for such Depositary Shares in the manner contemplated by the Registration Statement, the Prospectus and the related Prospectus Supplement and by such resolution, the depositary receipts evidencing Depositary Shares (including any depositary receipts evidencing Depositary Shares issued upon the exchange or settlement of Units exchangeable or able to be settled for Depositary Shares) will entitle holders thereof to the rights specified in the Depositary Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(a)&nbsp;When a unit agreement relating to the Units has been duly authorized (the &#147;Unit Agreement&#148;), executed and delivered and the Units have been duly authorized by the Company&#146;s Board of Directors, and (b)&nbsp;assuming that the terms of the Units and of their issuance and sale have been duly established in conformity with the Unit Agreement, and (c)&nbsp;assuming that the Registration Statement and any required post-effective amendment thereto and any and all Prospectus Supplement(s)&nbsp;required by applicable laws have all become effective under the Securities Act, and (d)&nbsp;assuming that the terms of the Units as executed and delivered are as described in the Registration Statement, the Prospectus and the related Prospectus Supplement(s), and (e)&nbsp;assuming that the Units, as executed and delivered, do not violate any law applicable to the Company or result in a default under or breach of any agreement or instrument binding upon the Company, and (f)&nbsp;assuming that the Units as executed and delivered comply with all requirements and restrictions, if any, applicable to the Company, whether imposed by any court or governmental or regulatory body having jurisdiction over the Company, and (g)&nbsp;assuming that the Units are then issued and sold as contemplated in the Registration Statement, the Prospectus and the Prospectus Supplement(s), then upon issuance of and delivery of and payment for such Units in the manner contemplated by the Registration Statement, the Prospectus and the related Prospectus Supplement and the Unit Agreement and by such resolution, the Units will constitute valid and binding obligations of the Company.</p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The opinions set forth above are subject to the following exceptions, limitations and qualifications: (i)&nbsp;the effect of bankruptcy, insolvency, reorganization, arrangement, moratorium, fraudulent conveyance, fraudulent transfer and other similar laws relating to or affecting the rights of creditors; (ii)&nbsp;the effect of general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, injunctive relief and other equitable remedies), regardless of whether considered in a proceeding at law or in equity, (iii)&nbsp;the effect of public policy considerations that may limit the rights of the parties to obtain further remedies, (iv)&nbsp;we express no opinion with respect to the enforceability of provisions relating to choice of law, choice of venue, jurisdiction or waivers of jury trial, and (v)&nbsp;we express no opinion with respect to the enforceability of any waiver of any usury defense.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that the obligations of the Company with respect to the Securities may be dependent on such matters, we assume for purposes of this opinion that the other party under the Warrant Agreement for any Warrants, under the Unit Agreement for any Units and under the Deposit Agreement for any Depository Shares, namely the warrant agent, the unit agent or the depositary, respectively, is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization; that such other party is duly qualified to engage in the activities contemplated by such Warrant Agreement, Unit Agreement or Deposit Agreement, as applicable; that such Warrant Agreement, Unit Agreement or Deposit Agreement has been duly authorized, executed and delivered by such other party and constitutes the legally valid, binding and enforceable obligation of such other party, enforceable against</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109559\16-22161-1\task8192442\22161-1-ki.htm',USER='109559',CD='Dec  2 16:36 2016' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">such other party in accordance with its terms; that such other party is in compliance, generally and with respect to performance of its obligations under such Warrant Agreement, Unit Agreement, or Deposit Agreement, as applicable, with all applicable laws and regulations; and that such other party has the requisite organizational and legal power and authority to perform its obligations under such Warrant Agreement, Unit Agreement or Deposit Agreement, as applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our opinion is limited to the federal laws of the United States and to the Delaware General Corporation law.&nbsp; We express no opinion as to the effect of the law of any other jurisdiction. Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof on the opinions expressed herein) that hereafter may come to our attention.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item&nbsp;601(b)(5)&nbsp;of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus and any Prospectus Supplement under the caption &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the Rules&nbsp;and Regulations of the Commission promulgated thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LOWENSTEIN SANDLER LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.0pt;text-indent:-12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Lowenstein Sandler LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109559\16-22161-1\task8192442\22161-1-ki.htm',USER='109559',CD='Dec  2 16:36 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>a16-22161_1ex12d1.htm
<DESCRIPTION>EX-12.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;12.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.<br> COMPUTATION OF RATIO OF EARNINGS TO COMBINED FIXED CHARGES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="14" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Year&nbsp;Ended&nbsp;December&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2016</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="14" valign="bottom" style="padding:0in 0in 0in 0in;width:55.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(In&nbsp;thousands)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from continuing   operations before taxes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(98,064</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(129,541</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(122,430</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(81,442</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(58,077</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(43,399</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fixed Charges:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest   expensed and amortization of debt discount</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">927</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,576</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,796</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 20.2pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimate of   interest within rental expense(2)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">817</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">949</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">906</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">883</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">838</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">841</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total fixed   charges</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">817</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">949</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">906</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,810</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,414</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,637</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss as defined   for ratio to fixed charges</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(97,427</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(128,592</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(121,524</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(79,632</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(55,663</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(40,762</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.1pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ratio of   earnings to fixed charges</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Due to our losses from continuing operations for the nine months ended September&nbsp;30, 2016 and for the years ended December&nbsp;31, 2015, 2014, 2013, 2012 and 2011 earnings were insufficient to cover fixed charges by $98.1 million, $129.5 million, $122.4 million, $81.4 million, $58.1 million, and $43.3 million, respectively. For this reason, no ratios are provided.</p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Interest component on rentals estimated to be one-third of rentals.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108224\16-22161-1\task8192482\22161-1-kp.htm',USER='108224',CD='Dec  2 17:43 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a16-22161_1ex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;23.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-3 of our report dated February&nbsp;25, 2016 relating to the financial statements, and the effectiveness of internal control over financial reporting, which appears in Celldex Therapeutics,&nbsp;Inc.&#146;s Annual Report on Form&nbsp;10-K/A for the year ended December&nbsp;31, 2015.&#160; We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ PricewaterhouseCoopers LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, Massachusetts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;2, 2016</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108224\16-22161-1\task8192482\22161-1-kw.htm',USER='108224',CD='Dec  2 17:39 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g221611bwi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221611bwi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  K (D# 2(  A$! Q$!_\0
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*6E2T4#44MC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g221611bwi002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221611bwi002.gif
M1TE&.#=AVP!- '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MQ00*$-OV(H!B?8Q+FKK9W;><;UBX!"V8TE1('-KW2M':Q[C\,-KYED0"%#"
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M0 $G*2YDZ[BB[BK(:\FPG11O9DPRJDB2LO%)  3*$0FPEP+62< Z#F!)%1T
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M)\/IKG3%I>N6+%(\(  #4,P/!5  NJ<BJA=;".!HV&1D%/!]!P%[@,!M"(8
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M'D !%!-^$!=QNR!^\GD4&ZF,=X2&_ D _C"&[L6;'K"4 &H!%(  ?6  OQB
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M8E@ KF6?D\&E<1L";>@',2B83K!>!)"P0'J;1:A*8#B2DA=UZP!O\$H &I#
M';R^ @J2AOJF!? 3)7F+^C>&Y\B )D67@,B@5Y)^!4 8!["%T':NENH$U+<2
M"::+URI_NZ"^KH5P%OB++GNY3X:: \!>V>JH\=D4;.:L$2!0_^B&/URI2C:+
MJ8IPZ8=W'#P!4K2BL?^%9$>G /K0C9+E!("P>C/E>LY5EHL6GQ(,?39LJ39R
MFT4< 0SVH;;:;E4[EWW:?W0EFP@W '35L( K6^[FQ@/PB%%8P^/HQE-*AZ!Z
M$$.PH(ZFQ>(7<0= HG8+M?]JRC&;KP/@3J?I;,C65Y.,B?HG 0?P#K5' <MH
MDBR' +R9P="G5Z\EEU,JN$.8EQK@EEUKJ7[0 O+ H"^);!)P=*)L 8[ZD;K:
M$E*4=!2 B_+'AT JL@<AB;87R.K+7F8E#\V(='TP!$HFNYUR9(EY:(# #R]K
MI&.8K5YH,!I@DL]L5PJPB0;! 2:@S4E(T!YPJY/!8H^L>Q58KRP6P;7)G!;_
MF+@G'=-16Q#T.%=*^CZ37(GN*$4=N:<-)X:5F-*?(8IF55<&>VB5N*&D>G1.
M8##\0'Y.,-6^=W3T1)4$04^*B7OBX01[R=5TDP"X"'$,*H^XQS>)0T]%_'Z0
M-A4#"&EL#1KTA#Y;Z=8RB7OJ6[&D^A")>!%LIG#IZ==;"1% ZQ"6%-A_W9#.
MU;Z;)X^-/=GNHV@A^J^4G=D89#"3=U);V,N:'=K/,JP$T&C_Z+.,+=JJ31).
M9E:LQW_CN]JR'1-'-X2VAV A"+FSO=O2UYI(_;+R]YB\/=P;L80]Z6C?V,K$
MO=P=X61]<(#.-:&ZS=S4S1".B  G!Z+9E]K5W=T,*5&!S#9H6.S=Y%T13)AD
=E0B;Y;W>B&UDP[G)[!W?,Z&^\EW?@&W?#!$0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g221611bei001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221611bei001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  K (D# 2(  A$! Q$!_\0
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**TJ6B@:BH['_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g221611kg01i001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221611kg01i001.gif
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MO=@B3BSK<4/0/*R8H=Y NNC7WC?ZJ3A&+R/>PN,^LX##S8PUBH,C?P/-DZ!
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MA) (B?#^!XFP"'!@"'(0#(U@"9.P I: "8I "3T0"7(P"(7 "(0P"($P"3W
M"(%0E$0 "8&0"(BP"(-@"(%@"$!@"8V "8S DXQ "<60 W( !(DP"(+PDH/P
M W'P SE@"/=0#_E0#Z88B>=@BNI0#^I@BI*H#NHP#W<9B?.@EY(HE^V@EWK9
MEX49#_'@CWN9F/&0EWDYF/40F// F'@9F'<YF'FIF/.@F9@IF>K@F(JYF)K9
MEW/IEX;9F*-)FGOYF>R FI)XF(5YEY'9FNW0E[0IF*:9F7NIF'WIF8\)FI\9
MFZJ9FYYYFWLYF9*IF(5)G'@YFWBIF_'0F9 (FX/)G+HYG+W^^9B=V9K!J9F.
M:9S;B9O1Z9RA&9RU&9U^Z8G6&9N+B9[9>9OKF9Z[*9SR"9R\>9FWF9K/"9^E
MN9YX^9KFV9QRJ9JC:9E\N9ZO69NRF9W?:9N_Z9WY>9Z^69Y[^9O5R: &RIS_
MF9EWV9T-*IZ7&9P+ZJ 3ZICX"9JC*9F3J9ARR:'CB9H:JI\#ZI\QNIGQ@ _G
M< ]TD -_0 1 H @P"0B&D AR, =R\ QTP F*L *:H)60H .-, AR0 >*0)5R
M, E X B#D B,\ ..$)6(T B!0*:!( >2T B9X @K@ F-P F@D .)  21( A_
ML @PZ0,_4 A2N@^5, F&4 EU>'#^#<$.-S "'_ ,DK #/- #12 $1, #.P (
M@H"4E3 ((+ #)Q #A  (B  )<A (0$ $0L #A$ (0] #1+ #A% (1G (0U $
M@B (0N #/: #<1 (FH (@! ).% ".! "=' )@1 (A% $.] #0M #@!"I0$ '
M]X .H;BB>,F7J\F7./J8FXFMCSF:W+JMV^J;X6J:V@J9JZFMY\JMUVJMZ[J9
MMSFN["JNXFJNOEFOZBJOY=JM]>JM\=JMX)JM^:JO]SJO_&JM.)JM \N7LVFP
M!:NO#ENNX?FO#SNP 2NQ[7J@",NND!F8^7JP[1JQ!.NQ#>NM MNO'3NR*'NR
M^TJP_!K^L@TKLI#9KQK+L"FKL@$[LN_ZL2UKL_":L0M+KQ.KL>C*LBC[LR1[
ML]_*#O:ZL[3)L=_JKS0;M-LZHG>)#/<@!SC  T10!$1 !$.  [-:!')0"7$@
M CM0 D.0"#_P")8P"#^ZK#V0"(*  UW+ V=Y T2@K($ "))*!#H@"+K:J83@
M C+@ B3 "(V0"$6 "$6  W ;!W]@!#S0"/M@""(  I0KA]> '87( R-@ M 0
M"CVP T5 "(% !('P!X#[ Y#P#(Y !([@ BKP QU@ C;0#,$ "7&@K$0@"( P
MNIE "(:@"3J@NLWZ SP@!YK0#,V  B(@ D+  COP"#^@"=#^X BYZKO-"@C'
MJJJ*P [FD _V,)IU>9?GJJTYVZWI:Z_C>JWX^JX&NZWL,+.+>;#@*J_[B:\/
M*Z[I&YKJ&J[I>I[;"K_["K#H:K+X:[_8F< MNY]"N[\J&[_G^\ &C*T'2\#G
MBZ[Y.[0@N\'Q6L'NBJT+6\ 33+/^B\ E/+0!7+\[^YX:K,#E"L @W+\8;+$
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M@0@ND8Y&C$(.F""%,W( !&F XA)RZ$0CTL$($;1 $!S44A$6 8(>H,,:C.A
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M,50X D.! 1(8 6;(L4-@A$-(,Z$K!4,P@69 @14X!$ @!!A@@15XAFK0!$7
MA'80A160GSLDBB(0@@GC 188!!;P 5%@ATI(A$M H!9H 1A A/92@160AA"
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M3+@$%'B$V_F!2#""/VB$?# $150$0O3-WP3.JTN''7B!$X"&1OB 'V0!%O@
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M %" &T6 "-@'J-B')0B #*   ,@ ;)B "0B !:  .S '!!B "X" SHU1!2"
MQVV#?2@ SV4#W+4.DWP],-6+:N&_(;K4&W20D1PL_H-(116N8XLB4/T,'8I+
MS:(_1+V,,FJN]?6MPDC3T.(:1.I).8V.]%U?1?J6AB-3:=,74Y(VW[I3W[@9
M4F,^/86:[Y(8Q*C>NI@'K00CS"!< =  Q*6 ?5"%QL6 R8W<"0"  B@'=3"
MSHT'SO5<T!5=?"C="D#=!J"'81"  HB&?7  !2A+>ZP#"K8  &B 9)@ #>A=
M#:@#<SB  9@!Q+V ?5@'Y%7>>VC^WGU8@\YEFZZJ"FETBRSCCSAE0-U8%ZB8
M!^$:MGZ\AQP(!!U0A!0@!$) QF?H@1X8@1,!!#'!SD'X@=ILA!^( TY8AF(P
M@4 PN4?@ 4!XA#\@!!<  F=PADH( C6F8[.UA!@HA"$ !!= @3B@LG3X TW
M@15 A!X A!5 '$=X!$R(V5(VY9>%L9IU 1@H@<?9 1#(!$+H 5>4!#J(@Q>(
M@0\8@N+L@7; A$ 0A#A.!$58A!Q BF&XG$B)A$A8 3F8 5$(!B7.@4589B((
MYHU+!QU( 1;@ 5UV 3F0 TDHA"1Q!$OX@"+(602--[U9"W89R/&@P+>XT4V
M7#=!@QG^L(<%0(!\W(<'*(!Y<( #0(!DN(,"*( W6 <#2( $R <+,  "2 8\
M  !5<!/0585?&  !6-($F(!\8(M]8( #B(=]N ,+;<<"6-Y]F $!, 8W40,
MP ;0;>EZF !N18 TT ,!0(/8_=1H@RYXQHH%D6?=DXN"*SBT !SB<XH*"5->
M@S7R$Z+NR\F)F0I.2AGJW5M]<T8!3"4P/1H7_+0U?:.WI)B"?",LJL"TL4G!
MP)OED[5VJU^D^9JHGM[60A=G:R7L,KA*TT&V,>JWP&*QO(Q\\(5ZW@<TR(!\
MT&=^]N>&1@ #V -A,.@+4 <$4  %V >')@!C %U;_5P V /^;"@  9B ?6@
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M.1B%R8C=2]"$7QX$=(X$12B%9UC^ :0J.Q4P!1B(A#_H@%+0A!]H@0\8A'M
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M9Y?[VVJF,*L5V@MNW <Y\(!F 05(Z( C[X$^! 02$ 0<X %H  4Y: 1" (1
M2 1-<(10^$=\6(=.D -G<)-*H(-A>-5[H 9(@ 1,&(1@1H1(6 1$9H%(QBG(
M@00?Z !F<(0B8,XVD80/^$,*E_S)7[%/0 )#03L2D(9)$ +^0BB!0F ' ,79
M1' G0M@!'$@$:R"%LU<$P:,(4L@$3&"'8\A&9["&:$D'N6>':$@'3NB$22"%
M1A *1$B$0,B$=) #[I;E2R"$1; $$7"!=G!C0O@#.:B'=7#*SUH* _'BNN2N
MOG%G1WJ*?3#X9*B'=X@'?2@'AE_S?< # 9"&!_AA!UB -#@ -:B' 7 #!;B
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M 0<P!P%2IH &S$, =I#F!(YA37440)MO", !3I*2?6  F".KB 4 L(0Z',
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M$"C"/G0"(CR"GQP?2[:D2[XDHR2?HJ3#"NQ "4A#(YP #]P 2+[ )91"&'4
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M+*4#/!@K1B$BP:V(>Z:AX/!-#38;':Z(3^A#/]S#'.!E#^Q  RT"'(C $+P
M)^S#61)!#H1"/30#'03!):2#$'P "3@"*<3!I-+!,!!#,FS^0B6 @MMB B&
MP =, C4HPA!P63U(P@K P1]TK2'LP Z(@",(@A$8@1#T& SDB9:-@"6\J>5>
M+N:V)#L, 0FD@#-<0K>(J1#$  Z  B/HB@Y 0R.H  F@@ W<@R(  2840S"8
MP TL0BGPR"6$0B4,0[$- QUT BB$WRD\0@RD0"D,PR3 @2*D@PV$D0I(@C3$
M@)A. BC<P X4 9_R@!$$0CND T<T%%6IE,8F+-TA%[+M3[B"X1AZ(ITAYN@T
M*^D(#7R&)HIFE+#UA$FH(D:)X%K(G;%ZH' Z7-<,J $/VVC(7<D=VX@B8A4N
ML+$"UGL":!E"AK[U6E*5ZRJ6S;_^P2%'21QB(M ?ZAM22<Z*L M2"0UR67#8
MA.?#)A7^/!RXJ:%O%I5*C1L;>FQI8&>_[1M5;6)&8=59/5>X10;IK$.$2C"S
M5ISZ_FH0>T@"TZ^T2:'_2EO.TF\(&QS'XBRRH1R'I"_^".*#.NL6NE*)'.W-
M?EP7$I=QY56$<D6+*.L*-RQ22.;#"B+FC!QJOE5+K$/LP.Y.MD#V(FXI&((0
MP  <5(,<L&X)]$ [R($<5((SD(()[ "1_A\H8$(E%,,ZH,,H2$(F!\(@,.D+
MH$ QS)$/2$(ZJ$ 4K0 E/(,*B)(F9,(+Y%X,P #WYLDB\,E*9JXO_S(P%XI,
M)LH GH#^$5@#)AA!$6#2Z+I )BQ"!Z  $00#-5C"$ !""P3",] !):Q#F79"
M)@!"(<0 )U"#"M]#FU'#)<1 (1Q")VB""<B!-32")%P#$+P (.  *5##,@R!
M#!2@)K3 "_3 2)*D(/37N-C9!R-%B18F24F7VYWO!XK<89[O_@@5B.RAZ6 Q
MG>%GM99BLTW$*X*K8A0$-F!#@5JB2*OB*E+$.P %%8^&T(X&7C!; L>+^PKF
M5DWTLWY@<KR5T$S7MH9TO=XGG5DB4>45",]Q8WKP.5 LK[D23&F@7OGK:@[L
M.=PA8.XK!X[HPHJ;-?HAKZUA?_(K1> PO8JAMY%<*K)O;H;^<'#"E!-V7&EZ
MXBF*(L_B1#ITW%N[[[G)F?I.33P$+38HZ&7>% ;>[Q@N*"U9U7]ZX7%9U=LY
M%XIDX4WXA,=Y*&4B18.*[$0=D$0S%#LHD#*/DA#<  S8[0=$;C-8@R,,01%\
M"TY60CKH  N 0B;X70Z0@C648BY9 SL\PR0$ 2  @BEH@@@T0CG0@21 @[<(
MP@Z( C0L PX0("0XP@KDGA!PR@X,PCYH2G('LWB/]R\/,Z*P0PL GS.$ @\0
M-"D! A%L*A$402*( AQ@P@ZP  SXP$-N C28@.$5Z@E,PAQ0@Z D QU,@D[*
MP1^4  I4 QT$PS/HP*X$ 2;,@2C^]$ 1]$ G!$(1 ((0C.2'+X(M8O!6]0-H
M;S!3E6@3HZ]HBO#!3F(M_:9<RS09BC1%;^$@?JAHHH,[F 2\2-=$96Q!\$2\
MC-R)F*%DH*'"U:LM717,$A?(NMWL,)3&-G97QQ1(__!<N:MP/K"[%H; 434-
M Q:OE9M6;W6V448A5B)P8@Z:&U5P=I1X2E1XEAN90QM@O@3 QG!HKQO"?>=<
ME=7\+O5[,D:QP2\??N#,!AM<,V*[/=P>#_G,SB?-:B/=..W^KK1H9N.UT5TV
M*NO,HBO&F<T9[N:QGMM+QRP-#Y4W8IS)>N,T>E4]Z(,YZ ,ED%($$L%X#0(G
M"($0^#K^'6C"#;! "P!!-52"I=[7(,1!?EO"'&!:H!P#'40""O1 (/3 "+
M-=!!,3"#])W $'#"' 3#>Y/"XP))B']X(]R#(YR ")@D><\[O</D)]2 B;E
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ME\92M=3B2]+0\N2V,.O)-FNPP$3^,3Q2PT,]#-"_$?N)[$(!/831<PTSMV[
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M@Q-R (4U+L*/B(% "/7:!S4J,<EFQ$$$3]P'* *Q@Q?$H1R- ((I<%"$$^B
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MH@X7@& $A, (-"@Q!V<L0P@=&,0^ZK%'A0P"'7.PY V$,-A)&.(00E@$(/[
MB'LT@K-4E*-'7.&$)PR7N$]P0AS^?YM<DLA#'E9P13Z@(*]YZ0)=:K1N&JW+
MQBY\P0M8:(5R/_*)&N2$!R-(P3,R,80A%,$'1-@+#UC  R)8(PB22,<B_.*#
M25QD!R 01"FH 0I0H*,<^UA'?T$PA'3L QW2X 2 0T&$#QSB(IGXP0I< $)%
MY, ://#+3C3QAP?VH B$L$=>$]1,8UK(:$<[ZDEUR@YS8@U%9S4;:N.1#^NH
MXUOS. U0S1$-X025K$,J!S;P60]AE*,X?L*,/7K\CG<TV4VTJ1I'SS0_Z3BF
M26G=S8]E@[?/M7B:0*U>F?=$/3,UB#:Z^=U:PY<.L]584?VC\YO5@5$"DFBN
MJW'>FQ?^=]$>A71!K?N3C""D( YY:$(KHI!9\[-0D"Z.0DE:-$HELYSVK.>M
MU@'/,D&DHH"B56_R68YFQ).\"XVI.VHJ'(_-81BHYD,=V*",V& C&>C4HQS1
M($TZIE.:V)CC,,1^S6G*&>9SP&,X>8Y,-HB=INCT@VKH:#)LCNRG-N4CUK2F
MFDD?@QAJG$/']#S'/<JM'D1)TS+_.Q&UURH9/UE5.?=8<".((-\= *(3BO#+
M#@1AC1EL8AV$>,$*! :K%8  $<6HABE4D0YT[ ,:,.!L'-JQ#W-((Q.BH$8H
M(FF(BU"B!S"XP238(0<@0$,'0V@!$1RAB2$ G(\6:<0(2N#^6_!F!!RV\/G/
M?S[&C[ "CEO$"-&Y8?2+()T>&VE%T3?"#9_?PN=;W,4M=+$+7=BBZ27Y A9B
M\81YS"L6ZEKCV:VK1NRND0MAV+E'Q$N2=*P%!N6X! X <0,BX" 2IS !#P11
M2F<\0PX_> $D?L""9=3#!RF86#,N88A1#&,4)YL$(SX0A&$,HQ)S\$0S5# "
M2=9C&2H A"-:\(,Y5",8/$@!(G90@E(@(@8\N$$AAF#B=.3CE^-IJV(PVDPU
M">_-_SO;D=JL#@M X )IN(<R((#9-#A  Q<X1CK:\08^V$,=22A'&M*PCVBH
MP1[UP,82%,,&7ZC! 128 #+,B8?^!S0@&LG(P!*P >QD+ $#V$#&##* &.KA
M%S!@'YR*;=(D.[K,<(RCG$J#R#0C'> A._@&U?IIRX($/ZH-; QGFN1LF8AJ
M3)A'IU),'8@&'=)!?40M@5QDH1HC0("$I8*)/]YL>'K$=!I*0H)I<UY',ECG
M=D!$HEQ*0SRG0TQ#?9H&,W:$H43-=E20>))P4>BIS, &G:QLF4A'?=0!FX[O
M?HZ'2U3MH("*'7Z! AS  =2@#NX@'Y !#?;/'MS  B: #XYM$R8@ ](@'B9
M BA@"<BA =Q/_2+  1X@#?"@#U2! 28@ GX!#=0!&"P #S'+#2Z@'I8  AQ
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M@0CD@!1.0 9 H!.0X0>&("H.P1D,@1)* 5I8X!(0 5IW8 B$  54,Q\F@05
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MKS0!%(!@%'2 !78@"*"A&JI!&DK@!!9!"'H@$1K2&39B%"1A$A!!!Q*A*F)
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M9J(<\B -*( !&& !)F )\(!M]V',/ I&1P=WCBH:[N .B.$PU$$/\. ?<).
M<NI&]* -@(&9?J<Q+*/1/LK/%B4_,%3N@>UP1/\]JKYH<%/= (@_WN%\ G1I
MPHJ"CP0^8AD-*/QS]^'$DT$#A,$!@&$3-*#<+, -?.$!]" "^, 7A,$8* "U
M'H 6B]Z$D7@\=:P!ZKH-?,$![L#^3F<^#[#!5I$1&(#A%UYC'1BQ ?  &"@
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M?-;#%VR8P (6D( %,. ":_"%.L)E,'$5E5WYN(   E  "PSJEHZ)!S#4<(
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M D$0"O<@#<4@"8W@")A "IK@")6 #CZP M!@#4"08BK0#(MP"(8013^ &(M
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M94:V I"0#O? @,M0E^@+(97@#*6@"3I "<UP ^N5#I= "'  !ZA%/Y,@"$3
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M"M60#L.P#OM0#(!U#NQL%>H #:(@"J1P@IA "9*@"<Y01CXP7D3@TZ4 !QU
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M6_@K&M'^M'V0ASZC$DT2AQZT$1Q,$%TH S-P!1PL R]P!1TLI#"( C$P@RG
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MD*WS!'_M\E60C7WU1'#,/L=HH,<2]N5C3CZ;O(7, PY), _^'@VXX8 ?^V@
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M,I""C:"4)!K8()LJCOB.<J3C/'5HHD6BIHYH;&0?)Y:@=68VMY?DB#OG88B
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MY,DO5CR/>S W !L"BO)^ ]W4PDR[A]N';0(0 ;V8(P'?W4E)XE$0M*?$'+\
M1CD,X\7A!* !]2!=<^%"% 5R1T=G[3U*D!K7RXKYJ[G54=")1MAZX"-O1>$J
M33 +X>_T3(W2TT@>Z[&/JL[#'N>HR(#<WYFJ/ LB]K!'/=;1DYTA#43D@SOD
M#$1PC>+^/$1GE(3+I /_N821D,WI\)]*2,=*T!UG501MP1QC 5".9!9ZM,;1
M](P]^-8EK$ M_4$1!,(DB$(0% $*>$(<^$ SB( D2(,BH  F8((C) (1_,"9
M51H.Z(D<\$ /I@ , $()"$(1P "90 (CA$(CK  C0$,.K$ PM  C1,()_$ <
M!(,B!((0"$+)L$ H[$,CK!HC<-L:LF&IV,(4=$$OB,,WH-<WN((5A($M@(.O
M<$$LV$>Q]$H]]<*RJ1.S&:(7($NNQ,@W6$L38(&QM:&FH,(1U H[N  @O  U
M= (+  (1$ $@ $(A7$(ZE$(*,(()J  U0,,^K ,IC (D%('^()3 R(D #CR"
M#8B,)2P"3B&")C0#) 0!)*B "7@""YQ (OR!)I@")K##/E1#-:  "C"""#S#
M.ER"' P"(,1!(!"!"VC"/IQ#RR"03S#'30A)^K'-SL#-4JBC<OP/.0(9SUB$
M](F-31B&_3C8A(4-S?0$X2B$6\'$.F1$ZOC78<A$.VC6V@!DTPA-W73$X"36
M?06)!/E<1!#64,"<1G#5T!6%8 T-T1F@9KU#8P7.5$5?^R"%S>7#+S1 :'%.
M:-6% S@7/.S#&@  >35&'3B YW .!>B=2R*#9,7&7[P!:Y3==!A$6:R!9GP>
MVNT#! @  A0?>;P&<P#>$D!&4&K^3_.QWF:T2!)DQE@@U4$DQ&N\PSY(P%]0
M %QPB !D7C[ @P(ID&^Q 60PF4+L0Q+\Q0*PB/80P  , !_L@U"$I( 1R7)<
M!V<A#545CAQ969;!S=?UWE@UV06Q!X[,@_\93GI Y,V01/[,#$ALW<I$@P0I
M248,QF+.A/XXF-2@1#0\1U215==L7=W 37@$F-)9S4@4UO],1$5H5H !($\4
M5E+@S6X:5LP@33_T3-C!A#U0PQER(A$LH1PD C.& @I 0@C$@#54PSY0 R:$
M@B.46PK<@"6(  \XP@J00BE  B*H  [THC-$0@\PP@F4 "F(P#\5@2N.0CW<
M@RJ:@ O^)$((3$,U6,(?#,(?Q$$*WD G[(,AP, +-$(D@LHL3$$5:.B&6L$4
M<(.%9DLLM,(ML$(9K (]V8<8?,.P^1J()M<^L,*R(8N,-MLZ(0LB>D$@[D,O
M7!NKN*BF?$(-5*(@/ (@5)*YF=LB! HBC((TR('$+4(AZ( A2(,TS  =0 (+
MF$ +# (CY, S&(PFB$(AW( +#((H4,(I/(P.,$(@M$ *Z( F#,(*6$,R) *!
M2@HCS $T7,(B+ (A/((@  (W.@)XYH,]%,4[G,-T>$US] _+U<STL$,ZI"/3
M6"1VO)7/ 5CZ@<1)YA4\G(-I&M9,(!EOWD1%!$TYG!@$I@[^9>%$;Z9':1X$
MS8W?D&W-4-1F>;C#=P1G1$A0Z,&<S]G$9!H%BS $=9!D:ZB#]:V.ZMB<T"#F
M&@F-]G1%6'0.WH$6!-2!DN1#&@" 'WQ8/[2! ]A%6& KYV"#7JS$<@7 7ZY&
M/O1#[ZT?/NQ#'A"  "0 4L4%'Z"%!;S?9&Y$/+Q#/F!#YR4!7,;'O:X>=)F&
M%QT#6QP -AC'] #%;X'&6@+>]DS ^P%. &U$/G27 -R>3^P#&_S% 92#RTP.
MOZ:%*B2DZES67KD&._X=9@FE=0C.8BJ-T5A9[P'G@&%'WK!(.5YD3/1,SD!'
M/$3#/!K$6W&6.>SJZ739SLB,@*G^*OLXI-P(G?TH1WI UF8.CF9"S6 48%7R
M;,XU'4JP1U-AUM?Y1.9DAP()R679@X/0P:!Z$B(D0B0DPB@40QQ<0D[U@ _,
M@344PPPT@B:P0 J\0"3D6S48C"6(@@\(82.$0IHZ@S/H@"/$P9OR@";(01"<
M0RA\FB(4 1 T@AQ( R4@PB,L:1$,@A!(PCZ PB(@0JO]Z*;HPK(I&[.U:.Z"
M2BS  HIJ"CBXPA2$@2O\+O!R2CZ4 2$BRQ<48A<@(HTB"SU4T_*"Z!$(::FP
M PZD@ @X0R7H0!STP!\8@B$XPB(P B=00SWT@ L<P@X4P2(X@RE  @]8@BG\
MP"A8 S3^H*DC( (F6$,B*((U(%HC.((I0(,U<((<X*\/3 (H/(,BQ,$-%($-
MQ$$[/,,E,$(B?,PBF*\GR@$[6,/^K8Q$[&-NK1]0B%]U!(TZA)\YC"509!UV
M0&1$KBU6S(.J@N!*2!#@G(ZT[J8<U>-%FH/3'H7-947BN&I.G,- L(1KRE4Y
MH(,"*<0ZE -"*LX_ MAD.AA$8$7EV83.G00\&!U46.1,1-9EK3%H-F; KF;9
MT4,V>,[CO&1/4H!,(L,>8(.WK@$VJ (YX,$&+%X%>,[G2( %^)W-T.3L_(4$
MP-BS=$9GV <Y) %H& "36:1[9$8&V%]_V0<RR 8"8 ,]6-C^9P2 <UE$ZT49
M&F3& D3#LQP@M+1! "B  @A  W31Y%Q 9DQ .=1?:=D'-I1R,OP&3=9!6QB
M,7012M"D&S SC+DQ8KR<""I.]<$&.2YQ;CV68G$5&VT$TM97W 9%;!9%%-,,
M8J95X60'S7E8#Z_114B-]P&'&.?$9::F6Y4-3^AKDH7'1W9'3TS-@!F-TA;G
MTR3$3E!9S^0PU0T-4AAFWIP#LS)-3LB- !80'?  $?2 QR1"2-&4-5A#$/1
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M?@1  !MT47Y%&3)00&H(0) 30 '\)65 A@9(;$)[43E4@&8$^0$D0 (@P
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MT"$=?\8K5F9KYNLPVFQ8OO$D.C$FWC'%\D$/OB4"'%0"&D ![J -'B "%&
M%& "', -VH !'$!9A$P"(D 5Y$(<\4;Y5.\DZLQD8X5IPI$C\H$<!" /!L(<
M!J .3G0@#N(];F9AK \\5 8J='1?$&)!NNG$[G9?$N(]#-?S\J$ WD!'5>$7
M&F4?WN$]6#)C$&(?5()JNI1RS/9C+2(G3L_ !N,F8<DGCB^_'H5?UM$K[J)K
MXD%2\LP<J&'P\)0MPL*_S,AD.5$4.4SPEH8Y.Z4Q$B(=2BIK9(I/*%(G:&(=
M&@HM!JG^PN0/5AH,EK!!&6CKUM;%MYXMO+P+*W7-N,B! !A@#1(  ) !& !@
M#\*#7=1W?0%6/+!+']07N"!UMA3PY)++N*)KMO@!'9)A%!0A$AQ!#@;A!XA@
M" Y!>S !!D9 >PB3&\I@%<:@")4U/NA!%W2!+\$#%KY@'KB &QADX+B "["@
M"QR.+9&I!V\F61%H@>:#'7! "Z5!$G"@M0X!$4@U$BH!&7SEY9+2UI*M!+EK
M'RY@ ,AA'\B! =Y6&8BL-'V!#?S@ BH@ #: '-I #_[!  Z F-@ N.P  M#
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M]D$!&,#^-.-W'Y*! "[@ @J@'_    Y  BI@ !H ?"&F  I@#39@ ,PX "Z
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M3@?DC#VBHR,>_4, $N!# P  #%\ X!_*8  RAL,D8 C #?TP0 /V :9];(
M^W!  7S1@ ,  P!ZJ!R9!-"F T#@'!5XPSX2"!D;<69P<#*</O(1C3RAQ27E
MR)O?>#(IH)!**^""BCF8PC.> (4JYN":3,X6#Y4(RU;@ZEF\NK:8Q3R%:_,X
MA]OT8D7(^.554_E5T\[QEJU4+3%.N\ECY"9'N6!E+4I1VM5^]K-3E<U7/%-'
MSOQQI00HP)'5,@"V$J"!))*,4UP4&V,P);:R$')L-0&CIQ"9+KGDHQP%. A/
M#* O;!C 7GP( #+V@0T+1*-@!C#^"DH,H('3/.PT:1  P9 1 #OL8Q.RW$<Y
M+##+-Q  (@U8P#UV(I%]P$1ERPH 'FA3@,OE80*GR4  %,FJIC F'6-#RV/0
M$4:EC,V0N*I(5_#!EB3Z<3&(NHHZT'D7J22E(E#1"3K4@3"@9$,=^ A5K78"
MJ'B,\D_F MNFQ :J0TD**T6!2=*FTI-; 25FZV '5%@"R+[]C"SFL&=3(J,,
MRI1&'X,;S8[>Q!F91N> --J':Q3@!@E<4!DPC-(#+*@'/  @-P (G2\$X <]
M'  9:DC +X()I<'5M#.RP^J-*$/3RM3C',0(PA &T8E&]" 002!$(>2P#TV\
M( 9_B!_^@\1ABU[451=XQ2L]Y"I7<,2B%=Q #X<\1(\GW"(?^>A%$Q3$U_7
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MYGJN3R!QXUH?80 %9< *'R=RIR'^!OD@#_ #6 42"UGP!5S !%^@FYCU6$Y
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M <K&!PD4 $E%Y!"13 &VNRN!=1POJUJXFE(1AGP47)-KOW)W1%B@N**8<;>
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MJBO9;SMYZG1$G7Z1:%-*8E0N7=10<1NTQQ=&0[NWR*RE.\MZ!GD>(@G7@>*
M2WS,D1>8K%MI6]SMO@(/%!85@%3^*U,33^"BLL1K*.D@H!:J8 M!(.5 3Q*Y
MEK?&VRI9R(6,R%31H19*4$FT3P3V%THSQO&U$Y:'2$$C*2XHM=@P&1WQ"KF0
MW_"C#;N "]I0"]WP"NX@\JSP#;2@#;JP"]LP"^$0"_:J#ZZ0\=O "I?1"MVP
M#[7P"OO@#:L $:_0'[D@'_K0"N&P#[CP"OK@#N:]#[!0"_N@#:YP&:Q0W[1
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M7H!FDAT 0200'ZHQQ9!*L,EGN>O^7%P.1N:8$V\?!R2XP  ] C GCP',V<>
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ML8\96>PCSA/?Y"-%*_NT(L4^W#P!SCY3C+%/&"A^$^.,KNS3Q1;[Q (%4$^
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MLP/BQBJV@ 4^$C8?9M C$Y30!";0U@E<B"1FCU #^.1#!R/^^$ G,%$"1-R
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M&8!(+(S!-\R#&:P"V)B!X]S" NJX#CN#(XA (5 #)9S #I":$"S"/E1"";0
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ME24WGL $+I!N)4]0RC>XT 0F]!:WM<O(/7H @Q(,8Q2 & 0C>% $'#R"!95
MRF,ORS'^6BL2.XI-=62C!;AORGJ\66*OE;8)3J7D+RKJK JR 'B9>7QO'?2Z
M,<O"XI :AVO/EYGG/L[7F&E5RXTE']B$/M.R#->161ZZCV6DPR(!?E$WG#''
MPO>!,*"-C38/:1E$) @128^I.CXGT<DBPASC)$PL@SZD)6%8G(IPQ;*M,=<+
M"3C [VPG5E(I6$0$2?2D8_TA.":[\LY>3HB$11U!_N8?84@^+^E#/>GB9ES(
M2B9N%5WH9$6RC];!=C[*.1X]GN!IZ(MF?:!&-9GY^(7H!>#39-$P-)*\"C_#
MG*U=QBL9\NIJG!X/[F7(2??YWJ;C 1A[L"-*:9^(>/46\+O^+?8IC*TZ1I1"
M=W:,8A24*,H-".$#1QQ"$(:(' E:0+GD<F,,HK,%M*&_CV_LHG.1DH@MQ-T$
M1L'D"678@A.8P(34(=O<&5F$(P !C4F\0!"8((((6E"$%!0/O0!C#:O+Y'4R
MW7^]J4:XK,&K3*@''^Y!*M)KX6@%3/3-K/(-+JB"96RL]$)#RS#CQ>0+XY3E
MQ3CMQCBM'PP-Y,@!J_Z+1F**H!3FA*Y#."XD,G*#7QR,[3BHAMJ'TQK#:-+H
M/I@H'X[A&,R!#X($&7[A-=H #?Z!@/ @#?8@*O[!#=J@#<AA'_; #=Q #R8#
M'XXP"?$A"IL0*?(A&OI@'WYA#9K^< V000_8P W2P!?2P0W.$+NTXAY\X3'H
M81/4X1^0P:Q\(1]\X0SU(#OV@ WJ@ U\X1RDD WVH$#R(1G$L W20!E^(5WT
MP1>@D G7( \%8P_Z"8M4P1?TX1B (4CRH!_ D!S((0W6X!ARSES^00W<X.:,
M@0D%T2%^@0WLH W8 !E\H1\N9 _P(0_.\ V 03IRCA$_\0YHL0WP8!^.@0_R
MX1?28 R300_6P W6(!@'R!G7 +N2X0S7( ]*9!\VX0SY@.Y\@0G3$!L^<2^L
M(@^4@@^V8@]^81]Z<!_(H0_IL0W0D!.Q 1^E\,+FZ#+8+BM(KRS2!3,<2XJ0
MY,^.18+^F$@S$"VNZ,G+ DQ9I@60UJ>&..K'T,=LN 4X%L.P9@2L&(,& R]D
MD.$8N&47NF$?O"$7K@,77"(<M.$>Y&$7V(,;7H$]:H$6]F$>6&$EPX$5Z&$?
M:,$6[H$>7&$;]H$;M&$?X,$E]T$E]Z$;<B$[<,$=]D$F]T$><&%*<B$<]@$<
MJC(?<L$;EI(;\H$>NG(?M$$I6]*L<@$<\,T<B"$=&L$$B* $3. /-"$0=D .
M]H$9".$1&B'Z#//9PB +L$ *2,<I;,$,(-,,FL +7&$B="$+E*"8Z$$*Q"W\
MG" ,H.T(:D"9_N $/B 8,*$'>$ ($"$0"&$1>"";HB(%K<?^_@(&U3+*L5J#
MQR;$WRBC-W\SWXZ#,@8PO1HN*H:S-0RPX<PJBV83.=<)77SLS9;D--*!+2 0
M,69#*RR#+#+/*N)!'^Y).O$B'6Q(+'+*1@RC.>HJ8J)#!2MP?08$-M@.1/J%
M@ #R;%9,*P*MYCYC'P"Q' 2@&--@'QH@#?B  ?P@'S8 00_40-4 #]"@ >H!
M M( #S8 #>I! A 4 M!@'R0 #?! #1P@7=S  ,@!&>R@ B; #LR!0^^@#8SA
M'Q[ &!G@&"YD'RQ $O,A LX! A@@2"#@'"C@0B?@0R6 #?"@#7X!&!@ #^S
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M 1R A VH I#"#M: '-0464E8'1Y@O2G >,Z!0O="&2A #[H[BT71 J0D'R1
M%2S  29 MO/  K3(&"9 'QR@'_9 #?( #]9 #RH8NAMU'R@U R1@ \KA'PY
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M%+##/?BF/ K481]\4-_FOD>!VNSC#3.LH3(V<($)7*<E^T"#.?* '7LD 1G
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M-'K'2TS#11:)-?R -1/YA%NF=[3D2W0GDBI'<CMA*)- !#H@!($@",?T!T*
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M![W%3C^OR8:2N?J@J]Y+^.A4W#G-[4L.-M@L1\Y$YY!3,#7&\51P.0]IFU*
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M0:B@!"G8> I*X (.Y8,:SI!$?2$NB$4@ A&.0L0-/B"(3@P"!H&PA"EB( A
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M))Q "CR"/[)KN\*)+JP"N[J"$TS!+F2)/'0!$_"CN\+)0#X>-&!"#!C!$+S
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MCBUJ:;Q&HIYEW'H$7_"3O7A$J;G'YE@EW@1AE;$81DPB0W14Y+Q;X>A&(\3
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MN0<^P3D/;?BS4*Z8!2QN@=%ZR*,5^W!%0><#"Y\6JE #T8<WSJ(-?#XSFK#
M13X N@^/=&,;]\"%+')1TI*:XZC^'\F'.]HA#E;0XA6RV.8]>C&+>,CB'"F%
MQRSHT8NS8 H>V"BI3;=AE:S8 Q:ST(8YN+@2=6C#&X[QC&!$Q3>](85;?]-+
M85I9CZVL!5#U,,=;C++$C."E4L4B#%[T5*@AQBU/K%(':Z$V%;L))3*H*E:Q
MDN*84G6K3\?J;%7BIBNUN.UK::M,J,Y&K*GP(VU%#&T^2D,'', )<4-X@2:
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M'-S!'+(A%\RA&[*A:E=BJ[I!8KVA'+KAH\1F*LXA"39@ R" =QO =X?- 1[
M 8;-=R,@ G2W=X>W 2#@=W_7 7K7=Y>7>)FW 907 C: >#<@>I>7=R%@>)5W
M>;EW>WV7>GU7 LBW=Z]7?+MW?<.7?<5W>)DW?<.W?:M7?,G7=R>@&O)!3R E
MGN8&T>3 #@6!!P!H$"X!$E+ "': =.9 2?[ !5P@!]!!!TB !'9 2S@A&J*!
M$WX@#I_!!.1@%,A!&AC!$$RA!$X !!J!'%; 3?[@$$(A"$>A!UA@!S1!-WA
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MEX"PVUJMY1JQU1JME^"LV1JL 1O^L.6ZL1&[K9-@ -JHE=;F7N]ADZ2,$'B
M$(3@#THA#F[@$43@!D:A&N0@!TR@" 1!!4JA'5;@00TA/G-0':1!#@;Y!$R
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M&#+A&9(A'R;T!$J@!()!'XK!&2JA%-)!$6X !(" 5 :!"%R@!!+!2^:@%&X
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MH%@7=8$0^+"&*85/H])1B+)#@I:'_)"'^<0.9[-#.'0G4"'^"U  !;.@1O
M!4^P"O>P#4S0#?M )/M !DZ@#FKD.XC2#K/0!+0%$S47#VTH!EIP!61@$_D@
M!5-P!?CDC%5P)U:P;S 1!DX0#Q9("_B$$4U0'S!37%Q##TT0(M6X3"1TA_NP
M!5#S(?B )UI#6UN !17H!%=C@<AE'TJ@#;:'3SP$!9H$$^' !*Z01MH0!7ST
M(=@1!K]X*%Z1"\&&"_<P!@P8@4S "_>0!5X0:/:U#U4 !CF$'6J44FFT#WW4
M#O[0!#@"$ZNH1OP C?S 43B91C8ID6;C*CID86HH/!%U/+JC$KP">]%2+0E!
M8D1V*WC!>[#7#\B"+-YR+'V&+)#^<A?>\BG\X&'M@$,&41=Y^%,I]7@<Y2TU
M>0_O@!=Z)ACZE!<$P95IR6=J!)>!EQ #60_\T [M@'J[DU/W8 X(8 QX1BH;
MME.HB [W0 <H #AQP -%4 1RD Z.T (ZT Q!  V,L .!  @^L#R=8#B'X#J)
M4 ITP ]F"!/HP [D0 ?>]0B@T (C< +0L _.H -_  CK90IP$ HJP .8L XK
M "]^\P>1( */L ^-  (I  D<"#3<L JMT J]@!'=69[)Q0W<H(FJE05?  M8
M@ 59$#-=8&LPDS6W!16VP 2S99XRXX%"@PXJ< (O  V=T -", 1"$ A$T .*
M< E#, C^I" *<Q *XM4")5 -TB ,Z> ")^ (/N "CU (FT!C>0@3C5,(B_ "
M/N ()* #Z3 ,&&H"XR59=% ,FH (/) )C, #@" $0L #._ '@: .ZR!X)!9Y
M^( /X<(K"[$[J:A"OW,M'613=I="",$K6#%IW'(K2(5"<A&*D6=WJ9A"8J,[
MO>,L]',J#J%F#Y&DP8(JP9.*='$.,!53<Y&*^E"5J@)"FZ=")70K!R&)7.H0
M&I8-LI%IFA8/VA /"%(/D+$>^C /\+!,E\8+#I$/W< *%"(+]1$.L9 /D5$%
M7: %N7$/8$!T9W /N- $W^ .'10.N, $VP /]S .C_$EY<#^#[/@!)>&EZ\
M!K-Z#_#P!#+R!%HD2CP'!6,0([#01TV0"_'P!%J BO!0<[S4!+-@#_+P*_)
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MK++&6TNGDG)GAE>W=Z=AU-+HEVZ5EP<1INYZ4]8[*14.Y'3^&IQ*4(^Q$K8
M"_#D&+,P!KP "V/@RG2W0U!Q#[!^!K.P<.8 !?!,!BSK;;-0!E7S6[\8!?:,
MN+P &P;U':]@!E*@; PM&7OR!%]@M>RZ'[F<"[)0!3NT!:O "Q,-"P!L!F1
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M( JBX RAT B6X -P, FFP (?, CI, J1L +4P XA( (E$ 28( UQH*"44 H
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M/3(6M&!:@=1!JWV4@4A8P((6FD"&T3R!6%!P!2Z@L(\JB<8*6V!E@>K1A%E
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M>(4L6+&*>G1#&TS<QC;DH0XO0'$5O/"3+L*@"U8 <16T$"$L8A&+6]P"064
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MR I:UL+5M="S*W3$X?"%3Q\V=$49MA&M4XW!G_/$<1G(L(TS&*C:LO#&.\[
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MPC+80S,0@1%<52.$ B $PB $ B@8@F#" " T0ST,PRA  SI P@H0P@I$@B#
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MZ+"E0M #*=(KOGYE+RB$+C"$&5#^ 7^*!#BP KY^@DFD#5R>0 DXPR;H0"2
M0ARD0 \0P@A(0CK003F40RF8@ _L@" ,P@LLG3-  S4T @HD EE0@C6,0B!
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M AK-@AA @16  9"T CQ0011( 9V802^8@424P3UL@12<B1F8P5:R0ADT 1D
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M_X,O/+B&_X.,F[@O_,OXD!A-F<,]5((@$,$@2!UY\8 IQ,'^*0!!5*A,Z/$
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MP0W'N),/<^P#$EDY3"(2H0A1*$(0* #%#W0 #1\LPQET^$$SZ- ('K @$2-
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MRJC,";YW>]E[*:0$)*1@O4M"'JB "9A@"UR"O3\!":"B!S1!$-9A&7@ $(8
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M!C=[1[$+W(*'_0D2;:?CP@DD.-,(#T'XD'0//@0"2!Q!1!+^B"8_)&**#3Q
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ML8(4".($,1C""8K8 VG%0 2 , $.XEN(2WQ1$RK@P2*<L0(3+.,%A, P#TP
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M\ =J- ,'I@"$( [1@60\8QV!2#,@<,"#0?!C&(K A ^8J(,?J* :G2A!(&
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MY89/[:&;ZN[FH+?]J759"PUZ]D$->W#B!>[B1#-4\ =- ,$0)1!$"1YQB!*
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M-G7^G3$QW./>K&VF:!+4.AUZ^J:/7D2 9DV'>/QD!L^M1#A7S72L=*693AJ
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MRPN<  M0 R@(0B(  1%\A,@81!RT R=X@ ZDPRC, 26(@BDH@AQ<PBBP S3
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M/3!"!Q!!.E2"'%!"*9!"(L0!)HR"/C0#"[  #IR "&AD) """8H "PQ!"/0
MMG!")2CE8L[!,%B#"G1 ,*Q#(1S""P2!*2#"K<1!7$QE)IS 3%QEH KJH.H$
M:PE%/1B!OTB#)/2 (/Q $3RJ*#P#98J (82""7R '*1#,8""8S6"(U0".4!#
M"73 'T2"#L3!(1Q"R,&!#P2""QC+!WBE-(#7(DS,*!2#-<C!!Y3 ,,@!"@B"
M("A@(!#!HR;"L>1#.AQ-1L$G["P/,";B')9HB#C>UYP/U$#K/)W'*\5F[R .
MG1 =3$W^R?35QT39B)'<QW/<&6ILR4(*AT>%E)0P2>)03^T8238J6)PD'Y#X
M'HG%T_J@68E61X>,*SCI6$,J%.K\A_+<8NS T\(JG3QECS"%"4J-QB_V(FBT
M S#*(8O@1'(D8C*I4S+Q@T,-;)]XQO@0WBSYG5.I&.6D&.%9SD)IARGR"(>H
MCSJ)#O2,HYE)#\&B*SW58F_NDWB$4SMY#H<HU21NR3B*SMCTV+H^G?>%B:50
MXCB%AKK.#\=N"+V&$Z2DS2O^5&K 4O5DK*:]3@-!EQP PB \*B#(@3.4 B 0
M 0A(0B6(0 @T C5(PRCTA2/ S/J-P <D AWH !$(02 $ RC^], 0 ,(+:$(0
M?$ +I ,A.4(C:((B!,,P4 ,0B$"OPH$,I%LU< *0:J8@]$!;1<((G, 4$>KK
MPBY5?@(7!44[]  (I  TA():%8$<, LFB,('J$ *E%8H]$ D-$,U6 ,I* +%
M4$,UM  (L$!W#<(TD()P%4,UC,(T_ $HD (+@( +E$,UI(4A4$([2)<C^$ I
M[,,@L&X(-(,E"(+;_L$718(]H,-QS"O=S$BG\.]KNLXXAIFD:$WEP";X$<Y_
M]2__&-Y5S0:0% B)9D;30!5_DNW,ZNN1;-5LA%3?N(:-E.@$8PZ3E*?G_<YI
MRHWG$=-YJ.N7V5.9L<TV4NOZT&?^BEGMWP79Y%T)=:)&E4R(CTA429G.UR)0
M-:4'(-(/A:WF<!"0:JS>B-1=EY'(#UM*@WI-0WTP=?*'GQ1>F[!)DN0.3EV/
M[D 5) 9)&6/>E92>H>T&EO5>?;X>Z*"=_BC(AMY(Y)2=>1X(;7(*>FRQ<.0&
M:5;-3_G8:;"//[+>@$0*C"A??)98-^D(\40)_-C-<N!'TKDG.=S#):C577P+
M<75  %["/F "$4!"*3QO'T0"D5J#-*# "+S *>!0-9 "-!##L8'",\2!*6C"
M"8P 6T(#)CR"(FQ".B2#5O0 -.P#'$2A"#Q#(\QO#] I(+P+NY# (\1N-FNS
MN\UN%[G^P.,&\P[(11$001$H@B@H!A'(03E<@@[<0$WJ@R@$02,(!A#(:BET
M9"!X@B&4PBCX,W+]P0_HV@E\P""< R<H@@Y  S^8  G<@ Z 0CD$0A$401P,
M R'T  \TRY$2@CVLPS)V"*9T(\=.L*'\AQK[8DGEANBL#P%9AY!41R >[8@P
M$"P1WO1]B:=DAB$FCQG#4G#>AY&8#VQ CM*EWL#R'HE$,<4Z3NAEV7YHV6X,
M4U#GSCI)B.<0$X<*FI7$HY^4$Y5)C^)\L#&2;3&:1[H*'RDZ5<6R-0&Q+*CE
MTIKE')QP39K4"9P$$)(U",OZ#6LLXT1!B-R<B71<63NIV?7^&&S<5,GF4-14
M@\YN#M[3CFN:88TI1JR,;G%V:F*/((HSOF'A+6A*66WBC$J'0 V08)^6[!PL
MA4VUKC6)<+8S?FUZ#II$/8=+5:S_2J-"0DL^B!:K%($/Q$$DB((/",(.- (Y
M3((-M$ (!,$^) P=C((U! $(M  =^< @9,(Y^S,H-$(G_  0G (I$'0C2(PA
MQ  ZI$,(H, -[,#^P0$@_$$AE )&2W,A$$)3DN +P  V;_-_ W@+VH,.0 (@
M+.X0#,$7(8(0  $HE (+C$ A5,(P6((-!*LH!(,D% ,IHP 1(@(/)((<!&&N
MLL,PC (H!,(@^( C9,(DE$ P[$/^,2B",XR"(/P!"UAI)0@!"<! ,' "$?0
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M0R,0$B 4P0MT5R7HP C80+[!@<P=J41.I24\ B'\08"C?,K/2SNTPU#\00J
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M(X-V1X3L8WEF)+!"@MMN"+*^ Y],+5;21'9HY1$KQ6\L*)V.9:AL!!WP01$
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M((A,2&,%'5"!*1)Q"$QP0A*A<$8R1D$)3&"""(KP! Q L -H!-0'I-A'#CK
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M("22(]W@E/I!!F" !61 !=YS!6#0!5A@!MY0!61@!610!?F "]Q#0[$ G_<
MF6&0"[6P"[: 6_/!"DR /\(S"UW !*?I'J[ !%8 "]T0123^:V4O(IG[0 M,
MX!X2(09VF0]BP 3@$"@O @]:  7W$ ]5P 19L![Q09Q<  _GT 18T LPQ@I6
MP 2KH!^Y ++>0PNR\)994""RP 3II3_= POB< ]OR7_E0P9.  4YV+,D0@L
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M[@5=U9S^'MHP"TQ&!HM)0*Q 0%0 !2]BF?*@#7E^A4V-G5:@!6;0!-U5#_
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MY,>*^[!'.+M)#WK@8S7>T(<[ZD&/U71C'^!P@A0"AX]NX -I77 %*V(1"UG
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M[@@';!(>MBHM>@BG>G"'=Q M<(C^)_3PN2>P1WO+&RB0@ERC@BF(F[AY13)
M4RF TF_PT7S8AB@0 W! GF\ @YGI5GCP!F=B#5SP&=:P;'HP RJP)DH5 Y[A
MFWB@U)4ZF[0)AW;(!2J08GC@@BK( KFI@F1$'K>+ JY("DKU!BNP F^@!8,4
M"WMK@G^[!U>P@KF1&VNMA\#Q+'OP!I6:!V]X@ED0!Y5R)RA@!79:8'GH!2HX
M6/,8@V-S BAH!7P@GWKXAE:0&9@)@X.U;7BXA2N8F2B@2GVP@C*($_F8ARD
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M> B'<( '<8"'58"%,BC[I8J%R[C^_%> M5N8!5&[C&V<#%NPMGT .6T !W#
MAUS@AC+ A:2ZA3(H-ERXA8S3N,N__%'3MC/H?#G<A5-T!]/_!GC@AES81J:'
MA3& M9/?!50S-<Y??KV+1Z?HA664!VWPN6W ^W1L!<H_2E$KC%AP-6V@+><R
MCQX=\TCSGI1=D.;)7U7*GTX[['=YF(R]K=DB<\)&POOWT+IFD$.;7_$!B'SW
M!-K+5W#@/7L'$Q*TEW!@087Y!$Z\5V^?M'MSB SY@8B0)A\XA* 0XF&9,TJ
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MU>(5M8C%+F*AB__<0Q>P>$4N<M$*5PSL%K7H12ODL0\&W4,>'JH%+';A"ES
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M, 4)]$#^"W3 M8D ([A (11!"$0"('S $-3-(Z3 #12!(I!"2V$"-6 "-)C
M"RB"#6#",Q15$0#"LA&"#C#"/F "")! (0P;$S:A$SYA7-P#]-&%$)P "SB#
M)'Q%W_0 ( @"(3S#,IC #IP (D1"(PS#.5C;(6B""H" 7R5A)BP")DP#(O2&
M#A2!(T"#)C ")7R "0@!#(B "H!"#R@".Z"#*$2"(V0%#H1 ,S1#(OQ!$?Q
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MG9#!.'3*-DA*+21$/?3",'U*+9A!&7 (M;Q"DL!>/M0"/"#^BQ(5:SQX03A
MY3884ZK4PBQ\2I;0)"N\J1G@ H35@[;"PRQX0Y6XBKE<JAEL@RZ @\-\0S5U
MB"VP@AF\0K:X0BM BP_Y$#CH@BZ4P3R(P3R4@39DD3QT@3?0PG_@ S>@T)C0
MRQC PAA "+!"V'K40CC\BK)X*SQX$KUL RZ0ASQ :Y"($4UFRT_>PN I2CV\
M@C=T@3QXDL!T@\#&'/><UY"&W,N.7/TX1SV1DYS!S)"^(@EAZ98>9CGYK"S6
MC'P,*7O9V6?N7\R$3'9MG'G0(G !%Y$"8-%B@SW0 7',#0_\@2#TP""0PC-
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MCQ<7^;R3Q9@?- 'I75.YFE'Y/42#/4A"8P!"%S(;#Q#"(OP!(C0#$)@ $7P
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MHQJ!X$H!!7C@!%)@!=(!&NA@$<A-)]3&$)RA*&9F!%:.!!Q!#3&A%/X@$W8
M!$J@V8B4'Y8!25_@!80@&)QTH0HAVR@'!QNT$T T#B_T<T$W=&L"%8X@J@P!
M9: !;3"W!PKA#Q2!'4PA!&[@! 0!%$"!':0!&B8A04\ !&) X$B $'R@$Y[A
M$!YN"!9A$*:A$P1"!$ @J$" !2*A!RH!&JJA'4!A% +A!%Q@!$HA'>@ *R!K
MYWA@$?;^H1S0\9UT9WT1!K-F+7E2LYOPH36_Y34?XP(_B^I:![5>$S'&-%^:
MCEQB*S3LH9I,BUY\D9N(QY_:-!=.B!SK 4W(*&%Q18G2: Q*L^T83QLVE17D
M@0R>@ GJJ]#$(!P8E0D\DHS(XQ46B$_XDA7V01>RI#!FH0FB(!=LH0R^00SF
M(5;T)!=V@<3<HPO("'W*J&);H4FBR2_SP1;F8Q[< Y;"P0N$SPNX((+J80K@
MXUG(B Q$#V>9X O>$7X<B=%:@?RNY#S,U0NZP4^4P(-@03QN(5E/U0QZ%1:\
M>!>VH2-E@8YF01OHB S@H17.($.LP IFLH_<1!9<H1? X#W^!(E@&^,+#N\6
MOJ$+<'5*(L0+Q"$,-NDI\^'*@"EG;T%._G$6XD0;*@,<4!D*[L<;%L3+Q$$,
M0HCX"!6%#*@66D$,;N%6]E(A\<$>H*@6RLN2!=D+O*$,ULL,NF$6L@Y<KBY^
MMV5?KC8"S6D#/RU.[[1VM#EVGE8QFC8:?1'4>F.T6I-<\.5JDV?6DA%,:\,X
M"]@<[B$.MFH'?.#FXH 1V@$31. &2B 22$$4<+<:Y,81>I<0/X $'H$'+#$.
M(H$% "$1%J$:+.$0!.$-PY/9>  3H$%%.2$4X("J1N 9UH$0"N$A>"XC0"(8
MA" 2%$%T83JF9=HD_LTE\J$'=*+^$TH!!G2F%=FM%#!A$5X $FS !J#!$)AA
M$5:@!SI!$B)!!TP $$[@0#N@;S[@#QZG!SH LJHZ!F1 $$:@!QQA$C*!!UI
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M(0<YP $4T) &*8"0U'0,8A$O^, '>N""%B "$C<HP@D< 81B@&(%COB!)8R
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M49<X2 P(HD@'(Q2! D"4H >A& 4F_H""$Q2&!3SH "G:88U&5,,1(B@""SY
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M R=0""K ;3L@!T2P XL0""U@ACU ">D@"HHP"M+ <BUPA3N "#@0!*7  8I
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M>AN9&V)JHX,4#VH:/T$Z?? 0/_4@I"XDJ;T #\7W$KEAI.#@J=U #Q^R#?(
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M(.($A&"$,RJQ A/T(!*%L,8]5#""%F@B&'*H!#3J88]0E, $('B!,_3B#$C
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M-F4%6V+//ZU4,;6%2XB7S?6@[KRA><43.>6% NT#.>2#)$BG_@E"W%R"(JA
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M"B@")HC !T@"-8P"*2B"(R3HO*0##'2 9[: $-Q /H*""NR $+A (_# ![B
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MG7L8V>$/0A91!!-H@DB!A5!&P>2/9D:1A)&#2($$DU&D*8::>B1AX:(33OB
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M 3K0C+4*8">;L@_NK&=]KLQZ'OUF,=[E,IP>%F%J-D797*LXC+[-TK#VP]I
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MTJ]H3BW^/>[#U^@H&ID(&0_R61;(I48P7JBFT([%I(:*&O(A!U: %(I$!X0
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MFA!!"*RD+[O6:[^V.NY!P+RD'GJ@3:2A$A"!$H1$$! !$DZ $Y:!!D9!#N3
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M&BI!>D+! P3!"(J !RK%!R8!<N#  P+!!4#!$HK!$!1!4^B #IH!$SBAO#Y
M"(C,$G0@YGI "(;@#SQ@&>RA&D!A'3;J$6Y@:C5!:QUA\6S^H]F\94!>LF$D
M1B:WHQ^.-S NH(BGIP'VX!@. '\4F0&F(Y3WH0'2]QO9( .T(@&0E($A&5>/
M5SJU IWKPAV/80- M2?\H  <0.XN@ WV00$HE \.0/+VX1\.8)8S>@+VX0$J
M&IK=60(*0 V,8@$NE/.F)40; $SYX0 H] WN0!\0H#'0@ _X00$^ W^UX@("
MFGA[H@+ U!PB&+W=P)W9U0"R%Y);;P,P>BLPA0(07!DN('RWU+NC-1\BN %V
M=,A[(@^(MP&6E+SGV \J.H4G8+SG^W@IH$?!"IH1F)86@$[9-<35('U'<GKP
M +KW 0_0X![:NR<FP +"=P&BU1[^)J"<R>$!'L!KD.$!%B ?V, !M,(7L+<-
M"J !O&("*IHN%(#)LS6AL+LG,F#->P(/0CP#L'P?T$ /E*&.AY>/PZ@-,@ 9
M_N$8^@&_N5D!INC,+W1_D0&Z&\ \)\ !M-Q?].#%)SI;+]D!O"(9MKLG@*&.
M;4@-&CT9CA<9(" -HCP)"OP;+\#)?SR,/X,?IN48<'T?,B )[/PS8%TK[.!X
M[V<?-F";?V&\)< \>\(!D+0>&-A^SW3/'?UX'6" =PTHID<"=+<GUH"&&^!>
MVX(Z"HDVY,HUZ,HE*VU;&N4>*,%E-4$.1, '&CL4J@$3J&$2:0 18F"V P$.
M,,%#="#^!!+Q;4J!J]OA&>C =\@G"(PL#AKN00C!!?"6"(3  YZA'FK.&A9!
M!! !!5!@$3"A$'I $O*!$48@!2R!L(->Z/WK+[>D'4 .!MZ$" CA#R!A$.1$
M!R!!!2S!! H*1$9@3HK@#RX7#D"@ W@@$S#!&H! $3B!&N0@$:R!$Q9A$*P!
M$S)A!SK@ _[ !U8 $/[@#P:!HRY!'0Q!!2(!!88R$A)!$" !$ 9!$ BAN8S3
MJ43&8H&(8:8&@!HM+?I! =P@#^Q@@)LY@1V #XX! :9G>MH UZ?GNO6\+)B7
M O2!'7X7&?; ?G/Y?D,<#<:;4=Q@QMTQ#=) 'Q* 400U \;^VP+68!\2H,*/
M>("G)P\H@ V&_ TN0!\N_/20P;\A( \40$ ?_ $78%&3 )H/  WN79;3@&#-
M(0':X [P($/YX:77H-W[H=7= $R] @\@V?@'] #2GP+2%PV&?/8H " FW,&#
M1]D^??KV[4$P(4^\??LL.&"39LV!?_OX--BW -@^7PI^_5*V(,F^!AD&VCFV
MCPV")'L@(KRG+P'+>OO.'3B7@8(>.WSRW;N7[V'/??WZ)4"S9@V&!/O2/%#Y
MCZB]?138[(N'<Q^R!/GRX?QU &N:"_M^6=C !]N$#'[VM4GB()Z#//O8X0S)
M!HT%-%C=0(2XYB7&??ST(4. #&+^2*00#QQCX&M?O:[_%JP9<-4>0GWY$B);
MX& -Q <8^2UHO(_<@GX?(>"A !&-263G%IR3N4_/ W[]%OL:O<\!GWW'#O@"
MILS!!(CYO"K8C09P&C0US>W#0!L?3@M:<1K7B6?@'=C\O+[N9VY!&V0'[@S$
MHW#!R%\*TNSSG!&!A3RP8=4 &V^PH=P^>6S D3'U_0(,?FH4AT$>>-B1S#ZA
MS13/ 8W5<X\Y"/!#P7]XQ$34B: 1M<]00H76XHEAM2@4AB^Z.-2*,@Y%SCV-
M $+('Y (DH@@0CBB@B,F<$)-)8^ 0,@0@!P"0QP^=-"!$*204HT/D8!2C1QT
MH,,)(8;^I$-))BYT\,$@0]Q0!"" $&&")9>P T<0BZ@PB0N.$+(()$+\V,@^
MDYPP@B.#):KHHHPVZNBCD$8JZ:245FKII9AFJJFCGR!!J34LG/ "-9+T\,<.
M@!@"BB4[P  #(3!<<LD^AO#@B0LO[" ("$)$T@DT^P0S"BF59!**(G0L@XDE
MG8A2S#[5<.+('R(0PL,+,&22@R+[2(+)"X*PT$(.F( B""!#$!&''/=0$QT^
M,<)H8U@L$A6=O?/&&)8^]B9D+U(),  ! W;L<\$;D#7 1S((X(13&PP<I,]5
M;01 CDPX^5$ ! XHT,9):I"S 0;(*; /&B0_A <$^^"3G@+^>;A&WUGZ&(!,
M$@@KT"%''N'$AP/[)+"''1;T,QUBK>WD@"^^'*#/ L<DP[0^>BQ CAX'I(?@
M! KH#-%L"5C=SP$69'#!!1?+M<$!#03H!@0'2(!3 V^0TP!@&B>1P0(9[*,&
MR_S@1 $#&&0PP7'VA(9<$@P@0-\$?%MP@0$849 $.1-8L \P!4CP0 !MI ?!
M X53<-@>%BAP (,XQ>,U/_?4PR$&"&SP0-_[7L4=1.<D(,'9$$!E8.$5U'$0
M3A+$E7A"ORQ TU7*',#.!LH\H(\:>E"P!S*F*T@!,+JA)C%'>[B103PV9Z!5
M0A#Q8<$""1C4&F,'+7!A8C7]XL#^+^.G)4 ##/A8XO"Q(O:9PP)L8P<#,)(;
MED@')[YH0!MHLX\DF$0Z"=$'3OY1@ 8X8 & 20(%R)$$EB7# !)P0 #2D**#
MG"0F4.,('ESSL:,$SF#Z$0\?SF& "V3@A]HA(#(*X( &+& "^E"& 7YX 9/X
MHG,+(( ?B *:A"@# PPPP!VPLH +5&!RE=D &K!!@;[] X4,&$!<BN. PDV@
M,HI+2'NTDY!^(( <"!R826JD+WKYT8_W.,B+J,A''/$1'X$TASWH0(0_Z  0
MCP"%)'Q0@AT$P@64V,0^X- #3;3@!4/X@PF(P A,K&,?HA@%)RY!"E HHA&A
MD%4HG+7^CV=T@A$\(,$B</ "&VAB!96XAR0LH0)"5-('G=!$( +! R'$P1"$
M8L$($+&I:EKSFMC,IC:WR<W!?*(&E$J'"U(@@F8\PP6!>,$B;N"#9ECC!J0@
M1)P\, QI6*,1+A!$$6SPAT2T0Q2)P$00>,"#%@C"!,THA0D$H8(A], %II!#
M,=:A"#G@0 B"@($EJO&,4'A@$#\H B1P8(U2Z, (A, !$7P@B72DXRJ@T=>)
M#A)(T- H.C&=:8OXY2) OJ@>5DO4P?*RCP?L(3D$A$T;'H AFJ0E8M&Q3$LH
M< YSI(<<"'# P YP#V28+ TDPTGAI/K$!@0/:&FHP#[NX(#^"Y@F :R1W<[T
M +3FH0$M]!M+61R@AWV\Q0''>(IN$-B !A1@#_WH:VTD8 [%&@PM)DN4,BIS
MD(DD@W^688 ?>%A8!D#%#4"#B %^P8:-W' #CFUJ(/$"$;+<8P(%@X@#_J&/
M Q3Q 4X#1L3V83B(-. PO',L&YAJTP1@A!WS\VML!4G%[= F'_U80%?:XS?
M#$8H!$Q"6/=1#CN08R=$Y<,"BG.."^AA OUHP![LIH^E38 ="=#'!@33E0-@
M8PUHL8,#*B"8A)S#L6Y@:FL,D+8%' <GYVC877*2ECW\H@#Z($<!#&(/%.W#
M'/H QC\H8(<)]#6ZV(!(='?C"PG^\$%!%=2/>M*##P+ZYASDV T_%," PA;
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MO)<3!^ 'T:-_#7,/_1 6!!1YP+ ';,$&:,$'$:,71847&8 &.G$5"T!9V*
ML#$QO2%@"9$'N[4/8J046J, @-$5>>%!>$$!UL4/!I ,:$ ;6M,&"W 5QV
M.)8 ]< ^B0$1QQ!94F5T$)$>$GC^/ 5 '_:@@4OP97<6%[L!-6V@( FQ '=
M$H-A ,;# 'U5#^FA00@A56^@&TA!.B=1,"XG4S.%+X;T+QE2(T2'+S/%4S-Q
M,:"@ H/P D3  SX "J$0 D3P 3_R!YW0 8E0"HF  G) "J&@"9 0!"F ""U@
M!$*@ BW@ D40!S#P BA@:D+P Q\0!XY "IE "C:P HS@#"L0 LOP H^  R(0
M S/P#(\ !X$P"#M0!"H "OMP"3!P Y%@;<18C,9XC,AH*>S0 X]0!-"0:(M0
M"'\@"(0@"+.D"2Q "CN  M8P"M8@#9)0"<40"(BPC8Z0 D0 ""(0"(EP XRP
M [9F!([^$ @I0 A$< *.0 *_9@C-0 ET4 W6, S5< )&0 HO@ G- %#RY"."
MT *9L _J !V!)!0J<B)NV'+V@B\S0A.!]H9BP0"L@1 BD@ /D ""\7.%M0!Z
MP <&T%D8 0Q HSB!9#X2\W@8D3$;@ P1TP8(,# *\(47MAI;83!O< =HH0\)
M9CP+\ !&M &'QCY\P#*A1S+ZL#<; $(0L0$QH1"(AQ-L\!P(E@#DP <'\ "D
M<3%X0)(+T !<09*=]3%I4)8+8 $)@08DJ0 9< ^4 1ENX!,=U  )H!]LT)(
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M 5N4<A0Y(QNII3$%2!DI2'_4AHI#+U>1#OO "#: "('@(X.P"*%0#([P J
M RM@#:' #LG0")S0#'&@"#!@ X^0:G(R"(-P Y$8"(]P XV@;HC  RP "0J7
M"'30#):@"-90#<LP#2,@!+_4"<$ "H1@C]1(""U@"OM@"?+$",FXJJS:JJX:
M*:AP!-KV B,P M!P"98H!(^P"(F0"(L@#<X0 HM(")AP"<Z #L, !#_ "#'P
M >ZX B90"IA0"L%0"C^@ B5 !*50"J8 B"' )R\  CL0"4 0!\5 #LW ")>
M"# P""'^4 W.T B*D B10 @]0 0[,"L1R9&#QI$9V5,SYU,]]4<#VR(8AB%C
MZ!6^H!W\P _D@ P0>V@/"['QD _\<&@Q(F(?B!@7 R/F@ \,2PXBRQN!(Y\)
M40_GH \)FA?Q@)01*Q-A(9M<AK)C2 Z^4 XN= XXE1,5AA#GT++ZD![GX##
MX$#^5;30T0\3BQO180[#44 7]K3Z<+!49 []4 XB&R#LL+07*[(/2PZ#!A'*
M  SWDA0M@Y0H*Y'Y8 YI.QAL"V/D@ W(D#9I\0L3Z8;G  RL86@_.&A!=PXZ
MZ[/+@Y3ZL+5R"[$\I2+L@+1.I;!TE \I:VB><0Z3*Q1/^93^EN$+%[(B\9"
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M"(#  ]'= CA0">LP"M(@"J)P"8T W8&0#I90"EN2"(HP"9<0#,[0#,N0#HR
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M'5 D%;B>:@B"12 %'$"!%[BC0) &43@%1Q"%1-@!&V@$4XB49J@&.<"$.,!
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MJ 836 036*87& 87F(1.( 0AD(%!*(5.>(9"2(% $ $8$ (6  016 1$$ %
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MCM"!96B&(Q4!']"!' B%%2"%2C"$(?"^DWV&')"D$3""+BG^@A18MQ 0A!0
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M(43L$ ,+P913C _I)"("(D.\$ <HC.@@1SO06&1/F)6!9^A;]H44TDCU/ #
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MB H"<8D_(*((/\#$#U9@B1C P1KW& 4GQM.)%0CB!8N @R/^4!"(87B &J-
M 2E>@(A!:"(1FF"$.JSA&:+M9D?R 8E)3C(_BZP! $;,QP,.4(\] * TX))
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MIHQLD)M<%^" &E,@#0A($P(>@ $%S)0-#V## 9+PBP/8UA<'0 ,%'&"D 3
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M\BV ,J!@!C" ])%#:,%@:I31/F0  62 !!Q .=R# T" ^4%%W/6# EA $A0
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MF8/C4(6(?,0^]$,!S)1%+(!A(F;=#0!J!H!@'$  $(!K-@"#@&;M+*91)($
M+$ "< Y5($!I"H#E/!X"\11UG%6:S(8 H $Y $":)$EV\"$ R!1]; 1)E!X
ML%Y8(< ":!4P'$/E04D"04@9Z</^ N!#/Q! 7B #^.T#&\BB$0E.UT!9:5Q
M32R EHA-'OR"UU4-=20 'Y # 1B%'CQ1 MQ$&K;! IB/!$!9!E1 >0H&'QSH
M_HCG/9@# =!6*L"4 J3G K")9^SB/2  ,3A 6H5>'CR1A3P1,A98U2! ;;B>
MFI!#X%!(X.1![?Q'D33 9R5 FNP# O #&LR4,8IF3FQH9=A(Y@21&G@5 <S%
M,12 BRF 7*5&/1@ -J"!Y>P#'J3&/9R?'48)X3! 6C6 &Y#@W['5@R3!E5(
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MP@[4VB4, Z3,0=,R B.0)294@S6XP,Q>K2/<9"60@CLU COLP M 0AR<6PJ
M ,9V+$=WM$>_9 VLBS6H  FT #6  @J,0"0H C3TP Z$"B?^F,#*)0(AH, Z
M0 ,E2((F6((A1 +08H)VF ,[& (CR $TC%(CT$$])$\^4$(G=$(C1((E:,(S
M6<,SA  A  (,",()9,(,F$(+$ $T,,(B@*LCV,,Z3%1&2&<WOM':$HE%8
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MK1I(MYX#/_!!8U5%+D/( FS"'8BFC3C 9RF $?7#>%) (RJ(:UC$'=B52QS
M'DQ G5K( G1J:BB#B>HO;$'(^:E![=S# F! FUK9@?Z#&'^6,3Y%%*LQ4&
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MA7W\]$EU(W'?A23[$B0Q>4!?@PP+'4A YL= /SP'E"75L^_ +Y;Z]B5IL(^
MLHX'\.7^N[<O60 UR,9.?8!,3P%D;23J6Y#A7)L%_!:\1I-@7VR&>)B"KM
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M,*#!CE*0>00LD,$)U(SZ$XC  T#^> 8_DC$*3#1B$64J$QW($8<82,,:/_C
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M,1=B"[B 1^C!"<3@&\0!',+  VW^Q!:D0 FX0!<$D#+W81>NP"Z?0 I ,_[
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MI#8'.D$:J&$%3J '3"$0?* 'SB08@J$81H$1+H$'A, 03&'^"%1@!="A.FW
M&=H!!42 !:"V&'Z !XS $4HA#OB9!P*A$(J $.Z!H3XCTZCM0\TM?8LQ)?1
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M<V] @(&1>=R1'AZT)B,!>NHA*L'^!>3LT^T$=IQSP09JG$-B&A9CO(\=BCH
MJ7+-(30!&@<]D 0&$  C(*3 4+"!'\0QMX\%$ARD3P9&ZB$!!2P'F\8%&!2
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MV*" /:0A ,I !@+NX(L$\*$>+7W^@Y%HE09/MN$ R.!#33&FCW-D8 ')2,(
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M(Z4*&/(^#K!;") #&Q\V '<*IP\7&X0")E. 0?#!+DSM@P(7,,BICE%W"3C
M%R1RG'4LD%#"$6X?;UC ].T RP-XJ0$!0H R^.%]],0/#^ F;T(.R< /R( '
M"+ /?* >%2!]Y( &WG=9&=!Z:. PG!<B!<)*!O P_9  R3!:H%< 6K)U%X!+
M"P I^R7^-^5A /.$# 1P#!IC$!MP!WFP=7[@ /7@@5&77F)G7AL #/W #YMW
M#,B0##+840:A@O;1$U1B'>/5@@M (%UW-P*% &J #.> 51E!>_B $ N0!MA
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M$ :NL!(*\0VM$ L4>1#YP 5.\ 10X&TVY(].<0]%5#[IP (D0 +,X#E%T *
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MR*  [&(IOL  !9 B=N![26 RR?<E"/ P/16=&8 '_8  3O(+"Q /"I ,A^(
MP,!.LH7^ 7C@GL<04H=2#_:7'&I  ?5@>^Z!*.IQ'D?2 'Q03 :!!@=P4=KR
M4\Q4#RKB"\J@!B5F =.9?5YBB:WT"VIX#D9%#@DP9'T&5 U  =Z7!ZRT 0L0
MG4G@!\-A'>CQG]'2@Z>B'^&Y(/U '!UU /"9!)#7=Q;8'18P5_9A';Y@ !GJ
M*I8G3'K@!@FE#PZ(6(XS?FF0!C=C'!=P *ZD=DD@G6B # M0-@86,O@I?^*5
M!%.H*PIP-S>## Z  )!E7_LD7Q 3(QN HO\ 7]:!H/T@@!X3'Q(@63R1$>=
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MS$<]NK!)PYC:ZLE#GW/PT.V7^;HC<S8]R,D'#S_VT7+"N]S"@(+F?BLG#_>
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M: $+,H&)'@R!!8<0! L$(01UK.,Z=(&+/IB4EY)E<"YQT0L^]&*0*"'C#0N
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MR&$'[8 &"AH1C'=( Q**P(0,\"?^"6BX@ <XB)XS@# *2R@0!YG01/18$ A
MW* (<;B'(D  @D803Z87 8<5]K&%;VP!=!CAPA9:T;F+W,(*9OA;1KC0A57
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MK_12$BK+)+#R2A.ZI>1;E4P2C$ C(]$XF5FZKD$:3#?;)$?#06_ZH+T M;_
M(D:""\E$H1CI(CF"/<B$)AD[L[E0O;+4L^_2"RU[LH$XEM:;+B%SOD?A(@3;
MH2YB)NKZH#)ZE \LH_A"3"D:/L#$O8PIL=3["SD;PHMA3@OBL'MT/E/:)NMP
M0-V\F)&Q(&C*)-W,K^S4F,^\,XOY+^5[D">LCO!SC#HRI2([H[V@LOX[IAK,
M+RJS2Z3^+"%VJ4P$*S&)\2_=[(]6TT(M+#+3>Z-JHI5[4(=]4(1U,X(B@)F!
M^@,0@(%'* 9T8(1]4H$XJ 9-P(1T8($7,(5'& (BZ %,0 =;4;%JP 0? $E+
MP 01$ 1KF -2L 85@($A< %1D(92B ,7^ !'8 1Z^X.I \I!8)F>B 1_'!YZ
M$ ,OZ((GW8(M6#B" (><(KEO$ =?S =N8 4ST#DMW3@MW8)>2$4K!:%O6(6K
MX@8K?9QOZ(4M2,5O$,=:_(8P4 @V_8;'P0(G6!THB 4L^ )RI =ZD =]E =Q
M8$6"T 4IF (I: (H *MOL 5= "M78 +6:0)-;0)%75*&^ 3^)!B>=("!ZEF'
M2[@Z(2!1(X"!4H"$8M.!9Y $'"B!&.B!:J #1,@$:, $$R "3>B$/Q $4A %
M1AB%=$@'3JB$4,"$E3H%30 $$R@%9P"%06@$:-"!&S@!':@$9X@!%K@!3! %
M%N@!R9.\(5@$>U 'UFPU$^)* K2]6?N8;AH-9-&D>D"&>)BF 50_ C1!P'!*
MTNNB]_JNS>M++Q,FVR.9Y\I+-2N']1!+O" S-_.OBC&9,#*'/(D+9*!/#JL^
M7GJ+<\"&,/*]*Q3$?$"&8T &9$B&E(4U-;JE$NRCC7&+<]B#<\C*'5DTMHPF
M9##,XCRC>5$BY[) 7#(_T$O,%_O^P/'0#<)QH^K+HRAYC(V%UQNZ+C7#/&H"
MO3\KEY7!H'[ AI)1L?V3S\2\AW/P$-WS)<SKHI4]AF,HAU+2RXBEBW,P!^3K
MHS<BS&JZQQO3M;R%%)_M&/G,&-?[3 Y$#,&@M<^T0)>EP,2-(U5[R^I@38M8
M)8K-S/^RH& R,Y.!09"1POXKF77MHR+"M=[K,-[4-=5]IG\!3 #TUUH[3NID
MW0"=F*FL+\4]INX0TB'@IT-X 1MHAD88@A+H 6=HA!>HGD" !CE !$V@!D=
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M>L7 /PHT)MH'/%B  9,SXSL69J*  UB  EB  \@ 4J%7!)61DT$,]W@U9#@
M!>@3)7DB>1&- KLA8!  _-A+CX$4'9.2:S*S?=B#-NFED F-"-1:*:D \<#
M5R,D.1JS8TB F\5DM]"#Y<!=(]0A#7(+/G" T-@'/5  *1$R?=WD:>:7"[@
M@AC9/"HU>1Z !5@ !3  \QHC3,OC,4L"#' 1@NB'ZD@#VR 5?^X8&A)$:-)
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M^(!I&]]]NF$8Z %[D*!&HVHB5+TOG(M".Z,\\1!R,( ^V0=UT T\NEGZ XY
MLD&WX >XI;]S '+U0DPO@J'M&K-ZJ(^H-0AST TP.0>+H')4(F:WP(?Z\#2"
M.(=Z4 "[?:(=-P</80<\RR:WR -5M@-5AB3$F.C&H#]?.(!R?F2"( <NTH<G
ML@@_)X@[4.5^]I!%VIA]F( &@( AWX<PS^,&8P@M)X@DL(#^1W^+B:Z^+1J(
M^KB -<@D?*"D)++;,?(0P#"'.B^("4B",2/SY]/EZUCR ;L-??B'!XCG/%
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MY4 ]&$2PSP%NU(/& ";)?DP!R!S#V6V3)0 Y:"A /_:!#ZL,X W\2$,"]O$
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MV$,:"E A!8SE' H@'@7P@(<&;* ?!BB@D/=1E(-8<WQNV, 7'?"=?3  &1N
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M).B #(  "'R "+B #E1".MR#-#@#)C2"(@R"Y?E4(%A"*2#"#8B $'3"(+Q
M(E!"* 0"(1#!#L! (:3<FS1*RHU=GE38HN"2'0Q/ IR#'3#(;8"8 2## V2
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MN$R"-2R"?BE"#P >*&#")50".WC%/M2--"1#,CB#C9A#.E0")W0")DQ"(?2
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MOZR++4#!!C<!%)3H^6%?^+J><5&-/1S"XC&#)'3 (?C )9A"!Q0").B *:A
M(<3 (9A5.G0"(505( C!'V "(US"XYU#/#C#(T##6#A#(T@#.V0$-13O)?Q
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MI(,FID/^,RB"-8Q% $J#.O1#/E3#)4@")A !$1R"(1#"()2"-6BO#_" $,2
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M'!@("" P<\D+*^Q "!$\]# ($8TXTTX.1;.  RBA4"+("HA$T@(IS] $(^+
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M#WC>,"ST)?&0#^;P ,FP#_U0#XV.9QBAZ,#0Y7""Y^!7OM[<$(V.+AQQ?_N
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M\(H :#H^:(,",(JD4 "K XI!+ S^!UB 7P  -J" S; # 3B !""U.KJ#!Q@
M $@ ;( )-$@  0" K'N,!3"'>"@ 'SD&!6 ':2.'<@@FOV"'!*,F93@'Q3$
M9$B#"1@09'  "E"&>C@'!L.&.S@<!J"F/? 0!#@&/GBP&R('<D  Z%FS7B.'
M?N"'-V" 9FRW>^ Y<\B#S=B?XUD :MH';HHXROB/??@'#\DAOTB+I4,&<O@'
M C '<5J#\Q"07\B-?3B 9$@"NM"/_- /7Z  _O">!CB' C">=]0'9.B<?8
MY(@W-H"X&CF ?#B I#"'O+@H?/"1/GH;/?.+!8 FA'-(_CA'/8"X'_.+#%@#
M9*A%<E#^A@$PGKLQ!VW,!W)H-_W8$-J@.3:81GT@,_T@HV/(C0;0G:Y@  %2
M@&;LM@!)D#=(@#W@!R2Y *[+FSWXR+((2&P@AW- !@8H"P90!KS(#W)0@'M
M _+8!U5T1APJM5F4O01) P@8D*Y@IGU(#-K8##T@C["0Q9GLC F@M 1+ W-
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M>QB][Y1.![82=C@  5@ FNC$ZJV;-\'5PF@ NR&' A" \P@</6 '<SB'@1:
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MGLU@@"KZA05XC+DE2H!CI;SI!SQ8V8P>)[Y( G[*#;7+L\;)!P8@AGWR"P=
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M:'&%57C OA+D,F"%5J#S/QX#0?9S5EB%#\P'+ CT3FX%*W 6)GB")C#U4J_
M-H>M3WZ800"!#P@&0\@J(Q""0 "%1$"!%OB %_  24 ':X@!$'@$(P $%5")
M(D !$+ $:E $4H #3. $:<@!.9"&4:"$'%AE:VB$#U !0'B!'GB!7(F$#_"!
M=4 '1MCU72^!.0 %0%!36Q&">UB'F5!@[_R/ 5O@.#&+3_2+"0" /3L  \#G
MV"T,KO"+.L!$*P*  "B  @B M_$# 2B  P  (-,T $"  @  \.B'<'),"T &
M AA+?,S^7P2H@PRHQ< H#?>]!^YMW@#X!7. BR0[!@@(1PF8@'H(ZLH,2>3
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MGUN'6P;!9:>8RE08N^QE(84YTZ[^3 441[7+,6 J4P#%Y):]W ,=^;@$#W"
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M4*(:RU !"S)-A/WR0!0AT 0I4/"(%R "")#0 2 T<8].L" %/1#S?,3!2(/
M I+F\0(W;)&%%UL!QUW(!Q;6;X;^&*0+X+A%%E!2/M0?>?0"&UE!@>R#&,!"
M>7#!/IC!%J12+VQ!>;!"*X!#%MR"07 !E6T!%5B!%"B!D:D2%)3!%L2"&63!
M>?0"%X@8^KW@>7P"$MB'/?" A'2")'P (FC"?Z6 "OQ ?#'#,FC""PQ!";1
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M#_Q ]4%#(/Q()+#9#V!",12#"OB .4'"9C@"$0""#P2!,S@#)_A (;A7(/B
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MK,8]YK""'OQ!"#=0A"- <((3R,$:A0!!*8H1B#\ 0@?'3(0RG0$-'>PRFBR
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M[ 0@"'&J(L-+'DUH KZ:H(M6Y6,+\^!&%\PP8^7$H@SY:$6OO),/+N3C]&5
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M%.8@& 9A9>) &DXA$O[ $A*!#NXA'>3 ! )/!SX@FY@!$J(L!L8D!B L%&Y
M$ QA^]Y%',!A7;" ^;0#%KK@";;@"\1 "J0O*>2A"[( "KJ%"Z9 Q9+"%<
M)L7@"Z0@#+0#'+I D[P@#+ @"UAR'\R "Y[@6;Q "ER,.'JA"Z"@"KQ #*S
M"FXO*<2@"0#)"41OR&(!"\J@":3 )TWR+5\%%3XAR82 !$#^ !0L@06,H AZ
M8 A>8!$,000 @0<B81\8@>M< !/X 2&)H!'(P1 Z0 0>01. (!% 01*<(1F*
MH1H: 1,,@0=,81% H ,6 1H4 0@"H13:01)6@.L@81\(80@.H0-,@@6* (>&
M  8*(>:D(]-R)Z+:(AY(R*+&(CR@QB@L"W> *T+Z81@M9RM84!W*IK&.I&M$
M(^@^YSI(9'T4B$1RD!W*@1S,P1PRQ&[<9A63#>1V(H1R W=FYVLR!!;K@CID
M4.2PAB<PY H3JG>6$(7T CNXRM?PPK=HYSKWXC&"AQ;'!Q+%[8&<QI^<1#DP
M*T?<#7F"HJ%&JPWA11#;T%WH;3O^?K,Z0%2&>&XXW&-',L>!:.JD_B>SXO!\
M^J'7GA%U/@,OQF,1A:.A:E0825'I-*<[="*V1D-)BD)*[@.XQD(RUK OGL<9
M!2@K",<8@Y0( 439-.,<RJ$<S($-F<)!Z((=LFHZ-F<?1"H]H#.#:")&/DAM
M8BNPK.TJV*%$:D)'IP,]GN<^QH(=TD%KN(*![,8O6*@G9N(>V' .8& (BH!B
M5. B/D 0;N 2]F$1>F8%1J$=AB&>)*$<,A %("$3?* 1.$$2GF$8I*$9&($3
MY. '3@$10. #&H8.>& 0G*$=%($%&DP3]F$00/ #%*$(6 "'B& '6&"/) $$
M2. 0X-+^5;CA&[B!&Z#@*KVC%52O5;XA66!E%1[ID&YL]%;A76[!+;WC&UHA
M%C@LE;Y!''I!'))U7?_%E?C%'G;@!&# &3*!)88@6!,F5 [A!H( CE; ! R%
M'13A!PAL%$I@"!@!%&(5$RYS% AP$R2A%##A!X"@%!9A"%* &9JA$N"@$=(A
M"%! !E: $:!A!;X.$DPA!H9 " Y!"%X@!@S!'M2A-TLQAIP#)RQ(.H'CN-PB
MV7@'%K.":Q*D0<#C>HP0)WID0\;";S:C:UI-.MB&LA#C,/@"2JO.0]:4,T"#
M< XC;"1CII1B<H)3-H:S*\Z#</A"KJCG.EP0&EDJ":\M;(_^%#GT(T(.R*;^
MA]FNK=Y&PRABXC%VAT9H1$>4@^"@S:D>2CER!W9\43M(M$I&#U[ HES=HUPI
M\1G/0SR<(C%V]CGF8R<:Q(!,U$ X#2@:JN% MVGX0C&4 B+2Q^!T ^>$CF:%
M1#1,*WPNY+!ZBWBNT78S;1G1XS'>@:26)#NN\4B(JSD(ZZ^2, E)R"J<BK8(
MZ$'_(JL(*(-BB[8:PP9WEMNDHA^^:G^<=VM J#WZ5H&HQT5TCK:\$8 &U1QL
M:&$HA@?H5Q02H0A:8"$-005.  5^0/[B@!*BX1),P!ZIS"$NTQ?(@1HJH1)$
M01.(X <2< A,P!F6@3(OP1I4@ 7^[(X2GF$%/A 32*$%B&!ENVX'+,^]D)5=
MB4,> "F0K&!:B<,5OB$?;J$7@D59]$47=($;RLH5P($>;CB'M>,;7$'X>IB4
M7&\?ON&&95CX<.46=.$IDV)9K" +6H_(7 $*P*$*G" 66#B,6ZE?\D$(M$L:
M)($%$D8'_F (6B 3Y* #2D .@H$:+L$& .$%@* :9B8=?( %3"'! F$'+J$:
MSH$<7H<<TB$:*&$'BH 00.$43$ .TJ$1) $:?* %BF ', $:@B$.9* #%,$2
M#I4(OBX$A: >VJ$X'%$9ZT&X:.N%D,LG"$0GB'?F-DXHC@JA- K<?LHFA.YU
M1P,,2</^:\[!VG -,1B+1W7Q<U[YD <(!\."?^J#-=[60D@J3IT#,% (I: F
MU(3B,O"P*9J'=&K6J9Y'.S=+V][J&<^'05HCZ'86<)HG-Y+-/\:4=XRN?2P#
MV^AC$7NGK(3-$3ET>SA4V$87<@AQ.W #/%;'/7JG>P11>624W":+=VI'=**T
MN5BJTOSB/EPD)N(!/Z@$+GA**^[G/,"###VD.'V+FZ?7-4[#X"3G+]Q#.NXB
M;20C3C$'H880I5G$./,B2TD**CKD+.0B,KQ'"O\FL.YSAAS$F<=T#J7">X2N
M1<*J+FXQ1FIN<EPYUKQ6.D=Z#AL'Z^Y!$5R@!XS D:',%.+^F 4281BH@1%N
M '\' 8XHH1U<X 8"^0?B0 <P(4O-(3S(@1V2@1)XH @$P11  00,81T4H1+4
MRP4  0=$01J"@>X\8!(<P09D\Y1CX%260;X*(8S[Y5J^81ZD0 RZP L^R0J.
MN RF( RJP"VG11SD8;7!0 R.T@K > RH( R<4CNZQ92D8 RXP,3VH1>L0/2"
MS"O=!0IH.PRDH),J3 ILH0R>8!:RS[37%16.(,D*P2Z7H1->0 =>X _&9 A.
M8F*$(!3D !-L@ 5>@ ?PK@^JP012($U\8 4T@0ZBP3N280XN006"@!"$( 5"
M !HP\QF@S% P 0B*@0B(X!! (1#^A. #\WA,"*&>O->I=")M**,;:?%!AY"D
MFG/<& B K";6?%F!7) [@.ZE^M9J\&8SS$$\$2?E0@VUB,L1#2N#O*8IE(XN
M\I/69F=UHR8>*B0R2&AK$*<]O'-V>J.AJ'8-T:+C^.IXP@=VA.2J>L/I5"B"
M;D(8]6T'&RBOSLJ=%<0LHN,\D)8TFN.AH\-**)=X.)0[. QL6^4\P]DW($=W
M0-K-&PI'IB<F6+<-C0YI@:X-5:02#8-\"&(JEN-"@6-"\ -"1$IR.F,X&O1]
MCJ-P3$-\=3I&3.U%C K1780SOCRJF^,Q2$@(P68OVJ(8(P<T'@,=T"&T#LIJ
M)LA$ ([^X:9MJ-J"K)CB>UBHIRJ1X:XF,G0*;\CB+UB.*U8DQ._C'FJ($F+
M!=(;!W H$4CA!X0 $% U$X* OH7 &D;!\;)+G' @,>< ';RC&.A@9(( $0 !
M!%: &NB@&DH!RE# !SAV&7@ GDSA!X)U!_[@:'A@CR[!6$O;N^$%"V8L#'HA
M'[! .^3%)H,/]HC#"K(5Q'1%.V+!*/<!E/9A"WQO'^8A"XB#"_;A%DP^*<(
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M/3P31R66  +##:1$TL(0,!!1Q F$Q+$/)WO_D&'OO8/32BO@#$0A<[>L8LM
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MX(JS:G:SFOW$^RXDA!&,H!.<V $1$F$81D1",$9PP3)T0 EJQ/ %@^C$0'@
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M>,$.$ &*?;3#!B @A#1&$8A-/$38-AB!",HZD&I08@[/:,8.0+"(C("B$"_
MP2#.80A"A,(%1&@!#RRQ6@\1X0^-V(<D1,L[SK(O#&8XWQ:^P8HO^,<*O1"'
M&5K!#2S4=1]B, ,X>M&%;ZQ"WP3AAA6X(8XPN"+@TLL'%V(!CEM\ 1Q?D ]!
M8''O;WA!%[;  CV68XM;W,(53O"XO%\.<P=]X@C%K- ]% ?^@V9,(@:$"$0/
M_M )1PAF;]98@232L8@7D!L2 [GV'TI1CE!THAR>*0</4B "'/RV&M48Q8]
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ME_ ('Q #X'@)BH )Q6 ")! E]8#^"2@@"(_  BL@!]3P##%@ H^P RQ0"H;
M W] ;CL AZ4  R6 .[AX(>LA!EQ@!OF !=9#$''E!;+H"ET ,;V !6* !69
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MS20T-4)?8* 6,Y[]K&:-UEEL\D;.2G.,T/"C&8> &12V7*7.,7,)H8?YGGW
MKWS&X]I+[N*XM;WY,UE=3_=<4K7<N4=FBN@!('[P@T2@. Z((,00I!&'#K2
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M@S#XAC*@@E;X @N+R(GL!2O E5;)#2YPA6_P BM@A2V(O/S" FZPA2P(@U;
M B<\2)V<O6NXAML+A"%@@6  A2( !"$(A$(8AG0@ A#8 6@8A#^PA& 0!?33
M!%" !!L3A6 H!FG8AW68A!@(,G(< ;(D 1>P!'78!VEX!E$8A4D@!8QX1T@8
MAF%P!"&@ VAH@?)*!U*0@R(@@A] A#&+!N(0*I@ &\D*#I;(CRY$,\: -\A"
M$H[2JA(9C,!HFYT@$I^H$&MJBA!Y!QA1JOK!$ G<BQ(A!VK JJ/0!R2QAYM(
M!FR $:CQ$/E8C/]30:Q@'U-T"O[^(8YX((=?,K,G2:;,@!NL>*S<6:J;0)R
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M))$<:T0@*4H'3=$C%C 0$5GD UJZ8)(H.4**)J2,PHXU0?00R""9$%&$)W$
MHH,/UK##22>87/(7)<'(Q\,C^9UPGR'KI+.()CU8 T@CA)C0SCHQW0/11/J
M]!-&+V%$E$X[F<../C2Q4]12]913#S[[W)-/C$3I,U%(YY#^%*-*";%3TD5
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M1?21+@4*W&$*SI37OYQ1XPW41SP3=O47/Z #/\Q!(62")?" 226""(#",'B
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MTC[$I??MA)G,V/UM!#QJ4F7>PZ84IJ(1A':= S:\RT/P(TD4!*G@Y414!$U
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M! (F. ,YK$#EE (E2$(QA,)DF8 (!,+4Z0#C($('-$(YL$,<F, AB  AK$"
M,$(D$ $A",%3R0$(C$!E8.AV<(,N3%SO/6@OJ*TX@$;:KNUGR,,NZ,(NP*UG
MT(/;ZL(?\H[:]D)MG.W@$NYFM,/^#8S "3P#)PC!(.R 3U%"* 3;'RR.)N3
MWUP"(Y0 #L0!(8P #Y@"-$!#*G8/V#B"*(Q")"S"(#@")HP"/T@#-)P"#W3
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M5'[$/51#/8B""B0"#A""A(QR$&0"K_$ "@0#)4P%(!!"#/B ^J0#'0!G">Q
M#/R:")A")(PA>[^ "I G*3B#(V2"#[S (NQ )H2"A? 6#/B ,:<#)NC #@3"
M#4B;)>3#<)7 )%3SA%-XA:O;QGE'.J@ ";P -#@#"R "#XQH'#!"< '!9'AM
M,(2 '#C^ R*@@'&QS0_LP D(PG<3 0J(P+#]  ^D0'&RP \  @@,P1],0B0P
ME@H8@C, 00B4@F^.@!"L@"@TP@_\0"%X" MHPCU80SYTS):I&/4.A2X9C=%8
M)$^HQ"_< 1[<P0WWD;]:X)9=Q#N\'9J11*)&Q+4\1)>7%Y3D+T68B17;F1$1
M6E1CC$S\D '7293H<9V*T 9%24^\2I,8,#O4=@1*RU"D-%KK1+\H=>]AGTML
MRQUI-A]MI:[(L/5=RP:K1"N!8$8$F;7*"FJJN@O#^NB]>K=.JY]8J[*P2B@]
M4PJGF+7VM8^AI+#[GIJ.D/BI5[YH5_:16$S(1+!3*[2[4;+^'O:[>!^U)%IV
M>=%6BM%,4/%X\?D^Q$,[_D3^2E,?'8MWM<3'F(3F240]#$1"W!?0S!&1G,,[
M'$2F"/6[7 1)4!+CM<2K=,2,*(4@6\3$@%]20(J_6)CTDO3H >;&MAU+W ,Z
M[$,FM(!^E"P@3$(HK( 0I( C!$(1!(.U%4,@H, D7 (E)$(1X  *( (.P$ /
MH$ *_('\\+@* ,)4\4!L$L%YGD(<K( B/$,.S$ I!#,AQ&80-$,CJ%0@^, B
MJ  F[,,EM  (F*V%<_U[BD,9=/U?56*&>Z@(.(,IM$ 1 !4AJ&XG6 /:DX()
MJ(  W0,U8((H8(+BH$ +:(((Y,_^5Y!"(FR4AR@"*"1&(NC "61"B!@"$& "
M>WYC+YI "6B""I2"W2="(B "(;P<"U@] B;P8S++]8HK:;(J]2K,,4R !*1!
M&UR !)B#$ '@1N+$%*4V/2TO>X5T4/1#C$3)SWP)F08D.4"L'QV8G\5#HJD#
M)<700[Q*C/1#9=)1T!!8E "%!<+?VY7[';W$14AJM&9:%)&^F*,U2,09JGN&
ME.2*K,;(26R*K"AECD!E#Z-F65-3KMZ21A"WL"C22E>L'P'$/H'Y]!74)U!?
M/84*[2D\B+">O8?Y&CI<F$_@OGL)ZSW<5W%AP8P;.4K,N!"EOG,B->[#>/)>
M1H$Q9\;^.WBO(TJ%YU#B"WGO7+EX$16^=,ENZ+ES[/3Y7'C.:3YU/ 76XZG3
MJM)^*.T)M'<.'=9Z_<SU&^HS'SNE0\V1(V>3H4Z,Y<R5-:?.:CUVYNKERZOO
M+-%S#942W1ES:MQZ\=01YNFS*]"^\9;VC8A/*3^."YWR3"BQI\IZ^"I^[GR/
MW+Y&+02U)K1(T2AKI%J0"A'$6K5]TC"5RN1#T8D;FD3P2%2"$J9$CUKT0+3(
M%"$7D7:4T)3B1B) H$!A2G</&C00,"RQ>%;M$B)$11(% L3"U#Y#*4 LDGD?
M?W[]^_GW]_\?P  %#' >5UAQQ< GNJ!GP 8=?'"_3Y (D)W^'EI  1U)BF O
M$$*>0V288G1@Y(5%!@F"$FJDF>&'3%H0 8=!@%CA&6>: 244(EZP(8Y0>GOF
MF1D&">0%$%X@)8X9JI&FD2#H4(0'18)P9A1%%EFDO4$ $>*1?=:YAQ^Q&**,
MH3!S:NJ<>$!:J*+';-J'#0?RD&F/-_8!+$V%R"0J,<OJP<D>RN"BS!["U,%G
MGWC4+&R?I?I)LYQ(?3JH(:="V@N;L.I1!YMS]BFJGK;863,?LI9"]%-[\'GG
M4+6&:BC0<_S2YYY[XF$G(K4*C<NGJ:X:S:@VE6**JU@3\LE2/?NI2")\_+H'
MGW[42>BA@ASJIQ]\^,%'VXZ8?6C^HXSTD<C,0D%"=2:-FA)S(?R2K72TD.YC
MMTR3Q+5(+(EH&HFB>#OBB%N/YNUIV]'.V0HEC.XAZ!V;-H,LHE][6D@==?SB
M+-;"^LHH'[^B-2?-S]@,=30RO5((88K3M$>=42/"2*I^R$$)T'C(X:DBH,R!
MRZVE+DZX'H%\*H<<O@Z.IY]\*$NZ89<TM@I7>\CR4]:-GB9L(4&[^O0JQUQ>
M#*J145)KLV+S3$DAGP9#YQXZB"BBM40(,6218H()@D1'$O&!$G2:F2&13%08
MP;@<@H"&F69Z"P*'%A01I9-2G'%&!3D&>>&#'4CI(0ATBG%DA48*\<&0')[!
M)!)"(FG^3Y M)=F'D1)8>!W"VFV_'??<,Y+'C-Y[7V4,<'0?GG@!V0$$$D'6
M880'(H@ 3A%$!&ED&&K.R2$'(F[HH9%G0M&$!T@PL<$[9TJA!))!,*DF#CFH
M(>6'1B8I1IIT+@EB$D>(L"23:^B8\0<ZB ,[H $*1; G$I'H 1%XL(,X^(4@
M.H'53G*2-IW\JB+)X@D[]F&.!E @'I_*RC[P< Y^O*HC2VD37HH2CXYE92@[
MP=6C8JB71FT%,TH9#-$T590[_<N".RD'3_*!CW*HPR4.J0M>-D,F1B6Q8D]9
M&=8N<B=LY859.AFB7%X2J(0H155$"50-)?@5-;&K81SQ"$?^L.64,)'F7_O*
MR 09LJNRW6=='=&64QIBK?ML)(B!M$=,!'8LBU#+(7)4EP4-N2MGW8<BR2**
MF7PX$HW\#"6>^== G**.E(DM+S@1"V8XHQ!^%$8?2)S)SWQ2%S$U9"MIPH@&
M&3(5A)FQ(55Y!T^N8BEUD*,Q# $*$>N!CBTJ1HP8R2#1RI'#/+'CBB[LB*#R
M <:(4&8P(S-4FT("M8N9A2%X"DRVT#:FP8!D34KI%DK,Q!-JU(,./O@!$'X0
MB2L%@A&BL(8U7-"#'? @!YIH1BD<,01-0"((HTB'-,YG"4&$PAD_4 0T,/$'
M1E#"&?6C1! LT0@>8 (3U@@$$5C^<*)"U.,9HZ##(!:1P!_T8 @.W$<G'O&(
M210/ISG5Z4YYVE/\M*,=%&+!"4:042$X3Q! :(0B&.&(1C2"%*4P!2F(T ,6
M!&('* B"/IT1"E)<@A*,B$0@XN",2X "&CD81",B08E1D&(4R4@'*%I0 AX@
M@@5"$$(G3N%51XC52HWX R%X\(?IK6,=]N@7,BDX,93@4(*""=HQ%E"'CPPE
M'^EX2M#4*$MJ7D16C<(+2 93F(9(15$1:4A=7(B.3F$%9H:YX#FP8;%ZW"P?
MHK0*97"UV4V!["56P0D_,J8V,18%)TK!I&S3= Z\8#(M07/)GA;2#W8D*UDL
M[*8O>?7^)YKD)6WXH-5(8H*LFUS,'MMR2D&,\AEQK3=>$GE)O_31WCK*:R!C
M8<D/+T.4^N;W9>):4T5DTD>C= PDFZF60^HKQX6)ETPO :2_^E&V9%&WE-/4
M26*"^\)2GF.7VKVO0D"&*(]E3599(=9.U.22Q/0*)5,A4P;/88Y"H>-F*$P6
M3F*"%7-$XQVE&F(GU9':>$U%-(91RD;,4;8^5<PI"]O44"BC6\>DL(*DLLJ:
MD#4:M; S);S<1R@ 45A$Q"&!3VT$)$8ABE-X0@@[>($@LOJ"9EBC&,L@1248
MP0A#!&(0T+B$*(*1@T@HPA&6J 0H1@&-=&!B!2;8P2)4<(C^/Y@"TY?HLR,(
M\53V\. 0A&#$/0PQU$CX%-6IQNDWNL -E^S##+U0]:PS(B$*[2 %)Q#T#H8@
MB$ $0FYH?DX/'*$)(YS@!(?0Q H,P0A2@**CZ+-$)!@!"4L8HA*8>(0EIAT)
M3%BBS]F^A"4>P=$AL( %.]!$)'RP"$3H#1&)& 0A_J #'LCA'HG5+2A3G"^R
MC0HT;)K*/O:P %^(D"'OV)1G3I:7M0#J8FER(2;5,L6%T(6S*IG95T#FIX1I
M!"0_4PF.+4:9(O_P*D\CHK/4<1>7*'QD:GE4H+B2DYTI-K(IA_FNOI*3F<C2
MN/22F%@>@Q54A1 _XU)5V2)RK]'^C-?I7*')8O&QK[(!;.K4DG &=2(N-7(L
MG,QJ+V3F:_2.R*0@;T0(UY&EV/_*Q%-5Z?)F)8EB=JE$5AU[%$2JR<(N'PP?
M[%#X<K\8=\<B;2W^TH=:!"(HBN%%;2LA5$7Z48Z=8&-G],HO@B<3%+C4MH@?
MJ3$F/1FR-=7CE'1<N*)$7)4\99--L6('4B+K6TI>L)'A70@U\D$''O  #H)@
M3Q'PJ9X@'/0%+"@!(!SA@D0PXJV:H ,D&'&)2!2;$8D :20LX0A%-.+;C)"$
M)#IQ":>N0!,[8($,>. )0L0A>HZ(PR,(08A!".'W=-C')$!  DO0&@ #4$"X
M(0NPP!;^!.(6K$!X!-"G; U V($'B$H:#,$%5N#W+I ( ($(@N /B, 16" 2
M.D$%>( 4VL$:?* 1",$2Y&"I&,'=5B 3+&$2(,$%KH01$*$1Y, 2XJ 1>B =
MVF%\5" Z7, 1>" 0<( (XN!Y+C &;& '_F W*@B9E.8<<")9S 3#!JP<]H$/
M#L 8]H&%VN0NG )1%B]4G(NQXJ'CJN(I+.^"-JXK:*M0SN%FNNZ'_@N1)D8=
MLF'(*F8J% N,<@A1_C"36 CAE.PMQD6V%@-7GLLG*(F<-D5:,JFW+L7P!J)C
M9F6:KH+I)L-BBFB^3D*Z1$B2($8NT(Z_ZBZ2-J8E$(*^=(+^CP2&O^A%O/ZH
M-.X.7&9B8A)L- 9)7!H.7C@C#_\D448Q75Q"--:%6CRB,CHF%P>"#>?%8@;"
M5ZA&,22";'B"'VK%6[:1'<H!5R##3,9%'QZE)/1B)\[I'LPA3,!I]JR"'-!!
M,X0)7F)BL6!Q*H8H(=YB(.@0A2KBF-3N*\"Q;))+N12"#;-BZ% L\]B%+Q1B
MWQAB(=F)'W@/"'!@!W:@!P+H!XJ@ WE@@32A!"9!$T;0%$PP!QSA#RSA^R*A
M$>0&!T"!$2R!!A7!)9]/#BC!<N1 LRQ!!U2@%(0@!ARA!P9A!0!!$'J !X;
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M,1*B'=BA'61A%734"V2!%[3W'L# %>Y!'>[!"[+ ']IA#*3 &ZZ "_X$#+2
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M"#U0&7]0"'2P#YHP09/ I_);65"@!$R0!54@!5(@==0Q*;W /24VOYAU#:@
MG=?1#C$ ""T #8U@C#^P"(J!""T "$3Z 8K0#M00!QTP"8 P!#NP T(@!"*
MIL\0"LZ@")/ #.LP SF0#J5P"8I 0A12 B* =SL058+ "#2@"-!0#X$  D!*
M<J?Z"(] !"$L!_>0#O< %1BZ(]%G-VIH%AB++_F5-W@4#0JP .L&FONP! N
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M'E -BB "CD (1  $F& )<< #.$(F_ADWC294;1$X6M'%)8X.N:8.TE0/O_
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M><8'07JP9 <5'9'&!WM":<$1$PBIS0='0-EG$A9(<$0]VV_'/??J\LD"G.K
MP2*67K8 KSS=CT=>.?:H8T>%^*!1Y -(JFFD!<A*06>83!BQ9)!(?" BB&?2
MD48433K19)1[XM"!D-E\..0&%]Q_!(=$6ECDGA!)H424:M;^>88->A"#1Q "
M$HO Q#+6$8H5V* %E*B&)$#P!WNLXR"# LJ/F'0VE-3C%PZP6<H8E0\^1& ?
M$] #G ZPA#0PX "F8H,)FZ( 8*CJ' X@QSDLD P*6$ /?%##/M+P@'T<XP!N
MV =%<D@0AY # G78AQT6$ V&Y*0L^3#& QQ2D R691]M6$/-W)*1C1D%*G9
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M$ (1FEA$)X*!CDRH8 4NP 0T&O$!0,0.!B"(1/+$.E:R.@<+4>C"%[I@"^F
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MV,:0F<RO6-'"-V:85FC<DWA(0 !!E$@\CH&/8[1!QY_<QS\R, $&\"'!]3!
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M$P[MM45DL ',?D)#/?20@"3NW0$48'XN#U"!!8@JF?DXAS'R\8M?>!$9"QA
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M@"7( S3  \0S!_!R/3O0.^0K"X4H!SYH+@RH [U3FH)9B PR">?CM(<J!WV
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M@'/ AK@SI?!;@#<"!C7( PEP@%;A(0FH  C8 SU@@ J0@ FPB J8@ ;P@WW
M@&,@/ FX@ C !ET",YJLA_.C@ 8X!CR(V_^J":TH!P7XA8; /'U A@PPAPB@
M@,R-!M?^Y(.XE0 *4 <^6  +.+MX( <*N  *2()\T ,D4@,)D( D,(<+D  &
MD  \$%VYQ0!UD #,?0 \P).Y=0!@Z%P+@( HJ14F\3.5H:B3P*VR2(<$73V(
M8@J78%!8^\&*L"0?69M\: 0A"(078 %JF 018(1EL 12< '($0)R"P4[Q(1&
MN(10$ 50"(9J0(?,*J)&W8=J #-R( 9T<(91 (4<E01,< 1+T 1RPP0?\ %
M> %FF(1F( (16 914%4!283A  $0J!TS!>%^ZP)6B YZ()XRR()>:,52#.&Z
M8@\U7=,A(($1@ 9-> $B0(0BR(%JL(1&P('-8 $12(10P+C^]"6%2FB$2JB$
M9@ %:8 &A:B&^ V$/_B#0FB$K'H(:1A@/?W#'"U42W@&4DB$#U@!:S $'9!?
M9X@!IQH@0&"'5]6'G7D^?)@D2EJU\LK,JG@+7\$\55$'!'  HDB&@_R%"XBA
M7JD'8\C $ZP7/J" &L('-=B$BO %O7 (/H" FHD*=%"HB[FE)P1E=3(T#;,T
MM4R^G0C"?FH(FI (CI&)1EF6J@"26#6)=(# 96H(;A'";:$9H2D8>T@' C06
M HQ)9'$)A3G7B%"(*TH(L&3:"6,^:)8)MQ0:9 :)4FXE-<!,P50%(%.8?:B\
M@CB&!:" !6A97\AD<BB /-@'" #^E&1( (<X$V60+X=P %%) U2*!W@A"#\P
M%SW: P&H@($RIG\5- %\9FU*DCPBBKW;$KU5A<)<"#>X@'N0 (*H7.YJ@'T0
MAIM-@\R+AX%&#C=POPFP@S9(@L6T '6@@'+ @XMVNS4HAP)0S#Q0 W-03.1(
M U$A!P:H(86H2 P@B@58 'Q AI:F "PQ/,$\Z86H #O@ _=;" K(3+T5!CU@
M@P%;B+U-I9RF/.10AYS^A07 AL&C&39 HAOB@VCHES^K"GYM%K'0LX52L*W!
M!Y5Y&2$T-;$Y* <U0J.%AYC$AGM0!!?X T0 !""(H,)F!&L0@?PHA6=8MDPP
M!4SHN4K^L(UJH(:'@(9+6(1#. 1!" 1%  5K$)IJ* 9$E00D-@5-P(1(L 1H
MZ)X/T %K* 0=4(10" :@<A\<&(38 0$2.(X6)F[D"8,O^ (QD +PD Y=B 7?
M^88Q*VZQ^H0C< \8.($6H(9..(0')H1$J(1TZ $3>(%G8 1"<(1F&(5 A 1,
MP 3^$85B> 8JDH8X0($1*(X.QF\0D(%">.)J<(9@$ 5*X!],@ 3X;@9'B -*
M6 86 ($X8 =.*(1#^(,?..P*LL$J!+%7#@INPQ(W.*^NU+KRBI*!@( (H-M]
M< /UB@<+>(!4#C(](PFI'23D")HUB)+S9%@K,JCA*UIZ4BC^B##+HO@8'<\9
M.<ZFX:HTBU"'U$L:3HN)BR$H6:L'="B+CT * @3F![.GHX#82TH(G B6= #-
M>L@Z&&O01W)03=(6A3'+?4R9?4 # <B\?E@(8$BA;<D'??B'!? 7!LC,>J@A
M9*B =RBB/=A5Y/B'0\I:>\F7 V@ # "S@>@2?]D'8$ EA_B% #"AA.81 N0_
M;"[SDV#7G<&Z(>P)"LB\J37,4I(N#>B)9-C=))B\<O"N>W@#=E8'!TB#-4"#
M<\@#"LB#/(  8$ &G<V#EY@ <IB 0??(7U@"52_;>GB -<CG>D@#=MX'-@@C
MEZ" ?K" 8SB'&4B"),B&"<!IJ<#^(7S!E,K;@%\P2#9  SW !@>H&63@V3O@
M2PJ0@#8@!X(@AYMM PAH S70 WN  #_H S2P7 =0 VM'AS: HBA* E_ @W,U
M4$;9O0F#3S0WFU^:ZXHX\Y01"Q"#F(Z0"MR2BG;@B*JX!P>C!"$0@C\@A$$8
MA738 1#8@6<PA$A([TU8+4T@!=>N!%%PAF?8[&*(@_TF@0X6@>)@@0/9!VB0
MAF 8J=_0A$G0!$D8AE)0<$L0!14P@45@ATH8A"DF D (JW<D@;":[EL0 RSH
M@C&XA>7H!3/8AUM(1=]9CBWX@F]H#ETH ^1P!6Y0CC HT[PG8>=X1>4H S$0
M RZ  K[^?XY\:/R%, /#GVX01@<6B ]IN(3.6@1!B /2+H$70,1[8(80&(1R
MJ 1&$'I26 1%H(1BH(9VD(00(($2X&\0, (> ('9.8$2* %+8(=J<*E&:(0<
M1;E*0(<?J%-VF)S9$05#H'G &H0B0(N5\'@1N\"$>N5G*:(%"&:<8)E]T #U
M@L\(P !S< "'D( :2EBIN9A5BTU^1+%^*J]464YG*BY# PAV]>K9V[<OW\!Z
MZN:Q8S<OX<!V#R'FNV>QWL-X S76,U=.G4)S( >J^S@PG\%\YMC92\C1G$B-
MZ@36BV<NWKJ1'.N=&ZG.W$:0(A4^5(=.84B(,DT.G0CQI[K^J E!:M3(;B?$
M>OCRH328$JFZ>#L79M6J;A\; 7SVG=N7YIC!@?OP)-D7SX :@VT:+%F@QF4]
MKP;UX4N)KV;4?0W:[%OC9M_9!WJ\WD/&V.NQ !GL'AYX&&2[F@.=8JU(F:O"
M>$4U3F2-5"9,JB3W4=B$KQR^> U^Y8O:X)@&H,DRD*.@S@'=@VKRL(50QXZ=
M>'<<N$& 9Q]/.Q(HY)L0C8*O?6X:4/B5(=H#/&F.W[ECQQX;YFC30/YU@(V"
M-/4HU(/@)XDZQ@WD #F!Y0%!=7;L4\<$>M0!##(.Y$,.!@NTP0=]^?"1! /(
M[!--!86U48$>=OA2CP-L4+" 2LC^X6%'/6U<AL=F(T$44UGFI#,/4&)-%58\
M89&$45,=^61/.C>!)9N169U#6CZ-"#+((H3$(4DG)\1PPB+[@-(!(]54(HDE
MEV2BB"*D#(-..H:8(,()<8X@A LER' """:H4$D]U0Q#22./D-+))8QL<LX.
M*$#33A E."I*(D00,JD@<N0S"0L?="D8IYUZ^BFHH1K4RA:ZQ(*%+F*4(=@W
M5MBR#RM4E)$%-YURT8L9K'3Z#1:]["///KI@\8U@6& AAD'?;.$*J+UT$>H7
MR(H*#A=;> $+/?N4*BJWW7K[+;@&M7/-M^RX,,((S%SB Q%Q !+(#\Y 0L@C
M,8S2B ?^(S13#!V8: ()(XE4,LH^A73  R(LL" #":!D,L+"+$2R0P==CE))
M(HY @DFAU83200>7=&($)(A@(DH<@13R1QQ#)'*/.O=T-I1".=4D44WID*2D
M3/M88,%!04(&P05V[3.!!OG$\T RY4B 450P^3A:1T!MM!$V-M;33SGO.'!.
M/;B5H_,\K+7CFHWW[',/0D.25)5J028DD&EL;Q3/9^2<<Q@Y.H4-%),WK9V/
M/0BI [;5$,$STD<R)56/0#]Y9E-9DC>)U%1)@H881J*54TY93HFV$U>"(=29
M:!"%)I9.8\T%P!T'&>0&,@H=%/8";SSPQ@*_[(.,!':4@UW^/?I4E,]A8BFO
MCU?(:X7! Y>]LP\:$AAD#M@HG<-&@?O\(@!]6"54-D=5I2X;2(6;EI(]+6&>
M%4WQ8&,.0AR=Y<9F^RSAAQ_YWQ%!/AB0C'WD@0+EH(#W$) _-##''!403!T8
M8XP%U&,)D]G' J)Q 6RT80(&208#?/% /1C #>< FE?2,)FE >,<]T #&OB
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M($B 3C0 @S$<P_P<@S% %^5]SCQ$!3;HS6O%0X&0 S),WU20G?290S*<X#&
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M04YMC<3^.CB:3!S6Z6$E1<P$VR#@VK!-X;A-67#.3EP%5V8%5^060MS# B@
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MXCT$/#1@@)7#/4C"#?0 (!0!( B!$(""FPB!)HP"H/( (.Q #JS#ONR##NR
M*#1"J?J [9Y#.S2$5LF+#PS"#VC"*:0 )>S#*%2#,ZR $  "#T!#,(B"(/!
M"'"")?P!KA+!'PS!$,C!/6 *"$";GK:O^WX+P'$#-WS#-^Q"OWW*+4@+%S#+
M%IS3^_ZON(B4MZ1#"[# "5B#)>  (N#N#@@"$?Q ,S0"F!;^PPIT0B&P@!#\
M0"BL0SE00PF00"#( 1!$@B;,04T*QC#0@28XPO("@@BH@#50 SF$@OFJ !"
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M(T@8(47DC[-ZSB85VI<N1B=I^4 1B=.)Q0D0EZ01&?*BR(]0ACJ)$G3"A"5
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MCW>,[A<+F, $(# !!R!C  M @ '(<0$'[(,<!P#&/O)0 &3L PTM/0 %&(*
M B" #_DP!@,&<(!HN"$ #$#JMQ"@AS0L8!]J", ! I !>[0A  M(@ ,VTYAH
M%" /^_!# !(0  FH0P\%N(D#+F('K%I@8&VKQSN.@@<#Y,NL" A3/@Z !PU(
M  (7H, "?+&  W0N%7I  #D,4(=\), -")C! LJE 0$DPRBPVL<;&L R!OB+
M(UI#!@&.D8]JE@,=R$L4*]=Q466>28]=.B9E<K4I35H,5NG^Z,P]&O$'0! B
MAIE88 M:\ -KH& 4Z2!$ P%1BCBZ:!'/D$8GAK&.H[##12(8!$74 0U0C,(:
MS3@$"""X#TP((09&<$0]Y*!<%[P !CU HR .(0A "*$1^>C$<#%A0@$/F,#N
M804K8K$*,X0A#+8H\(,A_)]TM$ $(W!&*(9@! 4)(1&:P,$+"+$"4@"!$]"
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M'QJ X^!N'Q[  #   68*Y]!@LPK@%PR@#>;%&-0N&O(@ #;!V.JA !2 5.H
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M&$A!$4A!%+K3!$(!'?0O<WT %)I!15* !#0A1XI "(J !0X!$5# C1IA!$;
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M!&!@KM52!62@!%P $PJS!TXZ$^3@AWC@GG= "-QH$CY@!"P!J-G=@GKA"9[
M";C@2.DC'VSAWFWA%IX@#%JYW4F3'78 $'" 06+@#PXO$(; !DS!$#J !'H@
M&*SA$HQ $'; $,@6$](A$$X@$TQA$!*!!RJA&JHA&?)$&JKA&2S!!HH $4R!
M%%)@$/[^.1.N",1BX!*B(1AVX 0ZH!%((7H P0CL&4K8@4I 9F+2(0EG!3$$
MPWLI@S$Z7##"MP'LH ]L< (^:P&68 +LX!@D@ *2H0WJ( *^;@G: .L%!6#S
MP0*P(0/4I!S<M0$V 0U^9@FF570:^1A:QEY^0;]%QPW<X X6( DP( F 0>..
M0@_0X%,&QAPV"^66X +0  . 3:JR;0_<(&K\(!KH7A60<8'_ 5J68 TPM0&2
M 0/*P1S3P XJX,Q,"@,N@ \P0).Y1 [A:4-O1QU:B](= Q_6>9V'Q??7V$Q^
M1TXNO=_?F&#7Y!Z,#AG*)0)TS1Z0X6>, A_JP(:%<9']A9K^TJT0RRS)8_S"
M^830DC!9^?A!-^8"]B".R&%D,0F:PJ0 =DYD+L5BS(3).T;1PF0>(L6QE>51
MTDR3 &+?OGL"Z^43N$]=O7H)U<7;A\_<PX4%U1T4F(^AP'OV+NZ+I[">.77[
M[,6K%^]A0X\)ZX7,=] @QH\,[:FSJ#"C/83XXN&CB% APGWY5&(TV#/HT(]#
M3\Y3-\^<N8OYU*6;MS!JN9,+4=;#9JYK2JSJRL%;R-6IN:<AN[H,^S8E5W7K
MYJ6%>S*=0JYOZYW;1V?''R-"  VY44H.B!*$FEEC9 31#4;/+EU*Y^,%*5"$
M"OD@14V:-';UI%$K-@D'H$>C-(W^F$1-$J=G<B+OZ%2ME(X2'2YI>B%$T(XA
M?U[(V6=HR M#2YL[?PX]NO3IU*M;OXZ1V[?JXKYX_R(FC)?MV,N;/_\<U1'K
MZ88@$I+.THLA18C@V+'#%"% .WI8HU-""2+XL(\B0$ B2C$FP%"(*7$D0@HI
ME8Q"#36;4 (**(D(48H@+*3@S"B6^,"(/2Z00((,BE SW!^+@+*#$<,)P<,-
M@M23CCTB+;077"[%54]4>Z&%CSIA@>352:3%,]4=:6"$303[W!%!/6WLX48V
M;EC@!AX:; *, ZHT$ \>>62PB3H18., -@\MH8$Z#NB1Q";S4*!*!/%8\*1%
M%*P13Q[^#RA#P3YVL*$&'Q @<TP;R520T#YGEH,,,O%DH$8$Y3B0C#%NW#%!
M/&JD<8$Z#^R1!AYXJ+%/ PSDDP$;]:@134:_/ #,.6P4NB8%T23!1P3';*+&
M!'V4DP8PH2J$U4ANQ7/.7NN$=-))\"ATDTM(HL0DDT.BA99$08KEEE4+Y7-/
MN@/= Y-;7I7+U5/[3,! 0OF4<],^%-P1S2]+,>0& )#RU0Y:?,53,,(IM3,/
M._'8E6176"4YUSYI )!!0_O@T0 R^WBZS[F?"D1!O2&=7.VS[];3$4%#W?-C
M5EVU9:17V.9A!Q]U[$&.JG@<4U0^ON"K#C!$__)P'WX88P_^.7W8L;,Z>JA:
M!S;'V'&''=@4I:TOY%253S)0(Y-/-'>H>L<Y1B]T3#)XW'$V.2&KDXPO^9AS
MC+_U((/-.5G?8=%)ZO"AZAXA$XZ'UD3ET8;>OUC$N##[J&*''G?T80X?=MAA
M=SSYJ$),2L*<C8>;/UJ5[<,\2N5N5V"].S%*Y=0%+K?9ZF6SX-2Z0]K,XH8T
MTCU_*3*?$$+<\,(?#A+R0B#4Q%$""2#$<4\@<$S2C"DCP/ B'(: 0HHDHV!#
M3267@/^'(*?\<0(+T'#BB Z5M(-""B>TP @U*PAQ2"2:W&"$& QA"#(BQ#XZ
M@0A!2 (]#&R@ Q\X'2B4 8(4K"#^!3^!!.NP P<I&($S)@$#&0G!""U81"(^
M< ,6,&(?D!A"('H@"G(L(Q(_D$0U%/$!$A#B%'*0PRA( 8U*.:,2HI##(#PA
M".DY(AJ-^$$CFH&.4, !$#UPQ#X6P8(8=$ 1@6@!809X R+XI2,WX4JT8H:5
M>)2#'37[D5U24I9TI,4KS3(',/!0E7J4PPT+60,%+N"W"&  &7E0Q3$F< $T
MY*,.$]  ,NR0#'BP(1Y)<$-1?F&!)2Q!9\:(!QORT08+:( /-"G'!20P@624
M@PW[V,34D*$L"O@"&VT@RCZ.(8$*:, "=EC#/MBPAU]H@ *&2X,$UG".#%S@
M K_PA0;^++>Q3Y8# Q*P9%7V\8L)4  #Y\C'&LK1AFS8X1BJH( %VI:!?6'#
MDA+Q%DJPY9)SB"0D:0R7D?C"(\'AJUK;&I<YUM&Z?-A#73(ABCUTU+J45:MA
MX H) FH9CV2<)!_D<("^]'".)20D'O; 1@$,\+4AO5%B2W**S$Z2L(@I+&43
M"XD" N OA>!##0O0 T9@L@\^\.$@FQC UU(2LW=1:Z':$MRY8*:1=+$K(UUQ
M5L.JU88T*$ ->;@# ]R0!@9L@J(&8*4Z%)"Q<E1)DWY8 ##TD  WH$$/OU@
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M]9(';) $=8 SQ$(4?% HZE!:%4 !$K 'ZO!V%! J$M!U>K &JE /0I<,#N
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M"" 0"L,0@L4!"!9&!Y<P"NLP"!_08B=P B4P!#%  BS  LLY HV0#IA0"8-
M0T00 X @"'$P#*0@ I' #'" (B"0"8&P X @!#MP X50#^O0$5XAB0W5%>V@
M%Q(Q4O70$_$@1UE8A7?51@OA++W3>@!E,%CY+-SE%>7 ;BH:$DM23U2X<0IS
M;RIS+HO8+N[R,.K@)FTDB#]2B&$1.WJ$+QS7%?=@#G_A,DH%,^?P$%1!;84X
M:@+5$1EA$;^V+NA2$"I!;M2&<V+^X2U!VG'QE(UP9&^E:(?H<A /\'.12"T"
MD0QL<  9DR\7DW9 Q4\0@W$2EZ<HX3!VVE ?!P 6L%&>TP!]L 09  &D)))Z
M<!!M< #D"(J?)XX'0X?8XB/96"[/1:0+81,54 [[H <8D Q_L@_*<  7(%SS
M4@]L8 %H4 [1L _1@ $]*0'(8 SU\ L8X!+]D'AV  P+< RVA RGR@ -4 \,
ML&IZ, $8H =OH*,^87:D@@&K9@? 923SP@ 7@ "_L EH4 \0D 1ZL =O(!!X
MD'?G0 &-8E'1<'3EL&H4D >3PP8+, \:D P>0P[%<A 9H'02D QI4"CFH  2
M  $)8 _^2[ T#-!U(T%=H+=YSO5H?&$NU>)4, E//3$2*9&&[C(2SI(5+R<2
MV. 6%,4/<M "// '11 #C0 )(.!\@^ ,@0 "P< )/Y (@& #@5 $D: (E  ,
MZ1 ''Y "[1D]ZYDB)^!\*3 )[& ^B; (@/ '-H (B  $W0<"D[ ,/@ ")# "
MI! '0U (0H #+G <CM!B5E2<::NVT+$+7+ /\H %7V &6" /:XM_J/ )UM$.
M,0 "(@ -F, #@* #.[ "F# -+Y "B_ ,/; #1! *E'"S@+ (A= (BM (AD *
M[= .H^ #7 L")^"R7/L!)M #I5!ZG= (C*"#@[ ?@H (I(#^"3ZP W#0#(0P
M D90#9JP O@1"$)0"(B6:]]V#FG8<E$!>EY:B!.3L3,#%;9#.[@3.US83FW!
M).#%(_B0#IUU,NQ6%F681L3HC#Y!,>-R:=A2A>B&A^SB+ND@$=BPO=3B$NX+
ML7H$I-JR$-E+76YA#Z,G3^RR5!]!$D4R$.28#_U@$'DD4"R#$G"9B,[8;MEB
M%Q0WOHTFCD$5,SBE+NBB#@40K_I"2BGA$4S2EO%P  50#ER3,KU3<7MJ4BL\
MC"R5,!4G5$&B  2@O7KW6LF0!QH5;0;Q"P60#$QE:QMQ<S2*J<QUB$95+>I&
MB>YR#A(@-ZL2,@NP"1G@!]"BL!;^@ W[X  *4%I\4 ]8Y9),H2SD$ W)H \7
M, K^I@#XXI1MT _OP "CP 82H%P8D 9WL 318 S)H YVO \,H "K5@>^=!.J
MX !A80<4\ \Z!PP"D =[< 'D\ L*2Q314"C[@ $7@ X-$ V,\@Z;H+#QT </
MD ]K\@!X4 ]X, $",0'^(@RMK"]L8 <9T%G1B :D9 P'@ W&(+(2.Z1 U2PW
M 1?!Z$Y96 \%<X7O-"0W(6[,DCJ$B$^<-R3W@ X%L@.', 1C&PK/P (E\ C/
M4&BB( G?1PB#( >*8+F-, KWL Z9L /2(P*@N[4@L!AQT SLP Z80 >,8 @)
M- A%( C^@\ )FE $,& (V D"1% -DK " B0(/- (^^ (+OMB=HO1:RL/W( 0
MMQ ++)'1,/8)0E8=Z6 #RB$-G'"$,; (E\ )/2 (@. #\$P"#.(,G> (BV (
M'I@(BJ )I" *HV /_. ,CM!>+H#4@7!A'#$,HG )D*#.<6!"D1 )IO ,($8"
M.J )// #@] #G7 )B3"V1I (]V -V*B5&3LQS9(6>L$PCT:%(T%Q'SH7:^&Q
MJV<.[H"%(3LD.>JQQ+R'[NJGX>@5#L.6DM8P]33-=Z@1-Q5[[%8/[T -$;-N
MP6AOQ#P7J\.A/\%YSB9/*?-/7?&$V]NAT0N7(-J\^=1QA1C^<;VS$$5R5[[H
MVAVQB/.&4"3Q"P1 -E^Q%]C$!T!C,/OPR'*J4I6F4@6S:5ZZVA'SHDY1+;\$
M /)X$N6P .H KQ @CPK!!F2C#@:0W<*,%5,J;TO%B5@Q+4%B4D2ZE1:\$/W
M!JOF"W? +JJ0 7!U$'60-5M\#(XL =MD#JI@24:"#(UD 1)P-<9P$&\0=O&
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M0'7[4 PLL[_%L _Z@&&PBPF8$ F@&8*!@ GI  0X< .(, B8$.F6\ $LT Y
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M3ZLGPG8QAC*\Y3Q2%Q2[$.AU#QOR""8 "="P&)H0")>0TX%@!"XP".T "8"
M"('P X'@"*-P"9C ">P@#0+1###CSO5_#L@PG^:#"1X($'\"(2I"*IT.'B\6
M#<*DZ%&C#B_:Z5CQ: BA?9T<.:*TS^-'D"%%CB19TN1)E"E5KAP)I<D3F$^8
M?#'9BPNX?=_R?</"C>5/H$%3HCJRDAV.$B"@7?H@HX@F31X:-=)Q:<20$T(
M[6 6:E"D140$)<+$B%([C^@:#>+^E._>)4.2SGEDQ\@1J4"'A#2*%$A4LQ6
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M$KH;";MR*  5>1)EO!)J (8-V8?^"Q" _"&>(-$<(;JJ?3B *1FL"\   9"
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M%/. 0N>:'$W9G$$='"SQ+EQYDE\0QMS@#^+ AA,2E*G]$W/^X"GM*!9/L5
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MN;KF"<V&Y>605<N'.WA%"VB *8FBU!T ;)!0#QTI"&'2?< &S2H  X"'7P@
M!"B  2@'-@  !!" !T A4CDOVD  !; 'VLBM#%$'7PB[;$  89@@+9U;134-
M_**1JYW.>IAH-A^>_ )/MTLN86;UN^D1]2B'=SA;D!0.0FG?2DF'CM)U$N$4
M-:D/@)S^(11ZWJ%#P^JH.VR>R'+0NJOM#^/(3H]TC>>8!\>K#N9PAP9!TM+0
M.F'>NI8Z!RU"G]1P\4M%#;,:C7R@!GW A!40A/.V 42 AJXI-1#/;U#P!!5
M@1<(RPYP@700!<9NA!9+!$? ! _3! 9K!E"PA->&!F@0@0Z( R&8LR+H!&=P
M!@\@A'V!A"( A6;8BAT@V8NPAT4@@1'XON&N>8W)!VZPLGX]B7FP@OP3@RJ8
MX[Q4F7S(OY!H/X^XA5XX>N@&)O"NI@F' 6I@!A'0]S\([%!@AFX2@1MH%H-I
M)T#  ;%<A%*H!!T(@3@P@1T8 @D3 18# 4)0 4([@2$( 3C^J(1F,(0(&P)
M4,F7-+07, $B, %H.#,B"&P>* %'^*H?.8>]G;6R"I!B":Y>QQTFHB*Q'18
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MBU;%EB%%/V%+/B0#!*0*583*HGV$U^Y#'T! !#R*K6BIAY[@5R"43^R#.43
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M 0L, <)" B8 @:#:T!^P,"$<@E0!0@SD#I( @L1*+,.RSB,( @N4; HP0B,
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M4[1F%,H0Q38_^0K JN8X1\WQ5U<QEZ:V-A5*GLQ=1$FC5#(3E9#\*F5A0\D
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M1NE3JH7^!G/C'N2 =?AC!P2!$ KA&4IA!?[@!2(!" R!$_+!&H#@$#P!!D
M!H:@!&0 %!SAAA2!\/H#$I[!$C!!$T*@!8: !3Y@!T@A!^:@'=:!$GK $ :A
M!7A@!:#!%*P#/7R !^B#\R[A T; Y;#.%W_Q1U9A#,+ #*9 #"#D"[I@"\P@
M#*Z@#'PD'[R M<+ ?W0K06"A"9K &A-$%Z+."FP!ZU#A""8$$$9@!)8!$_JP
M!Y8$/3#!&B[A!A)A!&+ &HJA'23AATC!$(: !%C $43."#Q@$2)A!"(A"'P@
M$;('$4@1!DK@$00+!Q+!$AQ!#BJA'8K!&F#@! 3!!3J!&BS^X0_^( Z*:! $
M[A[,X1[R8<?@[V[8R%_,3US>!66R+UI*HAY.ZBB\)90F8A_V0 />25JF!6UJ
MSV$DJM#T0ETTH@W> !@DH![*(2RJYM-Z,@.0 1F8RBXP(Q[H(0G<0,?2!G)$
MXH^.L"JRT"66 ,X>A]8,!\4L C3.":G4CR-N;2WD2 JK8BB$B8U03=S6$A]F
M+8V\AC;R3R3"R=?V00\& ,G.01A09F;4Z1<@0 UZ0AW>00$$@ ](!:9T9J$6
MC,WLYB-:8F%\9I3VS!@&H !R)EX>( ]^CI 4R1P@H)GBH0"\LB4ZT\/T)2((
M[=O0"*:*YFRD8BZL[26+*2Z.R2[^>*DGP*;-$@QL#*;;4L-<"@=54*T+V_(I
M]@)M3N2,N*)K)"(:HL%1/H<(F9,JCJDUT,$GTB$;O&;QQ+"@=(^6@K(DS,]H
M2"(>K+ NO4U6^F*1)*-ISF\BFH8J;.-S-N4>R*%T;H![V#$.0,$:+ $'"$$$
MAF =@B$?%,$0+*$3A@@$7F 10"#S/L 1$"%[;B"%1$ 3BN #<( %3N 12. $
M=@ 1(,$2Y& 4V*$8JJ$$6( C08$:)D$(N*<(?@ 1=B 2 @0$2B 0@-%)G[1!
MPF"U/$L<'L06NN EN&"!DFY"RN 9#^2 GJX+7N0;N" ,(LB!K  ,7@3K,BBX
M_H $7N#^&9HA!>ZC" "A"" A%$P !T9@$8@ $4Z! ^3@3T, #CJA%$R!!6!
M!': !5A@"&# "%  2JZG!8C@!%K !42 !5S %$(A%&:H!Q3!!VB@%% '$4J@
M!5"@&1QA20Z!!_Y !B:A'M8A)3&"Q=S(5&+)5$IB*X+R/!T,#34G:!Q#'=RE
M(_:A#98@'W*U+>?!"EED#Q:@+'.O9"Q*<#HG'WY! S*@#_9!;MHH8/+A&#0
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M#8,R7Q^C:-;A5)#2HS C7&AIV2Q%H2='&E9E'LK64HY0G[7^;8QZZLF^<"X
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M$G: B2.U$RY!!UA #GPH$5!1#@CA$$J@!(@(!. .$MIA'QBA%$:!%$XA%(
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M2K9R)3LS9E'S,LOF2&@#,A.&3[^B>SUQ2P1P?O6P!,  +ES14P1!,6JQ#\@
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M5"G&1V#Q*ET1,R<3N3)K;/^WK@\6@6T3M-06N^R0-RB0 I<0"43P 9#07C^
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M8K %8E <XB"H@JJ/A@H.7" &K;#^"F6P!65@'+K !?,8/<:1#U7@!%3 CI^
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M#/E0X"QEM^S)XPG;A[P.A4;QSZ9?XW1,X_&$T'6+2DK[@?A*9?K\MM\IY/E
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M!$6DHQ =N$0Z>->"#UCB#S#0 2#^BK"#..RC$R4@ 6I@MU.>]M2GJP$'%K#
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M3J &'OB $LB$1O@!2.@$25B&9) &4: $4M $6,L$$N@ 'Z#^!DOX 2 (A7T
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M 2*P!D,HA70P =EM 5"PW1_  1%H!$)8TC] +2+H <6QA!,0#<"E9K'" BC
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ML((+83@7(F.)*CC 8 3,J 01Y%4$(F@B$3QH 0MV8 T4T.$>@RA"1)9Q*AV
M@!'4$(4<3L$.5!&"!"!8!*K2,0PY0&,=AOB J?;QC!Z\0 B-V,<<5I".'2RD
M!X& Q!#^0(2'""(?Y[C'_FQ#MWC^] -]N@$0C\[!,_P)14:<:2$!<723?:1A
M,0*$2CGLT8<U1. 8'+' <>Z @7WDPPWEV<D^_" !F@FC ?;@23[*88Q?#$,:
M/*G'C_)&G33P81\7V,3@6@*,"\H%.2/<1QN6L \,4*,>.6F *O9QHWT,YACF
MP0V4,#,TSIV&)5 ]# 61A#J.I.-&4EV=.DSS.85&27R9\XB H)>^UP ()"!!
MG_E*@B#J[ ,/!B" &JR6#_;D8P]OV,<>T*"/<Y"#)/L0I'E.=9/Q7$<5&FC)
MX/81#S?<U0W:XHM528(^_)@5-_VQ#^TJ<P[WC*8?J!-0D#ARCIS)L$E!44F$
M;@*/CQS^J84TN4E4B%35RYSV2O>)QXY2<]LF!>VV.S&17,H!PP0-Q40G/$Q7
M,6O5L-((AR7DK0FI00VHV2@R7CUHBF 2NAB.=34M9!(+GP3>FBBI,5R[IR**
M(*]Y:N(/[(2!$*P1 DS8 Q!#:($@GH$<%HQ $]: IBC8(4@>6',2J%H'*.8
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MS U(@CG$P0B(  N8@B$, B@D0R7D  HT0S.,@ ]L@C-@PAPD@BFH  B,@!Q
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M6=U'&Y;5 >$(T&"7.N3,ZNR/_<263L!D;O &/YC#/<A!#^P "PC!"B""(ZA
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M_G%#+-1? F[!%X3!%UBGU,**NK"+$)S "TS#))S (\  ( B!$>S AVF""ZB
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M&/]3TME.-9*&T+6/:+'J05YC^P@4-=)$;B]L6MD..)Z*.>Q!&C@  A1  2"
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M&MC!)B!#W2B6)I)Q67G6:7<$[9 Q5.GP6B'D>[<=YBADQC\D2/#$!4S 'F!
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MU2 #9R %,R )," )?U $>5 $99 ):[ '?Y $2U %:S )FG#^!:7P!I\0 _+
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ME$$5+L "OO!TT, 8#H0!], !+  8,L "UD =EB #)@ 9EKC^B1V@#J+!@]E
M'2)@A'TA#19 5O.A#C1@ MA &B#@ AS@&(XABQD@*_=!#=;@.J(A&=R@ 30@
M UY*'=Z@AZ.! B" '+R- OJ 9O*!#9*ACAV #Z)A ISX'9*@ B*@#?)A"2C@
M E3!#I)!D2T@'2P &4YG"5BS9*98 =(@ ?3 #4"2 B+@%_C@ B8 &(S! 2:@
M+!&P<XA#/6*&;Q9S9&UGGE0CGHRB,AZ-H2PV,,;O>8Z&V@CJ.3K3/7+IT/"L
MSFX9K B'98&6TN+F_PB''2;*H9+B:&)# "&DF[\9.81*/Z9B'V0,_^+32&Y,
M.*]O*TP#0\!JQCKO&/P#&?C@*TO^.07[@ _B 1OT0!W8  WJH![N8 W2@ ^2
M017V8 CS@ ^60 WX  \B^AA.IAS8($!^X1<$>@G<H!R6^!R^T!CJ(![6( 7O
MH&BC81-4@0V^U1S4( W4 !DHLF^7+?EP)CHF@VF^KS/,.<E*\BQ")TB"64>,
M:2'O(1KJ@0YV(!)Z( 3:(1 \8!O5)!!LP@;:I6(8P1'FY!(@KAC8 1V @2@J
MX1RN0QA481^P 1CVZB- (>[<A)"HH1U\( YB8!':)!1"@0@^P!.<H0,:01",
M 'PQ86$R)7D1.[$5NWB)%U3P(0X@(7>#@6,B@4QLP = (0<T 040H01>" 6"
MX1D8P0_^(>&#-*$4*N'DT"$=@( 1?. 92J&U'7$=[@$?)"$32*$1(L$2+H$1
M,($:1B$%$"$03@ 14" A1*$%>,#Q".$#<, 2JJ)1L8HJ= 0J_Z,!&& -[&$!
M\. .&( /'( _\  -^B "X"$9(B /(N!9U0 /_$$"]F$"5"$"ZN$7-F&*-;4P
M[F$)'" #&, /\J !XCL#@&$!\F!A50$;D!*^,Z -,B #-F$!5.$!XD$/EL 7
MG'4L@>' C8$!SM4-,H /[.$!E'H?+&"ERJ%7EN"-(P")]6 !@$$#T  /_,,<
M\H$"#L !(D =6GF-54$#D@$/CH$!YGL/]C@/*& ?\L -EN#^A(]!PB_ )_-!
M O0 9>J! BY0'20@'RY@$QI '8S!N_6@#1I O6,2<4B69/V69.]F OT,.L1&
M>.0FHR"JFXUV<OY&H]"# 769 2UMT>@<0?)\,--CG!QS,FMYJ!_M,=I!;[.I
M, D'HCR#+U<VG+[JH0+C48%,1XHJGDM2.+FS'L@\&G[!6?D@#12\#Y(A SXM
M#>S@BM'@U(U!-4LY'9*A 8!!#?8@&=!! E3A%RS@=-: #<@A#^J@DMT@'O!
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M+?\.VD ":E\--@':-V$--@%9MPG$W6 "?@':[2#Y93@#_C4-D'4?KI(-1(W
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M!,0@"G&(1"RB$8_8(RE1:0<GB,$S2E&"/UBC$3'X  _@0(UTD$(:DT"!(&0
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M@0E*%.,>)HB!(X90"!ZL@ CWLT$B7* )% "!GI4H12@$A@G^2P!A$2KH 0I
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M'JD(5;/Z5J&8&]MZ48]214(WR W5IF95G'MJ@I[$H35]W0YWW+Z&DL1IVRO
MK=Q<VH.V]\C[+?:(QM6:.[.6#$6W'B$'.2"*#8^K QOG>$BBTQ$-1/=98#+%
MQSORXA5I8,,K]5@'/+!!\JM0^KGF6 =UX.';>#PGK.FF*G3N/0^6J#4>E!;/
M=!J>U.;$0SS9R0>;,:&)2$RB$7\X1'ZE,0H:.&,%<'#$(@HQA$ $X1+LJ,8H
MDL&.8/3^P B+R#$H>I"G1(!B$"M8! P6X0Q]C*(2Z_#N"A[Q A5: @6-((4'
MJE&)%ISB2XG(NB444>$3C" 0'^Z\YS\/^M OZ1Z#& $(F'&)'3S"%'"000\
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M4UGH.%;A.).C=(.I$1*H?^: #A*X?ZR)#KOKNQ((O+O[N[M;#NM0O/KGN^C
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M_3B'!2A:^.763SC8"]Y@#N[@D97?7ZV/"EB F<4/90C?^\B #-B'-]C>65T
M"W"  V" /=!; U &#$B !KC?_&AA#\Y6Z?QA(1YB(KY7$-Z/?QB Y+T//%B
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M57U]XW$^9W1.9P*I8Q,N@.0MX?KX!P3@7\$-@ C.WPS   S(@ 40W:D]!C<
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&SH>    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g221611kg03i001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221611kg03i001.gif
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M[_3T]/;W^/?X]_/Z_?CW]_CW^/GX]_[^_@
M
M
M
M
M
M
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MMQ:'F?"#DE"#-VB(ZT:( _$%@X!PF2 '7.!K<H (>%"'+\& ?C<!$?$%7>
M3&"!$$!_B) "?4<0&3 #&L 0)N")#W$&$(!L30 "$+$"8B@0(" ',R"%\5=L
M1V "(6$$ R$))G!J!I$%+, &>8<0KR8%2C"%!\&,O@8";! ()V".IJAL'1 (
M%7 &_ <#J5@1<< "C3@'(1 (#B"$K]8"TN@0K^:->* "F<",5H $]\<&RKA_
M:" !"!$(%_ "[2B$(/ $[A@1=M ![VB(3."*=AB/\\A_!C$'#P!L@? !AN
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M_?B;DI#^ %GP 5F0!2K E7;PHE?P )7Z!&= E+?&!@BI 58@""_P!!J0!0_
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MK"=HTDM0@U+P!"'@R\"\ E!0A!'X LYI ?0HDR@0NBP@"3>="5#@BE) CE/
MPWN=C11-S0S9!*MV!<=<F%!@KP(ADQ&8P,AF!Q: "!10B@RYN)M[!B_@J1WZ
MJ*[<E5R R1J]G<>(!#FZT:_&!%!@!2-@!4: !P0\ QB<"2. !5$P UB U>M<
MS<1X!$)XF0*-H'-@ ;=&NRH F%# AVP0@2N]EG. FUI:E"+^ 8O@6A%S$(X1
M<0'T6 =Y)PA6P,0]*M&^R0:%&0@@\,@2*\G5"0*GS 1HP (H+ 'FS<F,?097
M*A"(0 *2()1RH)8&?04:::.8<(Q2D(IG )@K, *K!@+YB:#P^0!XH+!14(/W
M.@*I^,MS$ ALT %Z^FI8L )G$ 4K@ FRF0E9<."K9@4O&\T["0%R( DG8 B"
M:@+D: B8T-<VZ;/?G*_6:+K()IMRD+EVZZ&8D)Q*B 31^ &3BP5X4 BH^]TF
M/@=/D *9T)0L4)A,P 86, =RH %XH)':* 5*KMZZ!I^9<.7Q*-3?_ "(8-&5
M6LTI&-H"$0@2>=4)^043;N)0,)?^$3L0MYH):3"4+#VY%]"UDI"<F1 "3_!S
M(S"7KW;3F) %3= %DRL%=ID)2S";\5C:T<B!VJD"F)#;-8R:()@%*$P0;# (
MKLL%YXP'WTV4*^"^\)N(FUW-RWKHMXB<IHS(-=@$49F*2B )?L@&C?[6L.GB
MDI ":DJ7._RM)M"(0EFIN:SA'([?;.[FA?V#HSP"5Y ))S 'Y;B\>4 !F( (
M38!L<F#!%1#1J/F#5J %>*#2.VD%S/@$SNG>PFH%@XSO<BX0=K "MZH"7T#G
ME1J-P=B\F)GO)%"83T",>0T#47 !>!"D=G",T\P&5ZS7O9@&$<@":CFSW!K=
M+R&N*/'^:A#H@!4@R!)I"(N.FV?Z:E9PWKU\ KVI 6&)":W-OQY*E!W @1J[
MQ)4:LD]  L[Y:HB0 :,: EP  EP JUF@L"%@JCB+NE^@L&=.Y9D EDP/ ]:H
M DA0 ::; E<P IF0 :G8F"[:!59 [ 31EXB@S)5*Y2?NO5@P H:@W96ZDRHP
M Z(K"3,M!78 PG>;[$^P!.UH].][LC[^:E\P D80C'-@DY5\WY4ZO!YY!EK0
M]$QL!TH/S4]@C2G/ L1ZLE[_!<2]\%>>!IF[T">(FD?0!"L@"1K[Y@,QF!"0
M@@PILUQ0KW..LS&/NDR !2I@!3T/JZ#9NB.@!0I^!(-NWEC^?.@,"0+';-M(
MV03P_0%5V?@^RI!5'[F!0,!GJ?0=(.99$)4;?@93H*O]F*C(QJI<< 6C[NHK
M_IMM_@((^6HL8 2BZZ%/,.6)*!  P8+)C!17"H[ U(%+)B28N)#H(@5/AR\O
M7F1*,4,*"4DFL,"8P?!%E@^(,F7Z0I'%"RXFOD2A=#(3B2<0V##,E.5$EA"2
MD+ @J6@&$Q,L\$C(A(A))DR9)(%H B$0SB<OL(R8VN$BTTQH-/A<D0F+"BX@
M\,29D.D*V1$W99*P$BB#H4 0&+*0RX;)"B8LR@8*8243DZE-D<R(8B*3"290
M3$CZ,*5I)@ML5"Q],N<DF[161G#^^6 G1$4D7&6>1IU:]6K6IRO8:1U;-FL[
M%&:G#B2)*9Z3)O&<@2U3TM1 9S1G"H2(>!HY324QRF2H*7'=)JV<8;/UY.]
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M20A!%', 1/B D<N$)V",R!F!&6"DP3""&-N.!=BB)V !&+ "O<J" \"",]"
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M,R!#+D"$QS@)$]#)QY@E+K"+.3 H) *!*)@$!$ 0K<N - B+&>B^3 B!%Z@
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M\, $.Y@CAL #%8"!*(@")- -%B#0B.*"BWB")_@.LN""'F.!%* <EI@!N<L
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MU60HRLD ""ADQ>88)Z9CFG;I,MP,!U"!$TBA6)Q/23#%Z5F &8JM"L^J0IB
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M@J;8.M_^FIX=^NC%B'>XD +)!!>RG&&@4EJA?D?1?(%Q-8TE'PPMZ*@GF$/
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M+ 4;1 83U,$@1,1(C(!@;$1&V,4+,,9@=$"XS4 +_-\IS8 D.,!-T4X;78%
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M"IP!"V!")!K" _C%0(  'FS5( R=>R"'6&5"JYU :#"!T0P+-C( NW $2+
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M'."!%=B.8Z4'$AS:P3S!"^@&%[" BC[! $C0RFIL (K**NE&F" !%AC" ;2
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M"3!$"F1!7:J:":"S)'0!<MS,\]5Z;TSYG[9+9B.\PV=-%[25,?,<D$ !N\P
M(12$[%B!U[[0O;T(7$1&$R[[X_:((=0@XJD0#.SCERF-$I!G%RR%(4RF&$5B
M'Z\D8J2547"!'61!3[<54D.!,PF);-C."%B@T,S!Z]1H%$S!"K1&\EU<X;3
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ML !B"U *$N:0 BM\ !$4O (+S&9 !A %"@%0GP1><  VL&$$42"!)+X@ 9)
MP1 @D(("V/ "$/P0*F=8P1<<T!XFJ$ ),X#"  95$1#   9?@,"".E4 *VB
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M#I"@ V8B TS'<%!,"NS@2K/4(E:M7M0'4*?##B @(5:@I:IL:::@"TRG?5)
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M-$Q/D(!!CW="C+9F7"V@3?>?GT"B+[JEV:^<Z;HN#*$ !B"O!4  !@"O!T
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M,\R/Q5O\7,02*.O/)X%RQ>%/Q3&RQYTRQHDR */2-&Z"$3Y\Y4:\R;]"$@P
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MD9.)1)8S)B"R^( 1T\1,B*2P>7'&2D1,9U2<L9.)!0LFF2!F&D$3"<R)5[Y
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MT( *=* $+:A!#XK0A"ITH0QMJ$,?"M&(#E0%)UC  42'SXQJ=*-^,80%)/"
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M)/PV$Y_X9#H>\-$L?.$'GTS!(W[SPRPGYS$/>L.'4_/+'#TU+P_.5T))$E*
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M @SWB-WQ9VUA!1CR9T_@@QKR!&3A(77 CB%Y)8;('5U6&EQ@8"\P.!7(B"8
M=T^P G^(B9EP!5$(-A4B!REP$C/0 ??! E'0!#-0-"(1!2_0 ;K!<(E#D32!
M!R:@ DS)(GYSDD"2$"J A<+!!8CP!$V ;BL $R)Q!ED0=E$P S3!!GLV&4\#
M!7)PDE8 >]XQ UAP!031&G^(!1*!!4L7!<!(&I,S Q>P<Q.!!R0@$B9A!%_P
M&:ZW@-R#%ES0!%%1!TMP:W8QCTA6;S%AE#)Y$AIB!5" "5" C8% D][Q D8@
M%91@AVP@,'VTD+<)/$[&-(;X GC^D 5'L#1JTCGW43?LPR +*#ILD5[_R" I
M@&Z'PQ!'H 2(D 6$X)L?$G72@1%)EPF*  /IT3>&Z!S(R2^&< 7J,0,EZ!L,
M8@):H"9G]F5RH 72PR"Q2!)<D'06D@8OP +A!AOJ@04SP *,PP($68$,\3QF
M684*!QQIUT"$DW8!*@<SH 29 R"2  4K0*#AMUT,,@.!4CT3D9TD<3_1078P
M$7MJLETMP2]2P +!(9E7IR5,4(85: 3S!@-'<!348P6"<)P-@02&P 6BDP?1
MP3G/PP8'V&Z-LQS4@P=:D DG8 70 SA($ 68@ B9B9M;JC:8$"C/A5S5I'K'
M=1A(<G;^AA&FI+5::NI;8Z1-N?09?P%=:IJFG%43@#%<=H1;I24)^R%N'R(P
MC%58FH(9G<FEAQHSPS@88_JG3,*H@O&HHA2I+S.IB&JIEXJIF:JIF\JIG>JI
MGPJJH2JJHTJJI6JJIXJJJ:JJJ\JJK>JJKPJKL2JKLTJKM6JKMXJKN:JKN\JK
MO>JKG]1S+>2F+01=DN5,PYI<J!5=QHJLWM2LSK4JQRI=TNJLQ65;R1I<ID6M
M>WJLDC6GTIJMV.HJQGI8X[JMNE6MTWJMO>6MS#5:8;JNR(JMAY>LNZ2LS&I<
MX'I;X<I<SAJOEF5:^"JL<32M PNPK#6O:0JOU?6K#>NPP /^!4BP!(_"!(^B
M!!1KL4S@/<$G/12KL17[L=*C?!U;/=Z3L=+C/4@P!>M1/4O@/23[LB![!%P
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M?<DF!!,-+[1:-9$)RPPVJ$GH/2-Z+&"!7[[0%=AE]NM,)*#X%0@#!N>Z*K@
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M^"'^[, %*00BBZW*0@J/<(8Y8,$R)WD!4BAAKY3A 1,O0,)P[#9/2TF//G;
M@A5>,H->S4 TGDD!2@VY+RE,X3M<:!,F.@"I,AKB"'-\WLCP0,(NDN +@K@
M'G:%!SRHP*E2L(*(4#.'*4#Q)9'^Q(,)EI5".62!19DX(4*@8*FBX>%QDM#
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M/<%C))#^GO:0D. % RDW4"C=C8:SDBQ4S0HAD,1SYC W+M11$A.83PD^\(5
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M7__[YW___?]_  Q  1Q  BQ  SQ !$Q !5Q !FQ R N$CE.($A*_T6@]![Q
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M?QD(.3@ )&"!$% !&3.$@!&B#GP!*=!""T"?[[B +"@E*W  O9,#L7E7+I
M)$" OPG^@=.!P#?) AML+LK(@A P4HNQ@BL+&!-(H=@8@$)Y "2 ,X#Y@A5H
M&R:HFOW"/%LZ6A'P8?X(GLY1 1M^G-\:@2E8+Q,PX(% FL6R@!DX@#DH&8$Y
M$3Q(H<2ZF2;X *A=K LHXRJ2@NBX@@. TT"P(A X@4"8 .WYG0O O"@ @>^@
MFZTA&1*P @:8/1-HGHN8,2E@ 6UZ*S8H@'"2$SR#@A=(ETX. <!TF@$X RD8
MF1"8 A7H@AO:F>L8",K#@M%* 2C( "PP@#4R8@78#(%@@0. @GJ!$B<\7828
M@$IUJ9J22CRP&1(0H _8'2[@&DDP@4K%B;>: 2A@ 05HGI+^4*H0P -&>[HL
M -V">0[,6YL9P ,*F->2RZ+V"H$L@@ YN(*QO;(3^((@M@H'L(,^@0&H&8@Y
MH& +5@%:T> O$"*9R ($J"7H2H$HT.!GYH\1N(+ZT0 9<A"^P2!"<YR"MJ7Z
M);9 B"<I0 Y,>0D)6)8Z(AEQ(J(Z.H/=6($URHW'D6$ND" 2T*Q,J%85<(Q#
M6@$RD1Z!R$(NS 0M$"?1>+'Z(JN>$1O%P )3TY H:"$VL(-XPBPY@ $L4(03
MZ )+V262**D,*"RZF(!ED9CVD0(8."A=_@_'D!PDZ-<O$*<Q.1H &(S_:)8M
MN;S-.*CC00@[2*:>G1!,J2]M%0C^Z'R"P"*OXX(:19P0-LH2ZBB:KI4$"!@$
M3/"D*[BF3D4,+, $"( O>YX$) BECA6(%)">G?@" L%>*!B9,Y"@0%B!2>BH
M3/"23;.CRUZ!/W8>Z]B-.2C)TL@JA' OINZ"H:H 2:@ 09$8-+A4'5,AZ9$"
M.VAF%7B2W/ /JXXR%9 $+WDU,T(DW_PD8F6#!>$FD>6(%9 W-K @+,B"(T 1
MZ?%9Q=" 8S+N"< $7K.C5!&-"@"AGD""+L@ !IN80N#<V3ZYQ,AI0UH8G@9,
MA'@=.S*21GHD1:K@3QJZ"B $X_9@Q9"F-' 9-@*5CL:NCR:CZSB#D2$(*=K<
M0%&!6I+^GTN:@\>)@SD@G,K0;CM()$.8;J*P ,%PC"=8&+IBEI= A#,F 3D(
MCT3^ (CJ;YR#6380@8>RF0R"D$  ,SO((B;@@C-V$78SUY=  IF J2?\CZA(
M<484*S^1'+.:#2[@6)/(+*YE@V5. 6V= SN  0&RVN'0+R2053N)I[W6 C/"
M*"R0EMK XBG@Z3,X+A+:ZQ+&8B80C2N0$ULY[IYX CRX+4E"HV#[/ N0M#I(
M)*D-N-!&B"6@CH2HKU;ZC-(X@]4(A([ZIA-X@@XPB180W4AC0YYFW1'H<Y+1
M#X&8 Y?.@O,^;D20 $%Y\;5"$8DY >DY9XYK5X$(@<@HJ<?^N>E Z +A@ (P
M^QL[:"^.">\I.(G/@#V"N#FEPAX4V361WH[ M2*G-80"@P!,8&HR@I!,Y''I
MG6TD^(!0&K:!&%80& [:>HD+Z'$H ?($4173& R6QC/3F(*Z>@%/VF\YJ'7C
MGH,9]Q,EF",FL',NL,(0MZ[C;I\4L(. 00@-2+LZP@,+P(,F^%T*F S'P*":
MJ^G<L);2  &;YL0.H+(\0(,K>X%N(9DKZQ4-L -:1PR(@@$YF("MQ@,1P ,E
M:,0L>FL\,X3(D8/Y@@*5#9@+PMZV(?K$D80,@Z&76'DNF'DC:X$JEQ:90 (2
MT"]7DQ\12#H2J ,3R+5O3:;SYH_^>Q6S%$B5U5@V"BBNU9CT)WB".1B!C@,C
MV:B B[L 29  ]TU\-%AD)/@.IT.6!>@)\AJU%E"9%+* S89!U$*?__B@_3;1
M#/@@$.@".3.G>$LA-EBPX<F80E\!0R ;Q(A\)+-/&@J!.1C\5_,PHAB!*J,G
M22";#M"F.HH#QY")%I[M%)@#L>9Q/D.("@CI[!8!9O$D/*"G"K(C+MN-SW\)
M.4N-71NMBW#\D*8:R@"0#^BJ,Z $$%!ZAVD6!LH V\@ @, # HL5$)(<R#'R
MY N)@W(RS<"4*1.F!8$R<,EDQ!#%3".B=&"2B4F@,RD"O7B2B5*F+!3LF& S
M(T4F+BK^ K'(\D)%I@5RY$ PQ "1B3-6K" B@8<)DB\G LW @\A*QXE6KV+-
MJG4KUZY>OX(-*W8LV;)FKTJ4<P73%RM?K@:Z,N?,2BY6V)R10U<2GDQXI-!E
MTW>.E2N(,IWI:Y40EBR!_$K*U,5*%ZQ?I#S6<O>+HC./KW"9H\@J&RD/2V9"
M9.AOZ#.2WF+*8H4N8BEUKB(B:"?3E\ASKN+!8F=O7[MOK0:2,SL3(X(/>5/.
M]),W(DE3,EXUFK$.FZML0G</5/U*E>=6Y6#"]%#06SE<Y(1'Q":0G? <);*-
MC$>2;+WP$3]6&1Y'#9*))%AP80<C:&E&6QI6:.%78!!DH07^2W%9\=@7$K5U
MAF=X9#%'=VUM%UZ!5MEQ6'>O91*(<,1U9 A=L7%1AR1GR*=8)A8PD45?;%B1
MQ6'2&?C<9!FQ-8EW5F"!"6HH2H'&1$#.-XARQY76W53#^64%)FA8(0='6> E
MB21'_?;%@KM9]04EGF5BAT03Y>98G)&1>%46%7"1$1O/Y3E=;Z^QY1=@4P:)
M)V8&_G:6HX]"&JFDDU)::5=SHE46II!N:BE9G7KZ:::A@K4IJ%^Q 0*IJUKU
M@7FLPAJK1%R8<&FLM^*:JZZWGHJ?5;[^.E%Z6)TZJK&C#DML5<%JE>RRIF:5
M;+'+,JNLL,_.:2JHTP);+5?96KO^5:?@4DL1M,W^ZJRPVA(+;+?3E@LNO%5U
MNZZWVWIK;[.8GCL12]>2R^^SMA(<[+CQ'LPLN]?NVK###T,<L<034URQQ1=C
MG+'&&W/<L<<?@QRRR".37++))Z.<LLHKL]RRRR_#'+/,,]-<L\TWXYRSSCOS
MW+///P,=M-!#$UVTT1+/>[322S/=M--/0QVUU"J;*0DFDDR2GB244#))UEAK
M?7765W/MM=A7IS>)U6JC#3;977]-"=J8L,VVU6[?G34E5H>-]]E7;\UWW7?_
MO37<>X=-]]J$^XVUW(8+OGC;8QMN-MB13\)UY(I/WC?E@*>]>-=D?_VYXY1S
MG7K7E3_^7GC9I<\]>.=O6Y[YYK9'-K7NNV=L" 4.*!"\\,,37[SQQR.?O ((
M*,^\\LDC$/WPSB__O/7-7Y^]]MM3CWWPW6\?OOC&.P#!8[RCG_[#B"C0@1$O
MP/\"#/#/'W_]\MM/?_SX[]^___G?[W_YZU\ ]W>_ ,YO!C,0( ,'Z+\"%E!_
M#(Q@!/G70 <^T( 3O" &,XB_^1UP@ CDX/] :,'^S0 $!="1^EKHPE4AP@!*
M*!?.&'&^%Z9,(E 8P&.2AL,? K$KB"@ $@QD+G/A9UCI22(3D=B1) *LB4J$
M(A- T $N@.B)Z>H((K( L"_. 3L&.D)D)(*%#J1D8$=\(KC^OJ"8)78D,DP0
MR;#P,(+(6.$%;)1(3#H2""Y\ 4CD,J)$YJ !^$$Q6_("EUZV"$=)D( $'P@$
M'HY#KXED;5V)A",GI^@K*++1B5,\(A25M,,;[DJ)04R?M(8VQ!GZ4%>(6,&9
M,B")[IPA19((1*-RF8DH,,%,F9@#(I+SFL<PH3ML&)$74T."[H1 #G?;S5PR
MH0@\U"$_+=)2"N0$)T.XR4!V&,$,B.07!V2$";5:YD0"@88'""8-7<K"&;K#
MG=3@@4T388$4(!*%U P3,;?9)2YW8X@Y<.0%?GH(6WI8DR*2@ E/H H[$6$'
M\?R&H!K3H0!0N<J/@G0K,2QB+'/^A8D4X$@^?4H!"&; A@]8P"@J2 $>4N"
M'F6B DSHP!>>P((5! (*B&%!3 *ADDQ<0:C20404 I&%#QB"!"K@PA4T\ 4C
ML. %=B#!!:3 A@&T  HL2($A7I#5D;#  5#@ DWB] *JP, *=DB!"KR8@K1:
M804KX((AK, %H^3!!"3 PA4^H(%&V4&/+<+#&;(@B0I$8:9VF$,&I& %R;Y
M RLPQ 0T@ 6BLD&L*N (8H!:S M<X+(H?4('0A ""]PR!5;H)\8XZE!=26(&
M3W@!$]R%F+Y ZYXAY9DA9K""W<CA!?(,VA"70,.)V8$%&&$#%H)I!1:PH0N!
MF  ;BJO^ C:XD2H:2&8F5( ()*B@GSH)!'M-(!%ZUB0J&>(""#"Q3)W^QC4@
M:($7'3 'D=SD"21 @B1,P 4C9&)^1V1#%+ X@Z-( 0\A.(-(+N"8+TQ@0']E
MTA4RT0(D&"(+'9B('?XI$P]IX;'=9<(("),)-IQW!$+]P%$0P80NI"$$+P@$
M$\K)H0^$(!!6P,-JLC!>3#"A3VE03B;(6MM,G-)A@; (&R(Y$4F05@+',43N
MTM,6(PX79Y@ 01:88 1)=& .,Z@,T%ZIL1M-1 E >@$CSG"$,WS!$!;XPA5,
M\ (/V4&\3+"#(D@0)"[T,S<D"(0D%, 1*Y3SQ4SZXP@0(07^)FC@"7TA2 =D
M$*$*S $*!98"%YB@ BQ@@0T\F0$,O,.%*338"DR 01:^@(499B!(2,A </Y:
M7:I 00:*X$(()H('$E!$$DPX Q<H48')J  %<L "=%!@@G^20#9008)=3' 4
MVLSA-T#*@AWL((44JD0*AG@/&SJ,!!9:+,H-"T0%<I>!-#@%!"G@ @!H$H41
ML. A,S !"#Q#VS#;+!!O0<1"**J2DL+,S1"_E22"G%PV9 $*5C#!"IA=" 5\
M@!)1B,D,['"3"QBA.T#EPA'^R8(P8D$2)R#Q!>Q05D0S:01/D((D+' $^HP@
M$R9( ;47@(<5X&$&<O@"$EZ "27^R,&E*W@!'J8PD3-<@0T'J ,4F)Z)'9_
M$*CUC 0(4VNOLB 0EPYQ!EI%E2<@@0UIAT 'NC@"(&4BY%+X@$HZ8(4H9"$+
MF$$"#.;P!:7:9"00_K,<+I"$3#S!J6F8P\MK]60H=%3*%,B=!HS2I [@X0*"
M"7JIN:#'%'@Q=PC'V0H DQ$Y]'/B+ALB22_&(06*"0V2@ ((@#H'97]A!K7.
MQ+ME_04N/(8-+P!QV.OPUF'^4R(R00*U&3$#+'P!*E(X/D>BP&TN=&<&MXS\
M"V: B"_P-DZL]I!(MHF)C*13H2V905.0, 4W_JF2O_PSC.70_M3,P!($$^1U
M'1=<7R[^=8<!9D$75 84N,9&,,$+S$?YW= 3+ &!*=L9S,#]9<09,((<)$<(
M( %M9 SF>12N;)>]N5$+2$'::<!/L  4, $40 $N-=/JX8S\U$2$R,'#_4QS
M?47"Y$O!B NZD-H,6%)9],E5-($^B87L$6&U],NE% L4HDNX9(6M79(6'<N\
M6&&PF*"4.8 DG)<&9,()O 4&<):(%!$;( $4]-,(4!N\A4N]"*$:'0O"2&$7
M[B'##,P4KI$?"J(0 J(@&HO 8.&V("*U]$N_<-N4S!P24,4BZHLA-F(>QLN]
M'&*T]$J^Q! L3<H71@O#& (2-)-OK<1S2<14^%$2J@LE]N'^M^3AOW#A%B9B
M(2H,)CH1(Z*+P)#A<R'-+V6>*)H%(HR J9G ;B!!"D3!#'!!%MP$#"#!"; !
M(Z3 ',W').)@S$@$(?#=$7@1T[V ZOG,2#T7."W3?50'G@T)8CR$(6""AZ1&
M9!0(&2I<7G $&9[?&6!")=$%H^7%+F5'>*P$(IS?;YQ/()"6'62?5;Q&>'S!
M&?S+C= %(43&8YP/>+')8W!9)A@"7GA&=NT'.P9"%^B('?"5($0&C%W98UAD
MB[33%WS!)) 61WX!0KX)/R[D%RQ7:@221TZ$(*0&1]RC1#S&+Z*C:U12\GV!
M>:@D1U1'-7F(9Y0$&LR'1!B"7N3^DHKT!B5P!#Q.A"($ EY "UB&1901XUDD
MS!3"BWTMTUO"95S"Y5C*95V^Y>3A01K8Y5[B@8CLY5ORDE[^I5P.PF#6)0C6
MDV'>)1[@@6%Z1GTHYETF1V3.)66^Y7,X"Z; QS+-02 ()F7FDV).IF6R06&2
M)@CNI>H!X5:X" E0F$%&01<TQ?EP@18\ >PAP?6U!0M Q$@P@2%(04P4T1P0
MQ*4Q'3U9VA<(WN'-B:U!P7\YR1.$U0C806\5EU*] !: V$3\VG^Y1>[0'Q88
MQ4,P 1Z(@).P@ 'Z1;'-@$@@0=3-P!F\@'9Q05-(@B0N0:,HU/;Q' OD#E-
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M18J$>%R6%33!'\4@'J@ ;#@7&^S<;YX!%D0%T^%9UZ5:B\Q $R"(CT9G)LA
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M(+?-  9<"$0*F  THQAB!G/P6^&LD 0I8"(%1C")%90@!4G^-(V";."")$R
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M>8&GO:0D$SRM54X>]K29:I=*4QO;M!KTK"L H324IVQG((%W=?B$"O#M!2/
MG (Z((D0V,@*<X@"!V0S@A5 2)'9UG>K91GL??];2L4NE!U4H &7G*$"D@ !
M3!H3O&/S)A,?^ ()CI")!]B("6S^Z, \1R"PLA$:X"&OE5-%7O(IH=K?4I($
M5^H6Q [X!LJIN0!^"C(#*+P@#BH(T 1.RH8*A$<%3W@"#%)M<J,ORMHI/_K2
MT0(KI4/))ESA@@GDD $\".0)'%+=<<:3B1"PP00!4H DSG"".4P@/,N6Q$KB
MG"52TX74Y'T[JMA,RP%^BA$&N#;3^<XI61OJ"R9@ N;D\('"&8&$; #!C;(
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MWB9 *B?^$P#GYQ !!/# #E( ,WD3;$:-.UT)+:4$-"+D!>K@Y28#$>@F>.8
M"_" !;* !>2 IWK'1HXB \)C!@J+"0+L.[LR&_O3E<+R3QPO$UJ FB9 $$Z
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M  HB$$[ !";C*F13 I!'!@K'!$#@@KX@!53'"D[@ TX@$S+@ :!@!&AN.D'
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M?PCW!6[.QF1&*'ACV0PIK["@+0L""O(@ X3Z/D_@+VRN)YZM;0R!"Q9/:2@
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MD(D((WRA'!,JO*#$'"QTX8"7!4DA !0AF%#!!YG(84(4*GQ84!8#@&!%!U)
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MP1!2B$75@1"U/,1FWD6N54K"7#)]!""PEI Z/&) ?NA85]3JGQ]]I*U=0>:
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MD!+Z&X;A8E>X4(L^QX?(*7#X,#<P2<#UB] Q4$M"91>/X*@DE#"=L9".VB/
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M"#I;#]VC)@)Q)<,HB$(!EG6R2O^ #>&<.<=3"#]0IT,I!&L;KK'$A(#DJOP
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MJ6!8[NU>%6R!&J&F#[@"\E*!"$C,\67>-!4*2F #T'3?L,4$#)@"?WT"#3A
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EN (KR (=+,""++ "+6A;L'9K.):$*[B"LT9K++ "+F"!@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g221611bmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221611bmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  K (D# 2(  A$! Q$!_\0
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**TJ6B@:BH['_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g221611bmi002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g221611bmi002.gif
M1TE&.#=AVP!- '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MQ00*$-OV(H!B?8Q+FKK9W;><;UBX!"V8TE1('-KW2M':Q[C\,-KYED0"%#"
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M0 $G*2YDZ[BB[BK(:\FPG11O9DPRJDB2LO%)  3*$0FPEP+62< Z#F!)%1T
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M)\/IKG3%I>N6+%(\(  #4,P/!5  NJ<BJA=;".!HV&1D%/!]!P%[@,!M"(8
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M'D !%!-^$!=QNR!^\GD4&ZF,=X2&_ D _C"&[L6;'K"4 &H!%(  ?6  OQB
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M8E@ KF6?D\&E<1L";>@',2B83K!>!)"P0'J;1:A*8#B2DA=UZP!O\$H &I#
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=E0B;Y;W>B&UDP[G)[!W?,Z&^\EW?@&W?#!$0 #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
